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ABSTRACT
EUNHEE KIM: Nonparametric and Semiparametric Methods in Medical
Diagnostics
(Under the direction of Drs. Donglin Zeng and Joseph G. Ibrahim)
In medical diagnostics, biomarkers are used as the basis for detecting or predicting
disease. There has been an increased interest in using the Receiver Operating Char-
acteristic (ROC) curve to assess the accuracy of biomarkers. In many situations, a
single biomarker is not sufficient for the desired level of accuracy; furthermore, newly
discovered biomarkers can provide additional information for a specific disease. Even
though numerous methods have been developed to evaluate a single biomarker, few sta-
tistical methods exist to accommodate multiple biomarkers simultaneously. The first
paper proposes a semiparametric transformation model for multiple biomarkers in ROC
analysis to optimize classification accuracy. This model assumes that some unknown
and marker-specific transformations of biomarkers follow a multivariate normal distri-
bution; it incorporates random effects to account for within-subject correlation among
biomarkers. Nonparametric maximum likelihood estimation is used for inference, and
the parameter estimators are shown to be asymptotically normal and semiparametri-
cally efficient. The proposed method is applied to analyze brain tumor imaging data
and prostate cancer data.
In the second paper, we focus on assessing the accuracy of biomarkers by adjusting
for covariates that can influence the performance of biomarkers. Therefore, we develop
an accelerated ROC model in which the effect of covariates relates to rescaling the
original ROC curve. The proposed model generalizes the usual accelerated failure time
model in the survival context to the ROC analysis. An innovative method is developed
iii
to construct estimating equations for parameter estimation. The bootstrapping method
is used for inference, and the parameter estimators are shown to be asymptotically
normal. We apply the proposed method to data from a prostate cancer study.
The paired-reader, paired-patient design is commonly used in reader studies when
evaluating the diagnostic performance of radiological imaging systems. In this design,
multiple readers interpret all test results of patients who undergo multiple diagnostic
tests under study. In the third paper, we develop a method to estimate and compare
accuracies of diagnostic tests in a paired-reader, paired-patient design by introducing
a latent model for test results. The asymptotic property of the proposed test statistics
is derived based on the theory of U-statistics. Furthermore, a method for correcting
an imperfect gold standard bias and sample size formula are presented. The proposed
method is applied to comparing the diagnostic performance of digital mammography
and screen-film mammography in discriminating breast tumors.
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Chapter 1
Introduction and Literature Review
1.1 Measures of Diagnostic Accuracy
The accuracy of a diagnostic test is the ability of a test to discriminate among alterna-
tive status of health (Zweig and Campbell, 1993). The assessment of the performance
of the diagnostic test is done by investigating whether test results differ for the two
health states. The Receiver Operating Characteristic (ROC) analysis are widely used
for the measure of performance, evaluation of diagnostic or prognostic tests and indices,
and comparison of diagnostic techniques or systems. In essence, ROC analysis is an
evaluation technique used in signal detection theory developed in the 1950s and 1960s
(Green and Swets, 1966; Egan, 1975). It was popular in the field of radiology in the
1980s and it is increasingly used for medical and image research in recent years.
1.1.1 Sensitivity and Specificity
For binary results (such as positive or negative), the accuracy of a diagnostic test is often
characterized by the true positive rate (TPR) and the false positive rate (FPR). Positive
test results indicate the presence of a particular condition and negative indicates its
absence. Then, the TPR is defined as the probability that the test result is positive
given that the subject is truly diseased. The FPR is defined as the probability that
the test result is positive given that the subject is truly non-diseased. In biomedical
research, the sensitivity and specificity are often used instead of the TPR and the FPR;
TPR = Pr(positive | disease) = sensitivity
FPR = Pr(postitive | nondisease) = 1− specificity.
Let D denote true disease status where D=1 if the condition is present and 0 if the
condition is absent and Y be the binary test result (Y=1 for a positive, 0 for a negative
test result). Then,
TPR = Pr(Y = 1 | D = 1)
FPR = Pr(Y = 1 | D = 0).
1.1.2 Receiver Operating Characteristic (ROC) Curve
Many diagnostic tests results are not simply positive or negative but are measured on
continuous or ordinal scales. Some tests yield qualitative results on an ordinal scale
based on a subjective assessment of readers. For instance, for the mammography study
of the detection of malignant lesions, readers can give a BIRAD score (American College
of Radiology, 1995) where 1=normal, 2=benign, 3=probably benign, 4=suspicious,
and 5=malignant. On the other hand, diagnostic tests such as temperature, serum
cholesterol, and blood pressure produce continuous test results. In this thesis, we
focus our attention on test results with continuous or ordinal scales and their analyses.
When a diagnostic test is based on a variable measured on a continuous or ordinal
scale, an assessment of the test can be made through the use of the receiver operating
characteristic (ROC) curves (Hanley and McNeil, 1982; Metz, 1978).
The ROC curve is defined as a plot of TPR (sensitivity) versus FPR (1-specificity)
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Figure 1.1: ROC curve
across all possible threshold values. Each point on the graph is created by a differ-
ent threshold value (See Figure 1.1). From Figure 1.1, we can see that the FPR (1-
specificity) increases as the TPR (sensitivity) increases. Thus, the ROC curve shows
the range of possible tradeoffs between sensitivity and specificity.
Some basic properties of the ROC curve are:
a. The ROC curve is a monotonic increasing function mapping (0,1) onto (0,1).
b. The closer the curve follows the left and upper border of the ROC space, the
more accurate the test.
c. On the other hand, the closer the curve comes to the 45-degree diagonal of the
ROC space, the less accurate the test.
d. The ROC curve is invariant to any monotone transformations of the measurement
scale. Thus, the ROC curve does not depend on the scale of the test measure-
ments, making it useful for comparing diagnostic tests of different scales.
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1.1.3 The Area Under the ROC Curve
It is often convenient to reduce an ROC curve to a single quantitative measure. A
commonly used index of accuracy is the area under an ROC curve (AUC). It reflects
the discriminative ability of a diagnostic procedure and can be used to make inferences
for comparing ROC curves. The area can take values between 0 and 1, but typically
it ranges from 0.5 to 1. The closer AUC is to 1, the better the overall diagnostic
performance of the test. Conversely, an AUC of 0.5 indicates that the test is performing
no better than simply guessing whether a sample is normal or abnormal, and an AUC
of 1 indicates a test always classifies a sample correctly. The area under an ROC curve
has several interpretations (Zou et al., 2002, p.28); (a) the average value of sensitivity
for all possible values of specificity, (b) the average values of specificity for all possible
values of sensitivity (Metz, 1986, 1989), and (c) the probability that a randomly selected
patient with the condition has a test result indicating greater suspicion than that of a
randomly chosen patient without the condition (Hanley and McNeil, 1982).
An alternative summary measure is the partial area under the ROC curve (pAUC),
used to make statistical inference when only a region of the ROC space is of interest.
Methods for estimating and comparing pAUCs are found in the literature (McClish,
1989; Wieand et al., 1989; Zhang et al., 2002).
1.1.4 The ROC Curve for Continuous Tests
Let D be a binary indicator of disease status with D=1 for diseased and D=0 for non-
diseased subjects. Let Y denote a continuous rest result and c be a threshold that any
test results greater than c are considered to be positive. For a given threshold c,
TPR(c) = Pr(Y ≥ c | D = 1)
FPR(c) = Pr(Y ≥ c | D = 0).
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The ROC curve is the entire set of possible true and false positive rates by dichotomizing
Y with different thresholds. That is,
ROC(· ) = {(FPR(c), TPR(c)), c ∈ (−∞,∞)}.
We also write the ROC curve as (Pepe, 2003, p.68)
ROC(· ) = {(t, ROC(t)), t ∈ (0, 1)},
where the ROC function maps t to TPR(c), and c is the threshold corresponding to
FPR(c) = t.
Let SD and SD¯ denote the survivor functions for Y in the diseased and non-diseased
populations: SD(y) = Pr(Y ≥ y | D = 1) and SD¯(y) = Pr(Y ≥ y | D = 0). Then, the
ROC curve can be expressed as
ROC(t) = SD(S
−1
D¯
(t)), t ∈ (0, 1).
Suppose that YD and YD¯ are independent and randomly chosen test results from
the diseased and non-diseased population, respectively. By the definition, AUC =∫ 1
0
ROC(t)dt =
∫ 1
0
SD(S
−1
D¯
(t))dt. We can easily show that
AUC = P (YD > YD¯).
1.1.5 The Binormal ROC Curve
The most popular parametric model is the binormal ROC curve which assumes that test
results are normally distributed in the diseased and non-diseased populations (Dorfman
and Alf, 1969).
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Let X be the test result from diseased subjects and Y be the test result from non-
diseased subjects. Suppose that test results are normally distributed in the diseased
and non-diseased populations. If X ∼ N(µX , σ2X) and Y ∼ N(µY , σ2Y ), then
ROC(t) = Φ(a+ bΦ−1(t))
where
a =
µX − µY
σX
, b =
σY
σX
and Φ denotes the standard normal cumulative distribution function.
The area under the curve for the binormal ROC curve has a following closed-form
expression:
AUC = Φ
(
a√
1 + b2
)
Note that the shape of the binormal ROC curve is fully characterized by two parameters;
the intercept a (standardized mean difference of the distributions of test results) and
the slope b (the ratio of the standard deviation of the distributions of the test results).
Thus, statistical inference can be made based on the estimated parameters of a and b.
1.1.6 The ROC Curve for Ordinal Tests
Some test responses are collected on ordinal scales. For example, for the mammography
data, the test results are numbered from 1=normal to 5=malignant. With ordinal test
results, the unobservable latent continuous random variable model is often used and a
ROC curve can be obtained by exploiting the latent variable.
Assume that there is an unobserved latent variable L corresponding to the assessor’s
perception of the image. The reader has decision threshold values that correspond to
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his/her classification. Let Y denote the reported classification. Then,
Y = y ⇔ cy−1 < L < cy, y = 1, 2, · · · , p
where c0 = −∞ and cp = ∞. The reader classifies the image in the yth category if
L falls within the interval corresponding to the reader’s implicit definition for the yth
category (cy−1, cy).
Our interest is in the ROC curve for L, the latent variables. Since Y ≥ y corre-
sponds to L > cy−1, we can express the true and false positive rates as TPR(cy−1) and
FPR(cy−1) based on the threshold cy−1 for L. The set of P + 1 points from the ROC
curve for L are identifiable from the distributions of the observed Y in diseased and
non-diseased subject:
{FPR(cy−1), TPR(cy−1), y = 1, 2, · · · , p+ 1}
Suppose that YD denotes a test result from the diseased subjects and YD¯ denotes a
test result from the non-diseased subjects. For the discrete test results, the area under
the ROC curve is given by
AUC = P (YD > YD¯) +
1
2
Pr(YD = YD¯).
1.2 The Study Design in Medical Diagnostics
1.2.1 Scale of the Test Result
The diagnostic test is used in order to classify subjects as diseased or not diseased. Test
results can yield binary, ordinal, or continuous scales. The binary test result is either
positive or negative: positive if a disease is present or negative if a disease is absent.
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For test results on ordinal or continuous scales, the classification rule is usually set by
a threshold, with results above it classified as positive for disease and results below it
classified as negative, or vice versa. Tests that involve subjective assessments are often
measured on ordinal scales.
1.2.2 Selection of Study Subjects
Enrollment into a study of a diagnostic test usually proceeds in one of two ways.
Subjects can be selected on the basis of known true disease status. That is, a fixed
number of diseased and non-diseased subjects are selected and then the diagnostic test
is applied to the subjects. This design is called a case-control study. Alternatively, the
diagnostic test can be applied to a set of study subjects from the population of interest
and true disease status is determined for them. This design is called a cohort study
because membership in the cohort is the basis for selection into the study.
1.2.3 Study Design for Comparing Tests
When multiple diagnostic tests are to be compared, a paired-reader(or patient) or
unpaired-reader(or patient) design can be considered. In a paired-reader design, mul-
tiple readers interpret the results of all tests. For example, each reader interprets the
results of both CT and MRA in this setting. On the other hand, in an unpaired-reader
design, different readers interpret the results of different tests. Under this setting, for
example, readers who interpret the CT results are not the same readers who interpret
the MRA results. The paired-reader design is more powerful than the unpaired-reader
design since it requires fewer patients and readers. The unpaired-reader design is used
in situations that do not allow a paired-reader design. For example, a unpaired-reader
design is used when different expertise is required to interpret tests and readers do not
have equivalent expertise in each test. In a paired-patient design, a sample of patients
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undergoes all the diagnostic tests under the study. An unpaired-patient design is the
one where each patient undergoes a single test.
Paired- and unpaired- reader designs can be used with both paired- and unpaired-
patient designs. Correlations between test results must be considered in evaluating a
study that employs a paired design. The most commonly used design is the paired-
patient, paired-reader design, in which multiple readers interpret all the test results of a
sample of patients who undergoes all the diagnostic tests under the study. This design
is also called traditional design. The data setup is given in Table 1.1; here, Tkj1 and
Tkj2 denote the results of test 1 and 2 for the kth patient and are interpreted by the
jth reader. This design is popular because it requires the smallest number of patient
(Obuchowski and Rockette, 1995). Furthermore, it demands one of the smallest reader
samples and one of the fewest number of interpretations per reader.
Table 1.1: Data setup for Paired-patient, Paired-Reader Design
Reader 1 · · · Reader j · · · Reader J
Test1 Test2 Test1 Test2 Test1 Test2
1 T111 T112 · · · T1j1 T1j2 · · · T1J1 T1J2
2 T211 T212 · · · T2j1 T2j2 · · · T2J1 T2J2
...
...
...
. . .
...
...
. . .
...
...
k Tk11 Tk12 · · · Tkj1 Tkj2 · · · TkJ1 TkJ2
...
...
...
. . .
...
...
. . .
...
...
N TN11 TN12 · · · TNj1 TNj2 · · · TNJ1 TNJ2
Note: This design requires N total patients and J total readers.
There are N × I interpretations per reader, where I is the number
of diagnostic tests under study. (Note that I=2 in the table)
In contrast, the unpaired-patient, unpaired-reader design is the most inefficient
design, but situations arise when it is the only design option. The unpaired-patient,
paired-reader design (See Table 1.3) and the paired-patient, unpaired-reader design(See
Table 1.4) are improvements over the unpaired-patient, unpaired-reader design but
inferior to the paired-patient, paired-reader design. Still, these designs may be necessary
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when the tests are mutually exclusive or when the readers of the tests require different
expertise (Zhou, 2002, p82).
Table 1.2: Data setup for Unpaired-patient, Unpaired-Reader Design
Test 1 Test 2
Reader 1 · · · Reader j · · · Reader J PatientReader 1˜ · · · Reader j˜ · · · Reader J˜
1 T111 · · · T1j1 · · · T1J1 1˜ T1˜1˜2 · · · T1˜j˜2 · · · T1˜J˜2
2 T211 · · · T2j1 · · · T2J1 2˜ T2˜1˜2 · · · T2˜j˜2 · · · T2˜J˜2
...
...
. . .
...
. . .
...
...
...
. . .
...
. . .
...
k Tk11 · · · Tkj1 · · · TkJ1 k˜ Tk˜1˜2 · · · Tk˜j˜2 · · · Tk˜J˜2
...
...
. . .
...
. . .
...
...
...
. . .
...
. . .
...
N TN11 · · · TNj1 · · · TNJ1 N˜ TN˜ 1˜2 · · · TN˜ j˜2 · · · TN˜J˜2
Note: This design requires I ×N total patients and I × J total readers, where I is the number
of diagnostic tests under study. There are N interpretations per reader. (Note that I=2 in the
table.)
Table 1.3: Data setup for Unpaired-patient, Paired-Reader Design
Test 1 Test 2
Reader 1 · · · Reader j · · · Reader J PatientReader 1 · · · Reader j · · · Reader J
1 T111 · · · T1j1 · · · T1J1 1˜ T1˜12 · · · T1˜j2 · · · T1˜J2
2 T211 · · · T2j1 · · · T2J1 2˜ T2˜12 · · · T2˜j2 · · · T2˜J2
...
...
. . .
...
. . .
...
...
...
. . .
...
. . .
...
k Tk11 · · · Tkj1 · · · TkJ1 k˜ Tk˜12 · · · Tk˜j2 · · · Tk˜J2
...
...
. . .
...
. . .
...
...
...
. . .
...
. . .
...
N TN11 · · · TNj1 · · · TNJ1 N˜ TN˜12 · · · TN˜j2 · · · TN˜J2
Note: This design requires N × I total patients and J total readers, where I is the number
of diagnostic tests under study. There are N × I interpretations per reader. (Note that I=2
in the table)
Lastly, a paired-patient-per-reader, paired-reader design is the situation where the
N × J total patients undergo all tests under the study, and each reader interprets the
test results of the N patients. This design requires the fewest number of readers but
requires many more patients than the paired-patient paired-reader design. It is an
efficient design when patients can be accrued into the study quickly and inexpensively
(Zhou, 2002, p83).
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Table 1.4: Data setup for Paired-patient, Unpaired-Reader Design
Test 1 Test 2
Reader 1 · · · Reader j · · · Reader J Reader 1˜ · · · Reader j˜ · · · Reader J˜
1 T111 · · · T1j1 · · · T1J1 T11˜2 · · · T1j˜2 · · · T1J˜2
2 T211 · · · T2j1 · · · T2J1 T21˜2 · · · T2j˜2 · · · T2J˜2
...
...
. . .
...
. . .
...
...
. . .
...
. . .
...
k Tk11 · · · Tkj1 · · · TkJ1 Tk1˜2 · · · Tkj˜2 · · · TkJ˜2
...
...
. . .
...
. . .
...
...
. . .
...
. . .
...
N TN11 · · · TNj1 · · · TNJ1 TN 1˜2 · · · TNj˜2 · · · TNJ˜2
Note: This design requires N total patients and J × I total readers, where I is the number
of diagnostic tests under study. There are N interpretations per reader. (Note that I=2
in the table)
Table 1.5: Data setup for Paired-Patient-Per-Reader, Paired-Reader Design
Reader 1 · · · Reader j · · · Reader J
Test1Test2PatientTest1Test2PatientTest1 Test2
1 T111 T112 1˜ T1˜j1 T1˜j2
˜˜1 T˜˜1J1 T˜˜1J2
2 T211 T212 2˜ T2˜j1 T2˜j2
˜˜2 T˜˜2J1 T˜˜2J2
...
...
...
...
...
...
...
...
...
k Tk11 Tk12 k˜ Tk˜j1 Tk˜j2
˜˜k T˜˜
kJ1
T˜˜
kJ2
...
...
...
...
...
...
...
...
...
N TN11 TN12 N˜ TN˜j1 TN˜j2
˜˜N T ˜˜NJ1 T ˜˜NJ2
Note: This design requires N × J total patients and J total readers.
There are N × I interpretations per reader, where I is the number
of diagnostic tests under study. (Note that I=2 in the table)
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1.2.4 Correlated ROC Data Structures
The paired design is often used to improve the precision of the analysis. We focus our
discussion on the following two types of correlated ROC data structure: (1) multiple
test measurements on the same patient and (2) multireader ROC studies with multiple
tests (Zou, 2002, p.274). In such studies, it is important to take into account the
correlations for the estimation and the inferences on the accuracy of the diagnostic test.
The statistical methodologies for the analyses from these correlated data structures are
described in later sections in detail.
The first data structure arises when each patient is examined by several diagnos-
tic tests or is repeatedly examined by the same test. Under this data structure, test
responses from different patients can be assumed to be independent although test re-
sponses from the same patient are correlated. One special form from this data structure
is known as clustered data. For example, in a study of the diagnostic accuracy of mag-
netic resonance (MRI) in lung cancer, different regions of the lung were considered
for the presence of cancerous invasions (Webb et al, 1991; Beam, 1998). Beam (1998)
described several approaches to the analysis of clustered data. Regression models from
multiple test measurements on the same patients are discussed in section 1.4.
The second data structure arises when each patient is examined by multiple readers
with multiple tests (or modalities). It is called multi-reader, multi-test study design.
In this setting, the results of diagnostic tests often depend on a radiologist’s subjective
interpretation. For example, after conducting a mammography screening, a radiolo-
gist examines the image characteristics and gives his or her impression of the presence
or absence of malignancy. Because of the variability in readers’ accuracies caused by
differences on interpretations, studies of such diagnostic tests usually involve several
readers. The most popular design for such a study is to have multiple readers examine
12
the same set of patients who have undergone each of the diagnostic tests. This struc-
ture is equivalent to the notion of the paired-patient paired reader design as illustrated
before. This design is most likely to occur in a radiology setting and is most efficient
for a comparison of tests. We discuss several approaches (See section 1.3.4) and de-
velop new statistical methodologies of ROC analysis arising from this data structure in
Chapter 3.
1.2.5 Common Sources of Biases in Study Design
Studies of diagnostic tests are subject to an array of biases. Table 1.7 summarizes the
common biases in studies of diagnostic test accuracy (Zou, 2002, p.69). Some of biases
are discussed below:
a. Selection bias : When the sample composition has been influenced by external
factors so that it does not represent the target population, we have selection bias.
b. Spectrum bias : Spectrum bias occurs when diseased subjects in the study are
not representative of disease subjects in the population, or if controls selected
for the study are different from population controls. A common mistake is to
select cases that have more advanced or severe disease and select controls that
are more healthier on average than non-disease subjects in the population. In
this setting, test sensitivity and specificity will be higher than would be expected
in the general population. Cases and controls in a diagnostic study should be
randomly selected from the diseased and non-diseased target population.
c. Imperfect gold standard bias : A gold standard is a procedure that defines presence
or absence of a condition of interest, such as a patient’s disease status. Different
gold standards are used for different tests and applications; Common examples
are autopsy reports, surgery findings, pathology results from biopsy specimens,
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and so on (Zou, 2002, p.15). If an imperfect reference test is used as a gold
standard, the estimates of test accuracy usually will be biased. This phenomenon
is called imperfect gold standard bias.
d. Verification bias : Verification bias occurs when the test being evaluated is used
to determine which subjects get further evaluation, leading to a diagnostic of the
disease. This problem is exceedingly common in research on diagnostic tests,
particularly when the gold standard test poses some risk to subjects. If deter-
mination of disease status depends on the result of the test, then nave estimate
of sensitivity and specificity based on disease-verified subjects are biased. The
verification bias is also called as work-up bias, referral bias, selection bias and as-
certainment bias (Pepe, 2003, p.169). For example, consider audiology screening
in new borns with DPOAE. If the test suggests that a child is hearing impaired,
then follow-up testing with the gold standard visual reinforcement audiometry
(VRA) behavioral test is clinically indicated and is performed. However, if the
DPOAE test suggests that the child’s ears are responding to sound stimuli, then
there are no clinical reasons to perform the VRA test.
1.3 Estimating the ROC Curve
In this section, statistical methods for estimating ROC curves, calculating the area
under a ROC curve and comparing ROC curves are discussed. We introduce three
approaches for estimating the ROC curve and the corresponding AUC: parametric,
nonparametric, and semiparametric methods.
14
Table 1.6: Common Biases in Studies of Diagnostic Test Accuracy
Bias Description
Selection bias The composition of the sample is influenced by external fac-
tors, so the study sample is not representative of the target
population
Spectrum bias The study sample does not include the complete spectrum of
patient characteristic
Imperfect gold The reference procedure is not 100 % accurate standard bias
Workup bias The results from the diagnostic test influence the subsequent
clinical workup needed to establish the patient’s diagnosis
Incorporation bias The results from the diagnostic test under evaluation are
incorporated-in full or part-into the evidence used to estab-
lish the definitive diagnosis
Verification bias Patients with positive (or negative) test results are preferen-
tially referred for the gold standard procedure;the bias occurs
when estimates of accuracy are based only on the verified pa-
tients
Test-Review bias The diagnostic test is evaluated without proper blinding of
the results from the gold standard or competing test
Diagnostic-Review biasThe gold standard is evaluated without proper blinding of
the results from the test under study
Reading-Order bias When comparing two or more tests, the reader’s interpreta-
tion is affected by his or her memory of the results from the
competing test
Context bias When the sample prevalence differs greatly from the popula-
tion prevalence, the reader’s interpretations may be affected,
resulting is biased estimates if test accuracy
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1.3.1 Parametric Method
The parametric methods model the ROC curves by assuming test results or some
unknown monotonic transformation of the test results follow a certain distribution.
Under the assumed distribution, parameters of ROC curves are derived and the smooth
ROC curve is produced. The most commonly used distributional assumption is the
binormal model in which parameters are estimated with maximum likelihood methods
(Dorfman and Alf, 1969). The parameter estimates by maximum likelihood methods
is fully efficient assuming that the models are correctly specified. If the distribution
of scores for true-positive and true-negative test subjects are far from binormal, the
parametric AUC and its corresponding standard error derived from a directly fitted
binormal model may be distorted (Goddard and Hinberg, 1990). When test results
are not binormal for continuous data, Zou and Hall (2000) suggested using a Box-Cox
transformation to transform data to binormality and developed maximum likelihood
algorithm for estimating ROC curve parameters.
The ROC curve is invariant to monotonic increasing transformations of test results.
However, the parametric methods for estimating the ROC are not invariant to those
transformations. This approach is not popular in practice because the fully parametric
method makes strong assumptions on the distributions of test results.
1.3.2 Nonparametric Method
Alternatively, the ROC curve can be fitted empirically by using observed data without
making any distributional assumptions for the test results. For continuous test results,
the nonparametric ROC curve may be preferred since it passes through all observed
points and provides unbiased estimates of sensitivity, specificity, and AUC in large
samples (Zweig and Campbell, 1993).
Suppose the test result is measured on an ordinal or continuous scale. By convention,
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Figure 1.2: Empirical ROC curve
we assume that higher values of the test result are more indicative of disease. Let
Xi, i = 1, 2, · · · ,m denote test results from diseased subjects and Yj, j = 1, 2, · · · , n
denote test results from non-diseased subjects. Let N = m+ n be the total number of
subjects under the study. Then, for each possible cutpoint c, the empirical TPR and
FPR are calculated as follows.
T̂PR(c) =
1
m
m∑
i=1
I(Xi ≥ c)
F̂PR(c) =
1
n
n∑
j=1
I(Yj ≥ c)
Then, the empirical ROC curve is a plot of T̂PR(c) versus F̂PR(c) for all c ∈ (−∞,∞).
As shown in Figure 1.2, the empirical ROC curve is fitted by connecting the points
(T̂PR(c), F̂PR(c)) for each c, which results in a step function. The empirical ROC
curve is invariant with respect to a monotonic transformation of test results because it
depends only on the ranks of observations in the combined sample (Zweig and Campbell,
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1993). However, the empirical ROC curve is not smooth and the trapezoidal rule tends
to underestimates the true area (Hanley and McNeil, 1982; Swet and Pickett, 1982).
The AUC can be estimated by summing the area of trapezoids formed by connecting
the points of the empirical ROC curve. Nonparametric methods for estimating the
area and its variance have been proposed in the literature (Bamber, 1975; Hanley and
McNeil,1982; DeLong et al, 1988; Obuchowski,1997). The area under the empirical
ROC curve, when the area is calculated by the trapezoidal rule, is given by
θˆNP =
1
mn
n∑
j=1
m∑
i=1
φ(Xi, Yj),
where
φ(Xi, Yj) =

1 if Y < X,
1/2 if Y = X,
0 if Y > X.
Note that θˆNP provides an unbiased estimate of θNP = Pr(Y < X)+
1
2
Pr(X = Y ).
Pr(X = Y ) = 0 for continuous test results.
θˆNP is equivalent to the Mann-Whitney U-statistic (Bamber, 1975; Hanley and
McNeil, 1982). Thus, the statistical properties of the Wilcoxon statistic can be applied
to predict the properties of the area under an ROC curve. The AUC is a measure based
on pair-wise comparisons of scores from diseased versus non-diseased subjects, not
depending on the actual values of test result. It is the probability that test results from
a randomly selected pair of diseased and non-diseased subjects are correctly ordered.
The variance of the Mann-Whitney statistic can be derived from theory developed for
generalized U-statistics by Hoeffing (1948). Define
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δ10 = E[φ(Xi, Yj)φ(Xi, Yk)]− θ2, j 6= k
δ01 = E[φ(Xi, Yj)φ(Xk, Yj)]− θ2, i 6= k
δ11 = E[φ(Xi, Yj)φ(Xi, Yj)]− θ2,
Then,
V ar(θˆNP ) =
(n− 1)δ10 + (m− 1)δ01
mn
+
δ11
mn
.
Hanley and McNeil (1983) proposed a nonparametric method for the estimation of
the AUC but used the assumption of Gaussian distribution to estimate variances of
the areas for non-continuous test results. On the other hand, DeLong et al. (1988)
developed the completely nonparametric covariance estimation by using the theory on
generalized U-statistics.
The variance estimator proposed by DeLong et al. (1988) is as follows:
a) Define the X-components for the ith subject, V10(Xi) and the Y-components for
the jth subject, V01(Yj).
V10(Xi) =
1
n
n∑
j=1
φ(Xi, Yj), i = 1, 2, · · · ,m
V01(Yj) =
1
m
m∑
i=1
φ(Xi, Yj), j = 1, 2, · · · , n.
b) The AUC can be estimated using either the X or Y components.
θˆNP =
m∑
i=1
V10(Xi)
m
=
n∑
j=1
V01(Yj)
n
.
c) Let S10 and S01 be covariance estimates for the X and Y components (S10 and
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S01 are estimates of δ10 and δ01, respectively). Then,
S10 =
1
m− 1 =
m∑
i=1
(V10(Xi)− θˆNP )2
and
S01 =
1
n− 1 =
n∑
j=1
(V01(Yj)− θˆNP )2.
d) Then, the variance of the area under the curve is estimated by
V (θˆNP ) =
1
m
S10 +
1
n
S01.
An asymptotic (1-α) percent confidence interval for the ROC area is given by
(
θˆNP − z1−α/2
√
ˆV ar(θˆNP ), θˆNP + z1−α/2
√
ˆV ar(θˆNP )
)
.
Hoeffding’s theory extends to a vector of U statistics. Let θˆ=(θˆ1, θˆ2, · · · , θˆk) be
the vector of the AUC estimators. Let {Xri } and {Y rj } (i = 1, · · · ,m; j = 1, · · · , n; 1 ≤
r ≤ k) be the test results of rth diagnostic measure. Define
δrs10 = E[φ(X
r
i , Y
r
j )φ(X
s
i , Y
s
k )]− θrθs, j 6= k
δrs01 = E[φ(X
r
i , Y
r
j )φ(X
s
k, Y
s
j )]− θrθs, i 6= k
δrs11 = E[φ(X
r
i , Y
r
j )φ(X
s
i , Y
s
j )]− θrθs,
Then, the covariance of the rth and sth statistic is Cov(θˆr, θˆs) =
(n− 1)δrs10 + (m− 1)δrs01
mn
+
δrs11
mn
.
The estimated covariance matrix for θˆ can be computed as follows:
a) For the rth statistic, θˆr, the X-components for the ith subject, V r10(Xi) and the
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Y-components for thejth subject, V r01(Yj) are defined respectively, as
V r10(Xi) =
1
n
n∑
j=1
φ(Xri , Y
r
j ), i = 1, 2, · · · ,m
V r01(Yj) =
1
m
m∑
i=1
φ(Xri , Y
r
j ), j = 1, 2, · · · , n.
b) Compute k × k matrix S10 such that the (r,s)th element is
Srs10 =
1
m− 1 =
m∑
i=1
[V r10(Xi)− θˆr][V s10(Xi)− θˆs],
and similarly,
Srs01 =
1
n− 1 =
n∑
j=1
[V r10(Yj)− θˆr][V s01(Yj)− θˆs].
c) The estimated covariance matrix for the θˆ=(θˆ1, θˆ2, · · · , θˆk) is S = 1
m
S10+
1
n
S01.
Let g be a linear function of θˆ. If limN→∞m/n is bounded and nonzero, for any
contrast Lθ′, where L is a row vector of coefficients,
Lθˆ′ − Lθ′[
L
(
1
m
S10 +
1
n
S10
)
L′
]1/2
has a standard normal distribution.
If there are multiple test results from the same subjects, estimation and inference of
the accuracy of diagnostic tests must account for intracluster correlation. Obuchowski
(1997) proposed a method for estimating the area under the ROC curve in the presence
of clustered data by applying Delong et al. (1988)’s structural components approach
to ROC curve estimation but extended their method to clustered ROC data using the
ideas of Rao and Scott (1992). Note that Delong et al. (1988)’s method assumes that
the test results are independent observations. In contrast, under the clustered data
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structure, test results from the same subjects are correlated though test results from
different subjects are assumed to be independent. The methodology for the analysis of
clustered data in ROC studies was reviewed by Beam (1998).
1.3.3 Semiparametric Method
Under the semiparametric approach to estimating the ROC curve, the data are trans-
formed to follow a binormal distribution using an unspecified monotonic transforma-
tion. A common approach to the semiparametric estimation of the ROC curve is to
model the ROC curve parametrically without making additional assumptions on the
distribution of test results. It is also called the parametric distribution free approach
(Pepe, 2000; Alonzo and Pepe, 2002).
The maximum likelihood estimation algorithm for fitting binormal ROC curves to
ordinal data has long been available (Swet and Pickett, 1982; Dorfman and Alf, 1969;
Grey and Morgan, 1972, Metz et al. 1998). Dorfman and Alf (1969) proposed an
iterative method for obtaining the maximum likelihood estimates of the parameters of
a binormal ROC curve to ordinal data. The methods for fitting ROC curves to con-
tinuous data are less established than for ordinal data. Metz et al. (1998) developed a
semiparametric method for continuous data to estimate the ROC curve. They assumed
that the data come from a distribution of a latent variable and created ordinal data
by categorizing the original continuous data, thereby using an ML curve-fitting algo-
rithm for the ordinal data. The computer algorithm LABROC4 (a true ML algorithm)
and LABROC5 (a quasi-ML algorithm) are developed for this method. However, this
method is less sensitive to non-normality than the direct parametric method. On the
other hand, Zou and Hall (2000) proposed the maximum likelihood rank-based estima-
tor of the ROC curve for continuous data. They derived the probability distribution
of ranks of test results using the theorem of Hoeffding (1951) and estimated binormal
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parameters from the likelihood which depends only on the rank order statistics of the
data by a Monte Carlo procedure. This method is efficient but computationally in-
tensive. Pepe (2000a) and Alonzo and Pepe (2002) developed similar semiparametric
methods to estimate ROC curves by applying procedures for fitting generalized linear
models to binary data. Cai et al. (2004) proposed two semiparametric methods for
estimating location and scale parameters in the binormal ROC model; (a) maximum
profile likelihood approach, (b) Pseduo maximum likelihood approach.
1.3.4 Analysis of Multi-Reader, Multi-Test Studies
For the studies with multiple test measurements on the same patients, we discussed
DeLong et al. (1988) in section 1.3.2. In this section, we focus on the studies in which
each patient is examined by multiple readers with multiple tests.
Obuchowski and Rockette (1995) proposed a Mixed-Effects ANOVA model on the
accuracy indices (e.g. the ROC curve area), where the tests were considered fixed and
the readers were considered random. They modified the usual ANOVA F-tests to cor-
rect for the correlations between and within readers. Note that their method makes
strong assumptions as follows: First, it assumes that the complex correlation structure
from having the same patient sample evaluated by several readers in a set of tests can
be described by only three correlations; correlation of error terms in diagnostic accu-
racies of the same reader in different tests, the correlation of error terms in diagnostic
accuracies of different readers in the same test, and the correlation of error terms in
diagnostic accuracies of different readers in different tests on the same patients. Second,
it is not clear how well the modified F statistic follows a F distribution, especially in
small samples. Furthermore, this approach does not provide variance estimates, due to
readers and due to the interaction of readers and test, and it cannot handle covariates
on either the patient or reader level (Zhou, 2002, p290).
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Dorfman et al. (1992) proposed a Mixed-Effects ANOVA model on Jacknife pseu-
dovalues for the test statistic. A mixed effect linear model for the jackknife pseudovalues
is fitted in which readers and patients are random factors and tests are a fixed factor.
They assumed that the random effects and error term in the model are normally and
independently distributed. This method has been widely used in practice but has some
weaknesses. In this framework, jackknife pseudovalues are treated as observed data
and considered independent, which is, in fact, correlated.
Ishwaran and Gatsonis (2000) developed a Bayesian hierarchical ordinal regression
models to deal with multi-reader ROC data and other types of multilevel cluster data.
The models include covariates reflecting characteristics of the units at various levels
of aggregation, such as individual patients, radiologists, and hospitals. We further
examine the multi-reader studies with regression framework in section 1.4.
1.4 Regression Analysis for ROC Data
The performance of a diagnostic test can be influenced by risk factors beyond disease
status. Thus, it is important to identify such factors to determine optimal conditions
for test performance. The regression analysis can be used to evaluate or control for the
possible covariate effects. There are three main approaches to incorporating covariate
effects into ROC analysis. The first approach is to specify a model for the test result as
a function of disease status and covariates. A second approach directly models covariate
effects on ROC curve (Pepe 1997, 2000; Alonzo and Pepe, 2001). It is called parametric
distribution free approach for the reason that it assumes a parametric model for the
ROC curve but is distribution-free regarding the distribution of the test results. The
third approach is to model ROC curve summary indices as a function of covariates.
Note that the first two approaches can be applied to both discrete and continuous
covariates. However, the third approach can be used only when the covariates are
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discrete and there are enough observations in each covariate combination to permit
calculation of the summary accuracy measure. Because of limitations in the third
approach, we focus on the first two approaches.
Let Y denote a diagnostic test result and X denote a set of covariates of interest.
The true disease status for the unit being tested is a known binary random variable,
denoted by D, with D=1 if the unit is diseased and 0 if it is not. Without loss of
generality, we assume that larger values of Y are more indicative of disease. The ROC
curve associated with covariate vector X is denoted by ROCX(t), where t is the false
positive rate. ROC curve can be written as ROC(t) = SD(S
−1
D¯
(t)), where SD and SD¯
are the survivor functions for Y given X in the diseased and non-diseased populations,
respectively.
1.4.1 Modeling Covariate Effects on Test Results
Tosteson and Begg (1988) proposed the location-scale-type ordinal regression model for
ordinal test results. They postulate that
P [Y ≥ y|Z,D] = S0
(
cy − µ(D,Z)
σ(D,Z)
)
with particular specification for µ, σ, and S0. For identifiability of cy, it is assumed
that µ(0, Z0) = 0 and σ(0, Z0) = 1 at a baseline covariate value Z0.
Under the above ordinal regression model, the induced ROC function at Z is
ROCz(t) = S0(−a(Z) + b(Z)S−1D¯ (t))
for t ∈ T (Z) = S0([cy − µ(0, Z)]/σ(0, Z)), y = 1, · · · , P − 1, where
a(Z) = (µ(1, Z)− µ(0, Z))/σ(1, Z) and b(Z) = σ(0, Z)/σ(1, Z).
25
Toledano and Gatsonis (1995) extended the regression model to include the situation
of correlated data arising from a combination of multiple modalities and/or multiple
readers and developed the the technique of generalized estimating equations (GEEs)
to account for the correlation between the observations. Tosteson and Begg (1988)’s
method has been extended to random effects models (Beam, 1995; Gatsonis, 1995) and
Bayesian methods (Peng and Hall, 1996; Hellmich et al. 1998; Ishwaran and Gatsonsis,
2000) when test results are ordinal.
On the other hand, the linear regression model for continuous test result Y condi-
tional on disease status D and covariates Z is as follows:
Y = µ(D,Z) + σ(D,Z)ε,
where ε is the residual term with mean 0 and variance 1 but with an unknown survivor
function S0. Then, the corresponding covariate-specific ROC curve is
ROCz(t) = S0(−a(Z) + b(Z)S−1D¯ (t)),
where a(Z) = (µ(1, Z)− µ(0, Z))/σ(1, Z) and b(Z) = σ(0, Z)/σ(1, Z).
With regard to techniques for estimation, parameters in fully parameterized models
can be estimated using the usual likelihood or GEE techniques. The delta method
yields standard errors for induced ROC parameters and confidence bands for induced
ROC curves. Bootstrapping techniques may also be applied which are often easier to
implement (Pepe, 2003, p.146).
1.4.2 Modeling Covariate Effects on ROC Curves
There are several advantages of modelling covariate effects directly on ROC curves
(Pepe, 2003, p.151, p.165). First, the interpretation of model parameters pertains
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directly to the ROC curves. The second advantage is that multiple tests can be eval-
uated and compared with each other within the regression framework even if the test
results are measured in different unit or on different scales which cannot be achieved
by modeling test results.
Pepe (1997, 2000) developed the ROC-GLM regression model,
g(ROCX(t)) = h0(t) + βX
where h0(·) and g(·) denote monotone increasing(or decreasing) functions on (0,1) and
t ∈ TZ ⊂ (0, 1). The link function g is specified as part of the model. Examples are
probit with g(t) = Φ−1(t), logistic with g(t)=logit(t)=log(t/(1− t)) or logarithmic with
g(t)=log(t). h0(t) is a baseline function specified up to some real parameters. The
baseline function h defines the location and shape of the ROC curve, and β quantifies
covariate effects. Pepe (1997, 2000) put forth an interpretation for each point on the
ROC curve as being a conditional probability of a test result from a random diseased
subject exceeding that from a random nondiseased subject. Then, they noted that
generalized linear model methods applied to binary indicator variables can be used
to model ROC curves and estimate parameters in the model. The key limitation of
the ROC-GLM regression model by Pepe (1997) was that the parameter estimation
required special programming that made the approach difficult to implement. Pepe
(2000) and Alonzo and Pepe (2000) simplified the implementation process to perform
parameter estimation.
Recently, Cai and Pepe (2002) extended the parametric ROC regression model
by allowing an arbitrary nonparametric baseline function for h0. Suppose that the
data for analysis are organized as ND data records for nD subjects with disease,
{(Yik,Zik,ZDik), k = 1, · · · , Ki, i = 1, · · · , nD}, and ND¯ data records for nD¯ subjects
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without disease, {(Yjl,Zjl), k = 1, · · · , Kj, i = nD + 1, · · · , nD + nD¯}, where each sub-
ject may have more than one data record, ND =
∑nD
i=1Ki and ND¯ =
∑nD+nD¯
j=nD+1
Kj. The
covariates denoted by Z are relevant to both diseased and nondiseased subjects.
Then, the ROC curve is modeled as
R0CZ,ZD(u) = g{h0(u) + β′Z+ β′DZD},
where g is a monotone increasing function mapping (−∞,∞) to (0, 1) and h0 is an
unspecified increasing function from (0, 1) to (−∞,∞). Using the fact that condi-
tional on the covariates {Z,ZD} and D = 1, the expected value of I(Y ≥ S−1D¯,Z(u)) is
R0CZ,ZD(u) = g{h0(u) + β′Z + β′DZD}, they constructed the following class of esti-
mating equations for θ0 = (β, βD) based on binary indicator variables:
nD∑
i=1
Ki∑
k=1
∫ b
a
w(Xik, u)Xik[I{Yik ≥ S−1D¯,Z(u)} − g{θ′Xik + h(u)}]dvˆ(u) = 0,
where the prespecified constants (a, b) are chosen such that P{Y11 < S−1D¯,Z11(a)} and
P{Y11 > S−1D¯,Z11(b)} are positive; X = [Z′,Z′d]′, θ
′Xik = β
′Z + β′DZD, w is a positive
bounded uniformly continuous weight function, vˆ(·) is a known increasing but possibly
data dependent function. They used a semiparametric location model (Pepe 1998;
Heagerty and Pepe 1999), SD¯,Z(c) = S0(c − γ′0Z), and estimated the parameter γ0 as
the solution to
nD+nD¯∑
j=nD+1
Kj∑
l=1
Zjl(Yjl − γ ′Zjl) = 0,
which is denoted by γˆ, and the survivor function S0 with the empirical distribution of
the residuals
Sˆ0(c) =
1
ND¯
nD+nD¯∑
j=nD+1
Kj∑
l=1
I(Yjl − γ ′Zjl ≥ c).
They then estimated the baseline ROC function h0 and the parameter θ0 simultaneously
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as solution to
nD∑
i=1
Ki∑
k=1
[I{Yik ≥ S−1D¯,Z(u)} − g{θ′Xik + h(u)}] = 0,
for u ∈ [a, b] and
nD∑
i=1
Ki∑
k=1
∫ b
a
w(Xik, u)Xik[I{Yik ≥ S−1D¯,Z(u)} − g{θ′Xik + h(u)}]dvˆ(u) = 0,
where Sˆ−1
D¯,Z
(u) = Sˆ−10 (u) + γˆ ′Z.
Cai and Pepe (2002) showed that their semiparametric methods fit the model with
efficiency comparable to that of the fully parametric approach. However, their method
requires to construct the high dimensional estimating equations for β and h, which
makes the implementation process demanding.
1.4.3 Modeling ROC Summary Indices
The third approach to ROC regression is to model some summary index of the ROC
curve as a function of covariates. This approach is feasible if covariates are discrete and
there are sufficient numbers of disease and non-disease observations at each distinct
covariate level in order to estimate the summary index. If we denote the estimated
summary index by θˆZ , the idea is to fit the model
E{g(θˆZ)} = β0 + β1X
using standard linear regression methods. Dorfman et al. (1992) and Obuchowski
(1995a) suggested modeling the AUC, while Thompson and Zucchini (1989) recom-
mended modelling the partial area under the curve, pAUC.
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Chapter 2
Combining Continuous Biomarkers
Using Semiparametric
Transformation Models in the ROC
Analysis
2.1 Introduction
Recent technological advances continue to provide non-invasive and more accurate
biomarkers for evaluating disease status. Thus, the assessment of accuracy needs to
keep pace with developments. One standard tool for assessing the accuracy of diagnostic
tests is the Receiver Operating Characteristic (ROC) curve (Swets and Pickett, 1982;
Hanley, 1989). Many methods have been developed to evaluate a single continuous-scale
biomarker in the framework of ROC analysis.
A common approach to the semiparametric estimation of ROC curves is to model
the ROC curve parametrically without making assumptions about the distribution of
test results (Pepe, 2000; Alonzo and Pepe, 2002). The most popular semiparametric
model is the binormal ROC model. Let X denote test results from diseased subjects
and Y denote test results from non-diseased subjects. A binormal ROC curve for X
and Y assumes that for some (unknown) strictly increasing transformation h, h(X) and
h(Y ) have normal distributions. The binormal ROC model is then written as
ROC(u) = Φ{a+ bΦ−1(u)},
where Φ(·) is the cumulative distribution function of the standard normal distribution.
Metz et al. (1998) categorized continuous data into ordinal-scale categorical data and
used an ML curve-fitting algorithm to estimate binormal ROC curve. On the other
hand, Zou and Hall (2000) proposed the maximum likelihood rank-based estimator of
the ROC curve by ranking original continuous data and numerically solving the score
equations derived from the likelihood function of the order statistics using a Monte
Carlo procedure. Cai and Moskowitz (2004) proposed a maximum profile likelihood
and a pseudo-maximum likelihood approaches for estimating the binormal ROC model.
Even though numerous methods have been developed for single biomarkers, few
statistical methods exist to accommodate multiple biomarkers that can be used simul-
taneously for disease detection. In many situations, single biomarkers are not sufficient
to achieve the desired level of accuracy and newly discovered biomarkers can provide
additional information. We consider a linear combination of biomarkers in order to
optimize diagnostic accuracy. One possible objective function to be optimized is the
area under an ROC curve (AUC) of a biomarker combination. Using this framework,
Su and Liu (1993) assumed that markers follow a multivariate normal distribution
in both disease and non-disease groups, and showed that Fisher’s linear discriminant
function provides an optimal linear combination of biomarkers. In contrast, Pepe and
Thompson (2000) proposed a nonparametric rank-based method for AUC maximiza-
tion. A second approach to combining biomarkers uses the likelihood function as an
objective function to be optimized such as the logistic regression model. Pepe and
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Thompson (2000) showed that the nonparametric rank-based method performs as well
as the logistic likelihood-based method when the logistic model holds, and better than
the logistic regression model when it does not. However, finding optimal coefficients for
a nonparametric AUC is computationally demanding when the number of biomarkers
exceeds 2. Furthermore, Pepe and Thompson (2000)’s method does not account for
correlated biomarker structure, and relying on a linear combination of biomarkers can
be misleading for prediction because test results can be affected by original biomarker
scales.
In this chapter, we propose joint transformation models for analyzing multiple
biomarkers. Subject-specific random effects are included in the models. Our model
generalizes the usual binormal ROC model and naturally accounts for the dependence
among biomarkers. The derived diagnostic rule does not depend on any monotone
transformation of biomarkers and is not sensitive to extreme biomarker values. In Sec-
tion 2.2, we introduce our models and give the best rule for combining biomarkers. In
Section 2.3, we propose an inference procedure to estimate model parameters based on
the nonparametric maximum likelihood estimation. The asymptotic properties of the
estimators are provided in Section 2.4. Section 2.5 presents the results from simulation
studies. The applications of the model analyzing vessel attributes in magnetic reso-
nance angiography as well as measures for serum prostate-specific antigen (PSA) for
prostate cancer disease are given in Section 2.6. A discussion is given in Section 2.7.
All technical proofs are given in the Appendix.
2.2 Model
Suppose we observe K biomarker measurements from random sample of size n (n1
diseased, n0 non-diseased, n = n1 + n0) subjects. Then, the observed data for subject
i can be represented as (Xik, Di), where Xik is the measurement of kth continuous
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biomarker from ith subject (i = 1, · · · , n; k = 1, · · · , K) and Di is the binary disease
outcome (Di = 1 for diseased; 0 for non-diseased). In a multivariate normal ROC
model, we assume that there exist K non-decreasing transformations H1, · · · , HK such
that (H1(Xi1), · · · , HK(XiK)) follows a multivariate normal distribution in each of dis-
eased and non-diseased groups;
[H1(Xi1), · · · , HK(XiK)|Zi, Di = 0] = Z ′iai + (²i1, · · · , ²iK), i = 1, · · · , n0 (2.1)
[H1(Xi1), · · · , HK(XiK)|Zi, Di = 1] = Z ′iai + (²′i1, · · · , ²′iK), i = 1, · · · , n1, (2.2)
where ai = (ai1, · · · , aip)′ is a p × 1 vector of subject-specific random effect and
Zi = (zi1, · · · , zip)′ is a p × 1 vector of covariates for ith subject with zi1 = 1.
²i = (²i1, · · · , ²iK)′ and ²′i = (²′i1, · · · , ²′iK)′ are K × 1 vectors of random errors. Here ai
and ²i (or ²
′
i) are independent and are normally distributed with
ai ∼ Np(0,Σa), ²i ∼ NK(µ0Zi,Σ0), and ²′i ∼ NK(µ1Zi,Σ1),
where µ0 = (µ
′
01, · · ·µ′0K)′ with µ0k = (µ0k1, µ0k2, · · · , µ0kp)′, and µ1 = (µ′11, · · ·µ′1K)′
with µ1k = (µ1k1, µ1k2, · · · , µ1kp)′. Thus, [H1(Xi1), · · · , HK(XiK)|Di = 0] ∼ N(µ0Zi,
Z ′iΣaZi11
′ + Σ0) and [H1(Xi1), · · · , HK(XiK)|Di = 1] ∼ N(µ1Zi, Z ′iΣaZi11′ + Σ1),
1 = (1, 1, · · · , 1)′K×1. We give the following restrictions for the identifiability of the
model.
(i) Hk(0) = 0, k = 1, · · · , K.
(ii) Σ0 = diag(1, 1, · · · , 1) and Σ1 = diag(σ211, σ212, · · · , σ21K).
The restrictions (i) and (ii) are imposed not to allow location and scale shifts of the
transformations and parameters to result in same parameters, respectively.
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Under the above assumptions, we propose to use a linear combination of the trans-
formed biomarkers H1(X1), H2(X2), · · · , HK(XK) for describing the performance of
such biomarkers. Consider a linear combination β1H1(X1)+β2H2(X2)+· · ·+βKHK(XK).
Since (H1(X1), H2(X2), · · · , HK(XK)) has a multivariate normal distribution for dis-
eased and non-diseased populations given covariates Z = (z1, · · · , zp)′, the linear com-
bination is normally distributed with
β1H1(X1) + β2H2(X2) + · · ·+ βKHK(XK)|D = 0 ∼ N(β′µ0Z, β′(Z ′ΣaZ11′ + Σ0)β),
β1H1(X1) + β2H2(X2) + · · ·+ βKHK(XK)|D = 1 ∼ N(β′µ1Z, β′(Z ′ΣaZ11′ + Σ1)β),
where β = (β1, · · · , βK)′K×1.
The AUCZ of such a linear combination is given by
β′(µ1 − µ0)Z√
β′(Σ1 + Σ0 + 2Z ′ΣaZ11′)β
.
As shown by Su and Liu (1993), the coefficients for the best linear combination are
βopt,Z ∝ (Σ1 + Σ0 + 2Z ′ΣaZ11′)−1(µ1 − µ0)Z.
The AUC of the optimal linear combination (optimal AUC) is given by
AUCopt,Z = Φ
√(
ZT (µ1 − µ0)T (Σ1 + Σ0 + 2Z ′ΣaZ11′)−1(µ1 − µ0)Z
)
. (2.3)
2.3 Inference Procedures
We propose to use the nonparametric maximum likelihood estimation (NPMLE) to
estimate parameters µ0, µ1,Σ1, and Σa and all the transformations H1, H2, · · · , HK . In
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the NPMLE, Hk(·) will be assumed to be a non-decreasing step function with jumps
at the observed data for kth biomarker and H
′
k(t) will be replaced by its jump size at
t in the likelihood function. We assume the kth biomarker measurement is censored
if it is larger or smaller than fixed threshold values mk and Mk. Our model includes
uncensored cases of biomarkers in which mk = −∞ and Mk = ∞. The indicator
variables are introduced to denote the censored status; δOik = I(mk < Xik < Mk)
and δRik = I(Xik > Mk). Define Xi = (Xi1, · · · , XiK)′, M = (M1, · · · ,MK)′ and
m = (m1, · · · ,mK)′. Under models (2.1) and (2.2), the observed likelihood function
concerning parameters of interest is given by
n∏
i=1
∫
ai
[
K∏
k=1
{fk(Xik|ai, Zi, Di)}δ
O
i {1− Fk(Mk − |ai, Zi, Di)}δ
R
i Fk(mk|ai, Zi, Di)1−δOi −δRi
]
×f(ai)dai,
where fk is the conditional density of Xk given covariates, random effects and disease
status, Fk is the corresponding cumulative distribution function, and f(ai) is the density
of random effects. Particularly,
fk(Xk|a, Z,D = d) = H ′k(Xk)(2piσ2dk)−1/2 exp
{
− 1
2σ2dk
(Hk(Xk)− Z˜Ta− µTdkZ)2
}
and f(a) = (2pi)−q/2 exp{−aTΣ−1a a/2}.
In addition, we define
H+k (X) = Hk(X) if X > 0, H
−
k (−X) = −Hk(X) if X < 0.
Then, bothH+k andH
−
k are increasing functions from (−∞,∞) to (0,∞) andHk(Xik) =
H+k (Xik)I(Xik > 0) −H−k (X˜ik)I(X˜ik > 0) with X˜ik = −Xik. Let θ ≡ (µ0, µ1,Σ1) and
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θ∗ ≡ (θ, Σa). The complete data log likelihood function for (θ∗, H+, H−) is given by
lc(θ
∗, H+, H−) =
∑
Xik>0
2∑
k=1
δOiklog(h
+
k (Xik))
+
∑
Xik>0
2∑
k=1
[{
− δ
O
ik
2
(H+k (Xik)− µ′0kZi − Z ′iai)2
+δRiklogP (Xik > Mk|ai, Di)
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2σ21k
(H+k (Xik)− µ′1kZi − Z ′iai)2
)
+δRiklogP (Xik > Mk|ai, Di)
}
Di
]
+
∑
X˜ik>0
2∑
k=1
δOiklog(h
−
k (X˜ik))
+
∑
X˜ik>0
2∑
k=1
[{
− δ
O
ik
2
(H−k (X˜ik) + µ
′
0kZi + Z
′
iai)
2
+(1− δOik − δRik)logP (Xik < mk|ai, Di)
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2σ21k
(H−k (X˜ik) + µ
′
1kZi + Z
′
iai)
2
)
+(1− δOik − δRik)logP (Xik < mk|ai, Di)
}
Di
]
+
n∑
i=1
logP (ai; Σa), (2.4)
where h+ik(≡ h+k (Xik) ≡ H+k {Xik}) is the jump size ofH+k (·) atXik and h−ik(≡ h−k (X˜ik) ≡
H−k {X˜ik)}) is the jump size ofH−k (·) at X˜ik. Note thatH+ik = H+k (Xik) =
∑n+k
j=1 h
+
jkI(Xjk
≤ Xik) and H−ik = H−k (X˜ik) =
∑n−k
j=1 h
−
jkI(X˜jk ≤ X˜ik) where n+k (n−k ) is the number of
positive (negative) observed values of the kth biomarker.
We apply an the expectation-maximization (EM) algorithm (Dempster et al., 1977)
to calculate NPMLEs and variances of θ∗ and all jump sizes, µ0 = (µ0kr), µ1 =
(µ1kr),Σ1 = diag(σ
2
11, · · · , σ21K),Σa = (σ2arr′), h+ik, and h−jk (k = 1, · · · , K; r, r′ = 1, · · · , p;
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i = 1, · · · , n+k ; j = 1, · · · , n−k ). The maximization for the jump sizes of H+k or H−k can
be done separately for each k and the likelihood is strictly concave in these jump sizes
so that most of the optimization algorithm converges in finding the maximum. In
the EM framework, the random effect ai is treated as missing. Let Eˆ[·] denote the
conditional expectation given the observed data and the current parameter estimates.
The conditional expectations of any functions of ai is computed in the E-step and the
conditional expectation of (2.4) given observed data is maximized in the M-step. Since
σ2 can be updated by maximizing
∑n
i=1 Eˆ[logP (ai; Σa)] directly, θ should be updated
in the M-step. Thus, the objective function becomes
Eˆ[lc(θ, H
+, H−)] =
∑
Xik>0
K∑
k=1
δOiklog(h
+
k (Xik)) +
∑
Xik>0
K∑
k=1
[{
− δ
O
ik
2
Eˆ[(H+k (Xik)− µ′0kZi
−Z ′iai)2] + δRikEˆ[logP (Xik > Mk|ai, Di)]
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2σ21k
Eˆ[(H+k (Xik)− µ′1kZi − Z ′iai)]2
)
+δRikEˆ[logP (Xik > Mk|ai, Di)]
}
Di
]
+
∑
X˜ik>0
K∑
k=1
δOiklog(h
−
k (Xik))
+
∑
X˜ik>0
K∑
k=1
[{
− δ
O
ik
2
Eˆ[(H−k (X˜ik) + µ
′
0kZi + Z
′
iai)
2]
+(1− δOik − δRik)Eˆ[logP (Xik < mk|ai, Di)]
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2
1
σ21k
Eˆ[(H−k (X˜ik) + µ
′
1kZi + Z
′
iai)
2]
)
+(1− δOik − δRik)Eˆ[logP (Xik < mk|ai, Di)]
}
Di
]
. (2.5)
Let θˆ∗ ≡ (µˆ0, µˆ1, Σˆ1, Σˆa), Hˆ+ and Hˆ− denote the nonparametric maximum like-
lihood estimates for θ∗, H+, and H−, respectively. We estimate the variance of
(θˆ∗, Hˆ+, Hˆ−) using the observed information matrix of θˆ∗ and jump sizes Hˆ+k {Xik}
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and Hˆ−k {X˜ik} by Louis’s formula (1982). The optimal AUC given in (2.3) is estimated
at θˆ∗ and its variance is computed by the delta method.
2.4 Asymptotic Theory
In this section, we derive the asymptotic properties of the NPMLEs under finite cen-
sorship condition. Particularly, we cast our transformation models into the trans-
formation models for multivariate failure times as in Zeng and Lin (2007), also de-
scribed in Zeng and Lin (2009). To this end, biomarkers are treated as survival
times and threshold values as censoring time. Specifically, each biomarker is divided
by two groups: (G1) Xik (> 0), positive biomarker; (G2) −Xik (> 0), biomarker
transformed to be positive by switching a sign. We have a total of 2K different
groups based on K types of biomarkers. Define Tl (l = 1, · · · , 2K) is a biomarker
in the lth group where Tl, l = 1, · · · , K is the kth type of biomarker in G1; and
Tl, l = K + 1, · · · , 2K is the (l − K)th type of biomarker in G2. Let Cl denote cen-
soring time (Ml for G1 and |ml| for G2), Zl covariates, and τ the duration of the
study (τ = Cl). Define µ0k = (µ0k1, µ0k2, · · · , µ0kp)′, µ1k = (µ1k1, µ1k2, · · · , µ1kp)′ with
µ0 = (µ
′
01, · · ·µ′0K)′ and µ1 = (µ′11, · · ·µ′1K)′, Σ1 = diag(σ211, · · · , σ21K), and Σa = (σarr′),
k = 1, · · · , K; r, r′ = 1, · · · , p. Then, the linear transformation model has a following
form.
H˜(Til) = µ
′
1lZilDi + µ
′
0lZil(1−Di) + Z ′ilai + ²il, i = 1, · · · , nl; l = 1, · · · , L.
where H˜(·) is an unspecified increasing function, ²il is normally distributed with mean
zero and variance σ21lDi + (1 − Di). µ0l = µ0(l+K), µ1l = µ1(l+K), σ20l = σ20(l+K), σ21l =
σ21(l+K), l < K and L = 2K. Note that H(X) = H˜(X) if X > 0 and H(X) = −H˜(−X)
if X < 0.
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Write Λ(Til) = exp{H˜(Til)}. Let Nil(t) denote the number of lth group of biomark-
ers that are smaller or equal to t. Our model implied that the cumulative intensity for
Nil(t) takes the form
Λl(t|Zil; ai) = Gl
[∫ t
0
Ril(s)exp
{
µ′1lZilDi + µ
′
0lZil(1−Di) + Z ′ilai
}
dΛl(s)
]
(2.6)
where Gl is a continuously differentiable and strictly increasing function; Gl(x) =
−log{1 − Φ(logx)} if Di = 0 and Gl(x) = −log{1 − Φ
(
logx
σ1l
)
} if Di = 1. Ril(t) =
I(Cil ≥ t) is an indicator process, µ1l and µ0l are vectors of unknown regression param-
eters, and Λl(·) is an unspecified increasing function. Define θd×1 = (µ0kr, µ1kr, σ21k)′,
k = 1, · · · , K; r = 1, · · · , p, d = 2Kp + K. Model (2.6) has the same form as the
transformation models with random effects for dependent failure times in Zeng and Lin
(2007, 2009). The likelihood for θ and Λl is given by
∏n
i=1
∫ ∏L
l=1
∏
t≤τ
[
Ril(t)λl(t)exp
(
µ′1lZilDi + µ
′
0lZil(1−Di) + Z ′ilai
)
G′l
{∫ t
0
Ril(s)exp
(
µ′1lZilDi + µ
′
0lZil(1−Di) + Z ′ilai
)
dΛl(s)
}]dNil(t)
exp
[
−Gl
{∫ τ
0
Ril(t)exp
(
µ′1lZilDi + µ
′
0lZil(1−Di) + Z ′ilai
)
dΛl(s)
}]
f(a; Σa)da,
(2.7)
with λl(t) = Λ
′
l(t) (l = 1, · · · , 2K). This can be written in the following form
∏n
i=1
∏L
l=1
∏
t≤τ λl(t)
Ril(t)dNil(t)Ψ(Oi;θ,A),
where A = (Λ1, · · · ,ΛL), Oi pertains to the observation on the ith subject, and Ψ
is a function of Oi, θ, and A. Note that H(X) is same as logΛ(X)I(X > 0) −
logΛ(−X)I(X < 0). For the nonparametric maximum likelihood estimation, we al-
low Hˆ to be discontinuous with jumps at the observed biomarkers and maximize the
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modified likelihood function
∏n
i=1
∏L
l=1
∏
t≤τ λl{t}Ril(t)dNil(t)Ψ(Oi;θ,A),
where λl{t} is the jump size of the monotone function exp(H(T )) (for group G1) and
exp(−H(T )) (for group G2) at t.
We establish the asymptotic properties of the NPMLEs, θ̂ and Ĥk, k = 1, ..., K,
under finite detection limits condition, i.e., −∞ < mk < Mk < ∞. We impose the
following regularity conditions.
(C1) The parameter values (µ0, µ1, σ1k,Σa)
T
d×1 belongs to the interior of a compact set
Θ and H
′
l (t) > 0 for all t ∈ [mk,Mk]. Moreover, for k = 1, ..., K, the true transforma-
tion for Hk, denoted by Hk0, is twice-continuously differentiable and H
′
k0(t) > 0 for all
t ∈ [mk,Mk].
(C2) With probability 1, limn→∞ n1/n = q with 0 < q < 1.
(C3) (Identifiability Condition) If there exist a vector ν and a symmetric matrix M
such that νTZ = 0 and ZTMZ = O, then ν = 0 and M = O. This condition is
equivalent to the linear independence of covariates.
Remark 2.1. (C1) and (C2) are standard conditions for this type of problem.
The following Theorems 2.1 and 2.2 state the consistency and efficiency of the
NPMLEs.
Theorem 2.1. Under Conditions (C1)-(C3),
|θ̂ − θ0|+
K∑
k=1
supt∈[mk,Mk]|Ĥk(t)− Ĥk0(t)| →a.s. 0.
To derive the asymptotic distribution of
√
n(θ̂ − θ0, Ĥk − Hk0, k = 1, ..., K), we
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first define the metric space for which such a random element is defined. We introduce
V = {ν ∈ Rd, |ν| ≤ 1} and Qk = {hk(t) : ‖hk(t)‖V [mk,Mk] ≤ 1}, where V [mk,Mk]
denotes the space of functions with bounded total variations in [mk,Mk]. We then
identify
√
n(θ̂−θ0, Ĥk−Hk0, k = 1, ..., K) as a random element in l∞(V×Q1×· · ·×QK)
by letting
√
n(θ̂ − θ0, Ĥk −Hk0, k = 1, ..., K)[ν, h1, ..., hK ] ≡
√
n(θ̂ − θ0)Tν
+
K∑
k=1
√
n
∫ τ
0
hk(s)d(Ĥk − Ĥ0k)(s).
Thus, the weak convergence of
√
n(θ̂ − θ0, Ĥk − Hk0, k = 1, ..., K) is with respect to
the same metric space. The following theorem holds.
Theorem 2.2. Under Conditions (C1)-(C3),
√
n(θ̂ − θ0, Ĥk −Hk0, k = 1, ..., K) −→d G in l∞(V ×Q1 × · · · × QK),
where G is a mean-zero and tight Gaussian process. Furthermore, the limiting covari-
ance matrix of n1/2(θ̂ − θ0) attains the semiparametric efficiency bound (Bickel et al.
1993).
Theorems 2.1 and 2.2 are proved in Section 2.8.
2.5 Simulation Studies
Simulation studies were conducted to examine the small-sample performance of the
proposed approach, and to compare it with the performances based on the nonpara-
metric and logistic regression methods (Pepe and Thompson 2000). We used an equal
number of diseased and non-diseased subjects but varied the total sample size n from
41
200 to 400. We considered two biomarker measurements for each subject (K=2). More-
over, two transformation functions were set to H1(X) = tan(X1) for biomarker 1 and
H2(X) = 2 log(X2+1) for biomarker 2, very non-linear transformations. No covariates,
Z, were used in the simulations. Specifically, biomarker data were generated from the
following models: among non-diseased subjects,
H1(X1)
H2(X2)
 = a+
µ01
µ02
+
²01
²02
 ,
²01
²02
 ∼ N

0
0
 ,
1 0
0 1

 ,
and among diseased subjects,
H1(X1)
H2(X2)
 = a+
µ11
µ12
+
²11
²12
 ,
²11
²12
 ∼ N

0
0
 ,
σ211 0
0 σ212

 ,
where a was a random effect generated from a normal distribution with mean zero and
variance σ2a. In the simulation studies, we selected the true parameters as µ01 = −2.5,
µ02 = 1.5, µ11 = 1, µ12 = 2.5, σ
2
11 = 2.3, σ
2
12 = 2.7 and σ
2
a = 4.5. We also considered
the situation without detection limits as well as the one with detection limits. For the
latter, we let m1 = −1.4,M1 = 1.3 and m2 = −0.7,M2 = 25, which resulted in about
4% left censoring and 8% right censoring for biomarker 1, and about 4% left and right
censoring for biomarker 2.
For each simulated data, we applied the EM algorithm to calculate the NPMLEs.
In the E-step, the conditional expectations for the functions of random effect ai were
evaluated by the Gaussian-Hermite approximation, where 20 quadratures were used.
The maximization in the M-step was carried out by the Matlab optimization toolbox.
Specifically, the gradient and Hessian matrix of the conditional expectation of the
complete log-likelihood function were provided by us for the optimization; a “fminunc”
function was used, where each search entails the use of a subspace trust region method
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based on the interior-reflective Newton method (Coleman and Li 1994, 1996). For each
M-step, we set the maximal number of the quasi-Newton search to be five. When the
EM algorithm converged to fixed points, we calculated the observed information matrix
using Louis’ formula (see Appendix A.2). The inverse of this matrix is considered as
an estimation of the asymptotic covariance of the parameter estimators. Finally, we
computed the optimal AUC using formula (2.3), and estimated its variance using the
Delta method.
Table 2.1 and Table 2.2 summarize the respective simulation results from 1,000
replicates for the situation without detection limits and the one with detection limits,
respectively. Column “Est” is the average value of the estimates from 1,000 replicates;
column “ASE” is the average of the estimated standard errors; column “SE” is the
standard deviation of the estimates; column “CP” gives the (100×) coverage propor-
tion of the 95% confidence intervals based on the asymptotic normality. Overall, the
estimated parameters and transformations are very close to the actual values across
sample sizes, and the estimated standard errors using the observed information matrix
approximate the empirical standard errors well. In addition, the coverage proportions
of 95% CIs approach the nominal level of 95% as the sample size increases. Next, we
present the true and estimated transformation values at six fixed points at each scenario
of sample sizes in Table 2.1. Similarly, the true and estimated transformation values
are shown in Table 2.2, but the transformations at the minimum and maximum points
in Table 2.1 are excluded by observing detection limits. This shows that the estimation
of the unknown transformation is pretty accurate in small samples, even at the tails of
biomarker distributions. As shown in figures 2.1 and 2.2, the empirical transformation
functions are almost identical to the true transformation functions for both biomarkers
even with the small sample size, no matter whether biomarkers are censored or not.
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Two biomarkers generated in the simulation studies are highly correlated. For in-
stance, from the parameter estimators in Table 2.1, it can be shown that the estimated
correlations between two biomarkers is 0.64 for diseased and 0.83 for non-diseased sub-
jects when a sample size is 200. At the bottom of Tables 2.1 and 2.2, the proposed
optimal AUC (AUCopt), with the nonparametric AUC (AUCemp) and the AUC based
on the logistic model (AUClgit), are presented. We can see that for highly correlated
biomarkers, the proposed optimal AUC estimate is larger than optimal AUC estimates
by the nonparametric and logistic regression based methods, and its empirical stan-
dard error is smaller than those by the other two methods. Next, we generated two
biomarkers having low correlation and estimated the optimal AUCs using the three
approaches mentioned above. We found that the proposed optimal AUC is similar to
those by the nonparametric and logistic model-based methods when biomarkers have
a weak association.
2.6 Applications
2.6.1 Brain Tumor Data
We apply our method to analyzing brain tumor imaging data from magnetic resonance
angiograms. The American Cancer Society estimates that approximately 20,000 Amer-
icans were diagnosed with brain tumors in 2008, so there is clinical need for a reliable,
noninvasive method of assessing tumor malignancy and evaluating treatment response.
One critical stage in tumor growth is the establishment of blood supply, and magnetic
resonance imaging is useful for detecting malignancy because it can search for the foci
of neoangiogenesis of abnormal vascular permeability. Bullitt et al. (2003) extracted
the quantitative measurements of vessel shapes, as visualized by magnetic resonance
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Table 2.1: Simulation results with complete biomarkers
n = 200 n = 400
Par. True Est ASE SE CP Est ASE SE CP
µ01 -2.5 -2.567 0.348 0.397 91.4 -2.551 0.242 0.256 93.5
µ02 1.5 1.564 0.310 0.355 92.5 1.531 0.214 0.232 93.4
µ11 1 1.047 0.351 0.372 94.4 1.015 0.243 0.245 94.9
µ12 2.5 2.576 0.379 0.418 93.6 2.542 0.263 0.269 95.0
σ211 2.3 2.526 1.170 1.316 92.0 2.396 0.789 0.765 95.0
σ212 2.7 2.791 1.028 1.111 94.1 2.823 0.711 0.769 94.2
σ2a 4.5 4.859 0.998 1.519 89.6 4.711 0.676 0.737 93.2
H1(−4pi/10) -3.078 -3.143 0.348 0.425 91.7 -3.135 0.240 0.255 93.6
H1(−2pi/10) -0.727 -0.743 0.173 0.183 94.0 -0.737 0.121 0.123 95.5
H1(−pi/10) -0.325 -0.331 0.116 0.120 94.5 -0.331 0.082 0.081 94.6
H1(pi/10) 0.325 0.336 0.119 0.127 95.3 3.313 0.083 0.086 94.9
H1(2pi/10) 0.727 0.744 0.183 0.198 93.2 0.733 0.127 0.132 94.9
H1(4pi/10) 3.078 3.180 0.491 0.564 91.8 3.113 0.334 0.333 95.4
H2(−0.5) -1.386 -1.415 0.263 0.289 92.5 -1.410 0.183 0.188 94.4
H2(0.5) 0.811 0.829 0.172 0.176 94.5 0.819 0.120 0.119 95.2
H2(4) 3.219 3.297 0.339 0.393 91.2 3.265 0.232 0.249 93.2
H2(8) 4.394 4.506 0.430 0.510 91.0 4.460 0.294 0.311 92.8
H2(12) 5.130 5.264 0.498 0.599 91.4 5.217 0.341 0.360 93.8
H2(20) 6.089 6.257 0.607 0.735 91.0 6.198 0.415 0.446 93.3
AUCopt 0.8812 0.8841 0.020 0.025 88.9 0.8826 0.014 0.017 90.7
AUCemp 0.8486 0.027 0.8457 0.019
AUClgit 0.8473 0.028 0.8451 0.020
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Table 2.2: Simulation results with censored biomarkers
n = 200 n = 400
Par. True Est ASE SE CP Est ASE SE CP
µ01 -2.5 -2.559 0.342 0.378 92.3 -2.546 0.241 0.256 94.5
µ02 1.5 1.554 0.304 0.324 94.5 1.530 0.212 0.230 93.2
µ11 1 1.041 0.348 0.363 95.0 1.011 0.243 0.245 94.1
µ12 2.5 2.565 0.373 0.393 94.3 2.537 0.261 0.270 95.1
σ211 2.3 2.492 1.170 1.287 92.1 2.393 0.811 0.798 96.1
σ212 2.7 2.784 1.052 1.113 93.7 2.820 0.745 0.799 94.1
σ2a 4.5 4.750 0.983 1.139 92.0 4.683 0.672 0.733 93.0
H1(−2pi/10) -0.727 -0.740 0.172 0.177 93.9 -0.736 0.120 0.124 95.4
H1(−pi/10) -0.325 -0.329 0.116 0.118 95.3 -0.330 0.082 0.081 95.4
H1(pi/10) 0.325 0.335 0.118 0.123 95.7 0.331 0.083 0.086 94.8
H1(2pi/10) 0.727 0.743 0.182 0.190 94.4 0.732 0.126 0.133 94.6
H2(0.5) 0.811 0.825 0.171 0.169 94.5 0.818 0.120 0.119 94.8
H2(4) 3.219 3.281 0.334 0.342 94.0 3.261 0.231 0.250 93.5
H2(8) 4.394 4.484 0.424 0.436 93.4 4.454 0.293 0.314 92.5
H2(12) 5.130 5.242 0.492 0.512 94.1 5.211 0.340 0.363 93.4
AUCopt 0.8812 0.8842 0.020 0.024 90.0 0.8823 0.014 0.017 90.5
AUCemp 0.8556 0.027 0.8529 0.019
AUClgit 0.8488 0.027 0.8469 0.019
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Figure 2.1: Plots of the true and estimated transformation functions without detection
limits (n = 400): the solid curve is the true transformation and the dashed curve is the
average of the estimated curves from 1,000 replicates.
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Figure 2.2: Plots of the true and estimated transformation functions with detection
limits (n = 400): see Figure 2.1.
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angiography, to assess tumor malignancy in a cross-sectional study and evaluate treat-
ment response among patients undergoing anti-VEGF and cytotoxic therapy. The two
most important biomarkers of tortuosity measures are (a) the sum of angles metric
(SOAM), which is the sum of the angles between consecutive trios of points along the
space curve represented by the vessel skeleton and then normalized by path length
to measure the vessel curvature; (b) the inflection count metric (ICM), which counts
inflection points along each space curve, multiplies this number (plus one) times the
total path length, and then divides the product by the distance between endpoints. The
data we used contain both SOAM and ICM biomarker measurements from 45 regions of
interest, where 11 tumors were identified as benign and 34 as malignant. To apply our
approach, we assume models (2.1) and (2.2) hold for these two biomarkers; that is, some
non-decreasing unknown transformations of SOAM and ICM follow a bivariate normal
distribution in both benign and malignant groups. After using the EM algorithm for
inference, we report the parameter estimates in Table 2.3. Table 2.3 shows that the
biomarkers tend to have larger means and smaller variances for malignant tumors than
for benign tumors. The dependence between the two transformed biomarkers is low,
with σ2a = 0.0217. The transformations for SOAM and ICM, plotted in Figure 2.3,
suggest that the quadratic transformations may be appropriate for obtaining the nor-
mality. Figure 2.4 further demonstrates that our transformations yield the normality
and can actually downsize some extreme observations in the original biomarkers.
With our approach, the optimal linear combination of these two biomarkers is
1.455Ĥ1(SOAM) + 0.676Ĥ2(ICM), where Ĥ1 and Ĥ2 are the two estimated transfor-
mations. The optimal AUC estimate is 0.9823 with a standard error of 0.016, while
the logistic regression yields a combination of 2.8270(SOAM) + 0.1376(ICM) with an
optimal AUC estimate of 0.9893, which is very close to the optimal AUC estimate based
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Table 2.3: Analysis of brain tumor imaging data
Parameter Estimate SE P-value
µ01 -0.094 0.3232 0.7716
µ02 -0.323 0.3358 0.3360
µ11 2.449 0.9773 0.0122
µ12 0.751 0.2611 0.0040
σ211 0.685 0.9839 0.4866
σ212 0.452 0.2457 0.0659
σ2a 0.022 0.1213 0.8580
on the nonparametric method. There appears to be little difference among three ap-
proaches, possibly because of the high discrimination power from each single biomarker
(the AUC for SOAM only is 0.9759, and the AUC for ICM only is 0.8262) and the low
dependence between the two biomarkers. However, in this tumor data, the advantage
of normalizing biomarkers in our approach is evident even with such a small sample
size.
2.6.2 Prostate Cancer Data
Next, we illustrate our approach with a prostate cancer study. Serum prostate-specific
antigen (PSA) is the most widely used biomarker to detect prostate cancer. We used
a dataset of 71 prostate cancer subjects and 71 controls who participated in the Beta-
Carotene and Retinol Efficacy Trial (CARET) which is a randomized lung cancer pre-
vention study that began in 1985 and terminated in 1994. Subjects had serum samples
drawn at baseline and at two-year intervals thereafter (Goodman et al., 1993; Etzioni
et al. 1999). We considered the single serum sample per subject measured at the time
closest to the diagnosis among multiple samples accumulated before a participant was
diagnosed as having prostate cancer or not, leaving 139 men (71 cases and 68 controls)
in the dataset.
Two measures of PSA, total PSA and the ratio of free to total PSA, were used for
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Figure 2.3: Estimated transformations for biomarkers in brain tumor imaging data
prostate cancer. We standardized the total serum PSA and the ratio of free to total
PSA measurements by subtracting their mean values, and defined the standardized
PSA values as Y1=log(total PSA) and Y2=-log(free PSA/total PSA). The correlation
between these two biomarkers is fairly high with a correlation coefficient of 0.56521.
Parameter estimates from models (2.1) and (2.2) are given in Table 2.4, showing that
Y1 and Y2 have higher means and variances in cases than in controls. The estimated
correlations between two biomarkers is about 0.41 for diseased and about 0.57 for
non-diseased subjects, suggesting the high dependence of the two biomarkers. The
transformations for Y1 and Y2 given in Figure 2.5 appear to be linear and Figure 2.6
shows that the histograms after transformations are closer to a normal shape than those
before transformations.
We found that the optimal linear combination is 0.5562Hˆ1(Y1)+ 0.0213Hˆ2(Y2), and
its corresponding AUC is 0.9199 (SE 0.0210). On the other hand, the optimal linear
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Figure 2.4: Histogram of biomarkers before transformation and after transformation in
brain tumor imaging data
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Table 2.4: Analysis of prostate cancer data
Parameter Estimate SE P-value
µ01 -2.032 0.2737 <.0001
µ02 -1.148 0.2313 <.0001
µ11 1.456 0.3825 1.9999
µ12 0.433 0.2437 1.9244
σ211 2.520 1.1182 1.9758
σ212 1.405 0.6208 1.9764
σ2a 1.324 0.3496 1.9998
combination based on the nonparametric method is Y1 + 0.191Y2, giving an AUC esti-
mate of 0.9095 (SE 0.0252 based on 1000 bootstrap replicates). In addition, the logistic
regression yields 2.0494Y1+0.4886Y2 and a corresponding AUC estimate of 0.9089 (SE
0.0256 based on 1000 bootstrap replicates). The coefficients of the optimal linear com-
binations from all three methods suggest that total PSA performed better than the
ratio of free to total PSA measured closest to the diagnosis. However, the proposed
method gives a larger value of optimal AUC than those from the nonparametric and
logistic regression methods, demonstrating that our method performs better than the
other two methods for highly correlated biomarkers.
2.7 Discussion
The proposed transformation model has several advantages over Pepe and Thompson’s
(2000) nonparametric method. First, we allow a completely unknown transformation,
so the diagnostic rule is less sensitive to the extreme values of biomarkers. Second,
since our method is applied to the biomarkers characterized by left or right censoring
and accounts for the correlated structure of biomarkers by introducing random effects,
it describes the data properly. Third, in our method, finding optimal coefficients for
the linear combination of biomarkers does not require extensive computation, as the
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Figure 2.5: Estimated transformations for biomarkers in prostate cancer data
nonparametric method does.
Our method combines multiple biomarkers but does not address selecting biomark-
ers. We will generalize our method to high dimensional data such as microarray data
and will propose a method for biomarker selection and classification in an ROC frame-
work. In addition, we will develop a method for longitudinal biomarkers and methods
accounting for the situations where disease status is not binary but in continuous scale
and the imperfect disease status is presented.
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Figure 2.6: Histogram of biomarkers before transformation and after transformation in
prostate cancer data
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2.8 Appendix A
2.8.1 Proofs of Theorems 2.1 and 2.2
The likelihood (2.6) in section 2.4 has a same form as that of the transformation models
with random effects for dependent failure times in Zeng and Lin (2007, 2009) and the
proofs of Theorems 2.1 and 2.2 are equivalent to the asymptotic proof for the multiple
type of events in Zeng and Lin (2009). Therefore, we only need to verify their conditions
(D1)-(D8).
First of all, Zeng and Lin (2009)’s condition (D1) is equivalent to our condition
(C1). The condition (D2) naturally holds for time independent covariates Z, (D3) is
always true because censoring time is same as the duration of the study (Cl = τ), and
(D4) is equivalent to our condition (C2). Note that function Gl in (2.6) is equal to
−log{1− Φ(logx)} for Di = 0 and is −log{1− Φ(logx/σ1l)} for Di = 1. Zeng and Lin
(2007, 2009) verified the linear transformation model Gl(x) = −log{1 − Φ(logx)} sat-
isfies the following condition (D5). Even though Gl(x) for the diseased group depends
on σ1l, the condition (D5) can be proven by exactly same arguments as Zeng and Lin
(2009) assuming that σ1l > 0. Next, (D6) holds naturally for the normally distributed
random effect a. (D7) and (D8) are conditions to ensure parameter identifiability and
non-singular information matrix, and these conditions are satisfied by the following
Propositions A1 and A2.
Proposition A1. Suppose two sets of parameters (θ, H1, ..., HK) and (θ˜, H˜1, ..., H˜k)
give the same observed likelihood function with probability one. Then θ = θ˜, Σa = Σ˜a
and Hk = H˜k for k = 1, ..., K.
proof.
Let θk = (µ0k, µ1k, σ
2
0k, σ
2
1k) and θ˜k = (µ˜0k, µ˜1k, σ˜
2
0k, σ˜
2
1k). It suffices to show that
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lk(Hk, θk,Σa|X,Z) = lk(H˜k, θ˜k, Σ˜a|X,Z) implies Hk = H˜k, θk = θ˜k and Σa = Σ˜a for a
fixed k (k = 1, · · · , K).
The marginal densities for kth biomarker given covariates and disease status are
Hk(X)|Z,D = 0 ∼ N(µ′0kZ,Z ′ΣaZ + σ20k), Hk(X)|Z,D = 1 ∼ N(µ′1kZ,Z ′ΣaZ + σ21k).
Similarly, for (H˜k, θ˜k, Σ˜a)
H˜k(X)|Z,D = 0 ∼ N(µ˜′0kZ,Z ′Σ˜aZ + σ˜20k), H˜k(X)|Z,D = 1 ∼ N(µ˜′1kZ,Z ′Σ˜aZ + σ˜21k).
First, assume lk(Hk, θk,Σa|Z,D = 0) = lk(H˜k, θ˜k, Σ˜a|Z,D = 0). Then,
(Hk(X)− µ′0kZ)2
Z ′ΣaZ + σ20k
=
(H˜k(X)− µ˜′0kZ)2
Z ′Σ˜aZ + σ˜20k
. (2.8)
If (Hk(X)− µ′0kZ) = γ0k(H˜k(X)− µ˜′0kZ), γ0k =
√
Z ′ΣaZ + σ20k
Z ′Σ˜aZ + σ˜20k
and
Cov(Hk(X), Hl(X)|D = 0) = Z ′ΣaZ = γ0kγ0lZ ′Σ˜aZ. (2.9)
Under the restriction σ20k = σ˜
2
0k = 1, γ0k =
√
Z ′ΣaZ + 1
Z ′Σ˜aZ + 1
and from (2.9)
Z ′ΣaZ =
(Z ′ΣaZ + 1
Z ′Σ˜aZ + 1
)
Z ′Σ˜aZ ⇐⇒ Z ′ΣaZ = Z ′Σ˜aZ.
Therefore, Σa = Σ˜a and γ0k = 1. Since Hk(0) = 0, it can be shown µ0k = µ˜0k and
Hk = H˜k from (2.8).
Likewise, if we assume lk(Hk, θk,Σa|Z,D = 1) = lk(H˜k, θ˜k, Σ˜a|Z,D = 1) for the
diseased group,
(Hk(X)− µ′1kZ)2
Z ′ΣaZ + σ21k
=
(Hk(X)− µ˜′1kZ)2
Z ′Σ˜aZ + σ˜21k
. (2.10)
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If
(Hk(X)− µ′1kZ) = γ1k(Hk(X)− µ˜′1kZ), (2.11)
Cov(Hk(X), Hl(X)|D = 1) = Z ′ΣaZ = γ1kγ1lZ ′Σ˜aZ = γ1kγ1lZ ′ΣaZ, which gives
γ1k = γ1l = 1. Then, µ1k = µ˜1k from (2.11) and σ
2
1k = σ˜
2
1k from (2.10).
Proposition A2. If Hk = Hk0 + ²
∫
hkdHk0 (k = 1, · · · , K), µ0 = µ00 + ²ν0, µ1 =
µ10 + ²ν1, Σ0 = Σ00 + ²M0, Σ1 = Σ10 + ²M1, and Σa = Σa0 + ²Ma, then
∫
hkdHk0 = 0
and ν0, ν1, M0 and Ma are zero matrices.
proof.
Define H(Xi) = (H1(Xi1), · · · , HK(XiK))′. Note that conditional on disease status,
H(Xi)|Di = 0 ∼ N(µ0Zi, Z ′iΣaZi11′+Σ0), H(Xi)|Di = 1 ∼ N(µ1Zi, Z ′iΣaZi11′+Σ1).
First of all, the non-diseased group log likelihood function can be expressed as
logl0i =
K∑
i=1
logH ′k(Xik)−
1
2
log|Z ′iΣaZi11′ + Σ0|
−1
2
(H(Xi)− µ0Zi)′(Z ′iΣaZi11′ + Σ0)−1(H(Xi)− µ0Zi).
DefineHk = Hk0+²
∫
hkdHk0 (k = 1, · · · , K) withH0(Xi) = (H10(Xi1), · · · , HK0(XiK))′
and h∗ = (
∫
h1dH10, · · · ,
∫
hKdHK0)
′, µ0 = µ00 + ²ν0, µ1 = µ10 + ²ν1, Σ0 = Σ00 + ²M0,
Σ1 = Σ10 + ²M1, and Σa = Σa0 + ²Ma. Then,
logl0i =
K∑
i=1
log(H ′k0(Xik) + ²hk(Xik)H
′
k0(Xik)))−
1
2
log|Z ′i(Σa0 + ²Ma)Zi11′ + Σ0|
−1
2
(
H0(Xi) + ²h
∗ − (µ00 + ²ν0)Zi
)′(
Z ′i(Σa0 + ²Ma)Zi11
′ + (µ00 + ²ν0)
)−1(
H0(Xi)
+²h∗ − (µ00 + ²ν0)Zi
)
. (2.12)
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First, M0 is a zero matrix by the definition of Σ0. We will show all elements of h
∗, ν0,
ν1, and Ma are equal to zeros.
∂logl0i
∂²
∣∣∣
²=0
is given by
l∗0 =
K∑
k=1
hk(Xik)− 1
2
{
(Z ′iMaZi)tr((Z
′
iΣa0Zi + Σ00)
−111′) + tr((Z ′iΣa0Zi11
′ + Σ00)−1M0)
}
−(h∗(Xi)− ν0Zi)′(Z ′iΣa0Zi11′ + Σ00)−1(H0(Xi)− µ00Zi) +
1
2
(H0(Xi)− µ00Zi)′
(Z ′iΣa0Zi11
′ + Σ00)−1(Z ′iMaZi11
′ +M0)(Z ′iΣa0Zi + Σ00)
−1(H0(Xi)− µ00Zi). (2.13)
LetA0 = (aij) = (Z
′
iΣa0Zi11
′+Σ00)−1 andB0 = (bij) = (Z ′iΣa0Zi11
′+Σ00)−1(Z ′iMaZi11
′+
M0)(Z
′
iΣa0Zi + Σ00)
−1 i, j = 1, · · · , K.
∂l∗0
∂XikXil
= −aklhkH ′k0H ′l0 − alkhlH ′k0H ′l0 + bklH ′k0H ′l0 = 0 (k 6= l),
which gives akl(hk + hl)− bkl = 0 so that hk should be constant.
Define hk = ck, C = diag(c1, · · · , cK), e = (H0(Xi) − µ00Zi), and e′ = (H0(Xi) −
µ10Zi). Then l
∗
0 in (2.13) can be rewritten as
∑K
k=1 ck −
1
2
{
(Z ′iMaZi)tr((Z
′
iΣa0Zi11
′ + Σ00)−111′) + tr((Z ′iΣa0Zi11
′ + Σ00)−1M0)
}
+e′
{1
2
(Z ′iΣa0Zi11
′ + Σ00)−1(Z ′iMaZi11
′ +M0)(Z ′iΣa0Zi + Σ00)
−1
−C ′(Z ′iΣa0Zi11′ + Σ00)−1
}
e− Z ′i(Cµ00 − ν0)′(Z ′iΣa0Zi11′ + Σ00)−1e
= 0.
Therefore, the following two conditions hold.
(A1) Z ′iMaZi11
′ = 2(Z ′iΣa0Zi11
′ + Σ00)C (A2) Cµ00 = ν0
Condition (A1) implies Z ′iMaZi = ck(Z
′
iΣa0Zi + 1) and Z
′
iMaZi = ckZ
′
iΣa0Zi. Thus, it
can be shown that ck = 0,
∫
hkdHk0 = 0 and ν0 = O. Z
′
iMaZi = O implies Ma = O.
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Similarly, for the diseased group, l∗1 =
∂logl1i
∂²
∣∣∣∣∣
²=0
is same as
∑K
k=1 ck −
1
2
{
(Z ′iMaZi)tr((Z
′
iΣa0Zi11
′ + Σ10)−111′) + tr((Z ′iΣa0Zi11
′ + Σ10)−1M1)
}
+e′
{1
2
(Z ′iΣa0Zi11
′ + Σ10)−1(Z ′iMaZi11
′ +M1)(Z ′iΣa0Zi + Σ10)
−1
−C ′(Z ′iΣa0Zi11′ + Σ10)−1
}
e− Z ′i(Cµ10 − ν1)′(Z ′iΣa0Zi11′ + Σ10)−1e
= 0.
Using the same argument as before, we obtain
(A3) Z ′iMaZi11
′ +M1 = 2(Z ′iΣa0Zi11
′ + Σ10)C (A4) Cµ10 = ν1
Since Ma and C are zero matrices, M1 and ν1 are also zero matrices from the condition
(A3) and (A4), respectively.
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2.9 Appendix B
2.9.1 EM Algorithm
Define (Xi1, Xi2) are two continuous biomarkers from subject i (i = 1, · · · , n). It is as-
sumed that there exist non-decreasing transformationsH1 andH2 such that (H1(X1), H2(X2))
follows a multivariate normal distribution in each of diseased and non-diseased groups;
[H1(X1), H2(X2)|D = 0] = ai + (²i1, ²i2), (²i1, ²i2) ∼ N(µ0, diag(1, 1)) and
[H1(X1), H2(X2)|D = 1] = ai + (²′i1, ²′i2), (²′i1, ²′i2) ∼ N(µ1, diag(σ211, σ212)),
with random effect ai ∼ N(0, σ2). The parameters to be estimated are µ0(µ01, µ02),
µ1(µ11, µ12), Σ1(σ
2
11, σ
2
12), jump sizes (h
+
ik, h
−
jk)k=1,2;i=1,··· ,n+k ;j=1,··· ,n−k and σ
2. The com-
plete data likelihood for θ∗ and (H+, H−) is given by
Lc(θ
∗, H+, H−) =
∏
Xik>0
2∏
k=1
[(
h+k (Xik)φ(H
+
k (Xik)− µ0k − ai)
)δOik
(1− Φ(H+k (Mk)− µ0k − ai))δ
R
ik
]Di=0
[(
h+k (Xik)φ((H
+
K(Xik)− µ1k − ai)/σ1k))
)δOik
(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))δ
R
ik
]Di=1
φ(ai;σ
2)
×
∏
X˜ik>0
2∏
k=1
[(
h−k (X˜ik)φ((H
−
k (X˜ik) + µ0k + ai)
)δOik
(1− Φ(H−k (m˜k) + µ0k + ai))1−δ
O
ik−δRik
]Di=0
[(
h−k (X˜ik)φ((H
−
k (X˜ik) + µ1k + ai)/σ1k)
)δOik
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))1−δ
O
ik−δRik
]Di=1
φ(ai;σ
2),
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where φ(·) is a standard normal density. Thus,
Eˆ[lc(θ
∗, H+, H−) = Eˆ[lc(θ, H+, H−)] +
n∑
i=1
Eˆ[logφ(ai;σ
2)], (2.14)
with
Eˆ[lc(θ, H
+, H−)] =
∑
Xik>0
2∑
k=1
δOiklog(h
+
k (Xik)) +
∑
Xik>0
2∑
k=1
[{
− δ
O
ik
2
(
(H+k (Xik)− µ0k)2
−2Eˆ(ai)(H+k (Xik)− µ0k) + Eˆ[a2i ]
)
+δRikEˆ[log(1− Φ(H+k (Mk)− µ0k − ai))]
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2σ21k
[(H+k (Xik)− µ1k)2
−2Eˆ(ai)(H+k (Xik)− µ1k) + Eˆ(a2i )]
)
+δRikEˆ[log(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))]
}
Di
]
+
∑
X˜ik>0
2∑
k=1
δOiklog(h
−
k (X˜ik)) +
∑
X˜ik>0
2∑
k=1
[{
− δ
O
ik
2
(
(H−k (X˜ik) + µ0k)
2
+2Eˆ(ai)(H
−
k (X˜ik) + µ0k) + Eˆ[a
2
i ]
)
+(1− δOik − δRik)Eˆ[log(1− Φ(H−k (m˜k) + µ0k + ai))]
}
(1−Di)
+
{
δOik
(
− 1
2
logσ21k −
1
2σ21k
[(H−k (X˜ik) + µ1k)
2
+2Eˆ(ai)(H
−
k (X˜ik) + µ1k) + Eˆ(a
2
i )]
)
+(1− δOik − δRik)Eˆ[log(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))]
}
Di
]
(2.15)
where Eˆ[·] denotes the conditional expectation given the observed data and the current
parameter estimates.
In the E-step, the conditional expectations of any functions of ai are computed via
Gaussian quadrature approximations since the density of ai|Xi does not have a closed
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form. In detail, Eˆ[g(ai)] is computed in the following manner.
Eˆ[g(ai)] =
∫
g(ai)f(ai|Xi)dai =
∫
g(ai)
f(Xi|ai)φ(ai;σ2)
f(Xi)
dai =
1
f(Xi)
Eai [g(ai)f(Xi|ai)]
and f(Xi) =
∫
f(Xi|ai)φ(ai; σ2)dai = Eai [g(ai)f(Xi|ai)], where
f(Xi|ai) =
2∏
k=1
f(Xik|ai)δOikP (Xik > Mk|ai)δRikP (Xik < mk|ai)1−δOik−δRik
=
2∏
k=1
[(
H
′
k(Xik)φ(Hk(Xik)− µ0k − ai)
)δOik(1− Φ(Hk(Mk)− µ0k − ai))δRik
Φ(Hk(mk)− µ0k − ai)1−δOik−δRik
]Di=0
[(
H
′
k(Xik)φ((HK(Xik)− µ1k − ai)/σ1k))
)δOik(1− Φ((Hk(Mk)
−µ1k − ai)/σ1k))δRikΦ((Hk(mk)− µ1k − ai)/σ1k)1−δOik−δRik
]Di=1
.
Specifically, Eˆ[ai] and Eˆ[a
2
i ], conditional expectations of functions of ai defined in (B.1)
and (B.2) are computed via Gaussian quadrature approximations. Next, in the M-
step, we maximize Eˆ[lc(θ
∗, H+, H−) from (2.14). Since σ2 can be updated directly
by maximizing
∑n
i=1 Eˆ[logφ(ai; σ
2)], the rest of parameters µ0k, µ1k, σ
2
1k, h
+
ik and h
−
jk
(k = 1, 2; i = 1, · · · , n+k ; j = 1, · · · , n−k ) will be updated in the M-step.
First of all, the score equations are obtained by differentiating L ≡ Eˆ[lc(θ, H+, H−)]
from (2.15) with respect to θk ≡ (µ0k, µ1k, σ21k, h+ik h−jk) (k = 1, 2; i = 1, · · · , n+k ; j =
1, · · · , n−k ).
∂L
∂µ0k
=
∑
Xik>0
{
δOik(H
+
k (Xik)− µ0k − Eˆ(ai)) + δRikEˆ
[
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
]}
(1−Di)
−
∑
X˜ik>0
{
δOik(H
−
k (X˜ik) + µ0k + Eˆ(ai))
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+(1− δOik − δRik)Eˆ
[
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
]}
(1−Di)
∂L
∂µ1k
=
∑
Xik>0
{ δOik
σ21k
(H+k (Xik)− µ1k − Eˆ(ai)) +
δRik
σ1k
Eˆ
[
φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
]}
Di
−
∑
X˜ik>0
{ δOik
σ21k
(H−k (X˜ik) + µ1k + Eˆ(ai))
+
(1− δOik − δRik)
σ1k
Eˆ
[
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]}
Di
∂L
∂σ21k
=
1
2
∑
Xik>0
{ δOik
σ41k
(−σ21k + (H+k (Xik)− µ1k)2 − 2Eˆ(ai)(H+k (Xik)− µ1k) + Eˆ[a2i ])
+δRik(σ
2
1k)
−3/2Eˆ
[
(H+k (Mk)− µ1k − ai)φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ(H+k (Mk)− µ1k − ai)/σ1k)
]}
Di
+
1
2
∑
X˜ik>0
{ δOik
σ41k
(−σ21k + (H−k (X˜ik) + µ1k)2 + 2Eˆ(ai)(H−k (X˜ik) + µ1k) + Eˆ[a2i ])
+(1− δOik − δRik)(σ21k)−3/2Eˆ
[
(H−k (m˜k) + µ1k + ai)φ((H
−
k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]}
Di
∂L
∂h+jk
=
δOjk
h+jk
−
∑
Xik>0
{
δOik(H
+
k (Xik)− µ0k − Eˆ(ai))I(Xjk ≤ Xik)
+δRikEˆ
[
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
]
I(Xjk ≤Mk)
}
(1−Di)
+
{ δOik
σ21k
(H+k (Xik)− µ1k − Eˆ(ai))I(Xjk ≤ Xik)
+δRik(σ
2
1k)
−1/2Eˆ
[
φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
]
I(Xjk ≤Mk)
}
Di j = 1, · · · , n+k
∂L
∂h−jk
=
δOjk
h−jk
−
∑
X˜ik>0
{
δOik(H
−
k (X˜ik) + µ0k + Eˆ(ai))I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)Eˆ
[
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
]
I(X˜jk ≤ m˜k)
}
(1−Di)
+
{ δOik
σ21k
(H−k (X˜ik) + µ1k + Eˆ(ai))I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)(σ21k)−1/2Eˆ
[
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]
I(X˜jk ≤ m˜k)
}
Di
j = 1, · · · , n−k
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First, define equations Ojk (j = 1, · · · , 6; k = 1, 2):
O1k =
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
O2k =
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
O3k =
φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
O4k =
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
O5k =
(H+k (Mk)− µ1k − ai)φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ(H+k (Mk)− µ1k − ai)/σ1k)
O6k =
(H−k (m˜k) + µ1k + ai)φ((H
−
k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
B.1. We need to compute following conditional expectations Eˆjk (j = 1, · · · , 6; k =
1, 2) from the score equations.
Eˆ1k = Eˆ(O1k) = Eˆ
[
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
]
Eˆ2k = Eˆ(O2k) = Eˆ
[
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
]
Eˆ3k = Eˆ(O3k) = Eˆ
[
φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
]
Eˆ4k = Eˆ(O4k) = Eˆ
[
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]
Eˆ5k = Eˆ(O5k) = Eˆ
[
(H+k (Mk)− µ1k − ai)φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ(H+k (Mk)− µ1k − ai)/σ1k)
]
Eˆ6k = Eˆ(O6k) = Eˆ
[
(H−k (m˜k) + µ1k + ai)φ((H
−
k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]
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Next, the elements of the Hessian matrix are as follows.
∂2L
∂µ20k
=
∑
Xik>0
[
−δOik + δRik
∂Eˆ1k
∂µ0k
]
(1−Di)−
∑
X˜ik>0
[
δOik + (1− δOik − δRik)
∂Eˆ2k
∂µ0k
]
(1−Di)
∂2L
∂µ0k∂µ1k
=
∂2L
∂µ1k∂µ0k
= 0
∂2L
∂µ0k∂σ21k
=
∂2L
∂σ21k∂µ0k
= 0
∂2L
∂µ0k∂h
+
jk
=
∂2L
∂h+jk∂µ0k
=
∑
Xik>0
[
δOikI(Xjk ≤ Xik) + δRik
∂Eˆ1k
∂h+jk
]
(1−Di)
j = 1, · · · , n+k
∂2L
∂µ0k∂h
−
jk
=
∂2L
∂h−jk∂µ0k
= −
∑
X˜ik>0
[
δOikI(X˜jk ≤ X˜ik) + (1− δOik − δRik)
∂Eˆ2k
∂h−jk
]
(1−Di)
j = 1, · · · , n−k
∂2L
∂µ21k
=
∑
Xik>0
[
− δ
O
ik
σ21k
+
δRik
σ1k
∂Eˆ3k
∂µ1k
]
Di −
∑
X˜ik>0
[
δOik
σ21k
+
(1− δOik − δRik)
σ1k
∂Eˆ4k
∂µ1k
]
Di
∂2L
∂µ1k∂σ21k
=
∂2L
∂σ21k∂µ1k
=
∑
Xik>0
[
− δ
O
ik
σ41k
(H+k (Xik)− µ1k − Eˆ(ai))
+δRik
{
− 1
2
(σ21k)
−3/2Eˆ3k + (σ21k)
−1/2∂Eˆ3k
∂σ21k
}]
Di +
∑
X˜ik>0
[
δOik
σ41k
(H−k (X˜ik)
+µ1k + Eˆ(ai))− (1− δOik − δRik)
{
− 1
2
(σ21k)
−3/2Eˆ4k + (σ21k)
−1/2∂Eˆ4k
∂σ21k
}]
Di
∂2L
∂µ1k∂h
+
jk
=
∂2L
∂h+jk∂µ1k
=
∑
Xik>0
[
δOik
σ21k
I(Xjk ≤ Xik) + δRik(σ21k)−1/2
∂Eˆ3k
∂h+jk
]
Di, j = 1, · · · , n+k
∂2L
∂µ1k∂h
−
jk
=
∂2L
∂h−jk∂µ1k
= −
∑
X˜ik>0
[
δOik
σ21k
I(X˜jk ≤ X˜ik) + (1− δOik − δRik)(σ21k)−1/2
∂Eˆ4k
∂h−jk
]
Di,
j = 1, · · · , n−k
∂2L
∂σ41k
=
1
2
∑
Xik>0
[
δOik
( 1
σ41k
− 2
σ61k
[(H+k (Xik)− µ1k)2 − 2Eˆ(ai)(H+k (Xik)− µ1k)
+Eˆ(a2i )]
)
+ δRik
{
− 3
2
(σ21k)
−5/2Eˆ5k + (σ21k)
−3/2∂Eˆ5k
∂σ21k
}]
Di
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+
1
2
∑
X˜ik>0
[
δOik
( 1
σ41k
− 2
σ61k
[(H−k (X˜ik) + µ1k)
2 + 2Eˆ(ai)(H
−
k (X˜ik) + µ1k)
+Eˆ(a2i )]
)
+ (1− δOik − δRik)
{
− 3
2
(σ21k)
−5/2Eˆ6k + (σ21k)
−3/2∂Eˆ6k
∂σ21k
}]
Di
∂2L
∂σ21k∂h
+
jk
=
∂2L
∂h+jk∂σ
2
1k
=
∑
Xik>0
[
δOik
σ41k
(H+k (Xik)− µ1k − Eˆ(ai))I(Xjk ≤ Xik)
−δRik
{
− 1
2
(σ21k)
−3/2Eˆ3k + (σ21k)
−1/2∂Eˆ3k
∂σ21k
}
I(Xjk ≤Mk)
]
Di, j = 1, · · · , n+k
∂2L
∂σ21k∂h
−
jk
=
∂2L
∂h−jk∂σ
2
1k
=
∑
X˜ik>0
[
δOik
σ41k
(H−k (X˜ik) + µ1k + Eˆ(ai))I(X˜jk ≤ X˜ik)
−(1− δOik − δRik)
{
− 1
2
(σ21k)
−3/2Eˆ4k + (σ21k)
−1/2∂Eˆ4k
∂σ21k
}
I(X˜jk ≤ m˜k)
]
Di,
j = 1, · · · , n−k
∂2L
∂h+jk∂h
+
j′k
= −δ
O
jkI(j = j
′)
(h+k (Xjk))
2
−
∑
Xik>0
{
δOikI(Xj′k ≤ Xik)I(Xjk ≤ Xik)
+δRik
∂Eˆ1k
∂h+j′k
I(Xjk ≤Mk)
}
(1−Di) +
{ δOik
σ21k
I(Xj′k ≤ Xik)I(Xjk ≤ Xik)
+δRik(σ
2
1k)
−1/2 ∂Eˆ3k
∂h+j′k
I(Xjk ≤Mk)
}
Di, j, j
′ = 1, · · · , n+k
∂2L
∂h+jk∂h
−
j′k
=
∂2L
∂h−j′k∂h
+
jk
= 0, j = 1, · · · , n+k ; j′ = 1, · · · , n−k
∂2L
∂h−jk∂h
−
j′k
= −δ
O
jkI(j = j
′)
(h−k (X˜jk))2
−
∑
X˜ik>0
{
δOikI(X˜j′k ≤ X˜ik)I(X˜jk ≤ X˜ik) + (1− δOik − δRik)
∂Eˆ2k
∂h−j′k
I(X˜jk ≤ m˜k)
}
(1−Di) +
{ δOik
σ21k
I(X˜j′k ≤ X˜ik)I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)(σ21k)−1/2
∂Eˆ4k
∂h−j′k
I(X˜jk ≤ m˜k)
}
Di, j, j
′ = 1, · · · , n−k
B.2.
∂Eˆjk
∂θk
(j = 1, · · · , 6; k = 1, 2) from the above elements of the Hessian matrix
are derived below.
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∂Eˆ1k
∂µ0k
= Eˆ
[
∂O1k
∂µ0k
]
= Eˆ
[{
(H+k (Mk)− µ0k − ai)φ(H+k (Mk)− µ0k − ai)(1− Φ(H+k (Mk)
−µ0k − ai))− φ2(H+k (Mk)− µ0k − ai)
}
/(1− Φ(H+k (Mk)− µ0k − ai))2
]
∂Eˆ2k
∂µ0k
= Eˆ
[
∂O2k
∂µ0k
]
= Eˆ
[{
− (H−k (m˜k) + µ0k + ai)φ(H−k (m˜k) + µ0k + ai)(1− Φ(H−k (m˜k)
+µ0k + ai)) + φ
2(H−k (m˜k) + µ0k + ai)
}
/(1− Φ(H−k (m˜k) + µ0k + ai))2
]
∂Eˆ3k
∂µ1k
= Eˆ
[
∂O3k
∂µ1k
]
= Eˆ
[{ 1
σ21k
(H+k (Mk)− µ1k − ai)φ((H+k (Mk)− µ1k − ai)/σ1k)
(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))−
1
σ1k
φ2((H+k (Mk)− µ1k − ai)/σ1k)
}
/
(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))2
]
∂Eˆ4k
∂µ1k
= Eˆ
[
∂O4k
∂µ1k
]
= Eˆ
[{
− 1
σ21k
(H−k (m˜k) + µ1k + ai)φ((H
−
k (m˜k) + µ1k + ai)/σ1k)
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)) +
1
σ1k
φ2(H−k (m˜k) + µ1k + ai)/σ1k)
}
/
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))2
]
∂Eˆ3k
∂σ21k
= Eˆ
[
∂O3k
∂σ21k
]
= Eˆ
[{ 1
2σ41k
(H+k (Mk)− µ1k − ai)2φ((H+k (Mk)− µ1k − ai)/σ1k)
(1− Φ(H+k (Mk)− µ1k − ai)/σ1k)−
1
2
(σ21k)
−3/2(H+k (Mk)− µ1k − ai)
φ2((H+k (Mk)− µ1k − ai)/σ1k)
}
/(1− Φ(H+k (Mk)− µ1k − ai)/σ1k))2
]
∂Eˆ4k
∂σ21k
= Eˆ
[
∂O4k
∂σ21k
]
= Eˆ
[{ 1
2σ41k
(H−k (m˜k) + µ1k + ai)
2φ((H−k (m˜k) + µ1k + ai)/σ1k)
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))−
1
2
(σ21k)
−3/2(H−k (m˜k) + µ1k + ai)
φ2((H−k (m˜k) + µ1k + ai)/σ1k)
}
/(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))2
]
∂Eˆ5k
∂σ21k
= Eˆ
[
∂O5k
∂σ21k
]
= Eˆ
[{ 1
2σ41k
(H+k (Mk)− µ1k − ai)3φ((H+k (Mk)− µ1k − ai)/σ1k)
(1− Φ(H+k (Mk)− µ1k − ai)/σ1k)−
1
2
(σ21k)
−3/2(H+k (Mk)− µ1k − ai)2
φ2((H+k (Mk)− µ1k − ai)/σ1k)
}
/(1− Φ(H+k (Mk)− µ1k − ai)/σ1k))2
]
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∂Eˆ6k
∂σ21k
= Eˆ
[
∂O6k
∂σ21k
]
= Eˆ
[{ 1
2σ41k
(H−k (m˜k) + µ1k + ai)
3φ((H−k (m˜k) + µ1k + ai)/σ1k)
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))−
1
2
(σ21k)
−3/2(H−k (m˜k) + µ1k + ai)
2
φ2((H−k (m˜k) + µ1k + ai)/σ1k)
}
/(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))2
]
∂Eˆ1k
∂h+jk
= Eˆ
[
∂O1k
∂h+jk
]
= Eˆ
[{
− (H+k (Mk)− µ0k − ai)φ(H+k (Mk)− µ0k − ai)
(1− Φ(H+k (Mk)− µ0k − ai)) I(Xjk ≤Mk) + φ2(H+k (Mk)− µ0k − ai)
I(Xjk ≤Mk)
}
/(1− Φ(H+k (Mk)− µ0k − ai))2
]
, Xjk > 0, j = 1, · · · , n+k
∂Eˆ3k
∂h+jk
= Eˆ
[
∂O3k
∂h+jk
]
= Eˆ
[{
− 1
σ21k
(H+k (Mk)− µ1k − ai)φ((H+k (Mk)− µ1k − ai)/σ1k)
(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))I(Xjk ≤Mk) + (σ21k)−1/2φ2((H+k (Mk)
−µ1k − ai)/σ1k)I(Xjk ≤Mk)
}
/(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))2
]
,
Xjk > 0, j = 1, · · · , n+k
∂Eˆ2k
∂h−jk
= Eˆ
[
∂O2k
∂h−jk
]
= Eˆ
[{
− (H−k (m˜k) + µ0k + ai)φ(H−k (m˜k) + µ0k + ai)
(1− Φ(H−k (m˜k) + µ0k + ai))I(X˜jk ≤ m˜k) + φ2(H−k (m˜k) + µ0k + ai)
I(X˜jk ≤ m˜k)
}
/(1− Φ(H−k (m˜k) + µ0k + ai))2
]
, X˜jk > 0, j = 1, · · · , n−k
∂Eˆ4k
∂h−jk
= Eˆ
[
∂O4k
∂h−jk
]
= Eˆ
[{
− 1
σ21k
(H−k (m˜k) + µ1k + ai)φ((H
−
k (m˜k) + µ1k + ai)/σ1k)
(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))I(X˜jk ≤ m˜k) + (σ21k)−1/2φ2((H−k (m˜k)
+µ1k + ai)/σ1k)I(X˜jk ≤ m˜k)
}
/(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))2
]
,
X˜jk > 0, j = 1, · · · , n−k
2.9.2 Variance Estimation
Let θˆ∗ ≡ (θˆ, Σˆa) be the estimates of θ = (µ01, µ02, µ11, µ12, σ211, σ212) and Σa at con-
vergence. We estimate the variance of (θˆ∗, Hˆ+, Hˆ−) with observed information matrix
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of θˆ∗ and jump sizes Hˆ+k {Xik} and Hˆ−k {X˜ik} by Louis’s formula (1982). Note that
Hˆ+k (Xik) =
∑
Xjk≤Xik Hˆ
+
k {Xjk} and Hˆ−k (X˜ik) =
∑
X˜jk≤X˜ik Hˆ
−
k {X˜jk}. Let li(θ∗, H+, H−)
be the complete data log likelihood function for ith subject and δ ≡ (θ∗, H+, H−). De-
fine Ui(δˆ) =
∂
∂δ
li(δˆ)
∣∣∣
δ=δˆ
= (U ′i(θˆ∗), U
′
i(Hˆ
+), U ′i(Hˆ
−))′ and U˙i(δ) =
∂
∂δ
Ui(δˆ). Then,
the observed information matrix is estimated by
−∑ni=1E[U˙i(δˆ)|Xi, Di, δˆ]−∑ni=1{E[Ui(δˆ)U ′i (δˆ)|Xi, Di, δˆ]
+E[Ui(δˆ)|Xi, Di, δˆ]E ′ [Ui(δˆ)|Xi, Di, δˆ]}.
Complete data log likelihood function for ith subject is expressed as
li(θ
∗, H+, H−) =
2∑
k=1
δOiklogH
+
k {Xik}I(Xik > 0) +
2∑
k=1
[{
− δ
O
ik
2
(H+k (Xik)− µ0k − ai)2
+δRiklog(1− Φ(H+k (Mk)− µ0k − ai))
}
(1−Di)
+
2∑
k=1
{
− δ
O
ik
2
(
logσ21k +
1
σ21k
(H+k (Xik)− µ1k − ai)2
)
+δRiklog(1− Φ((H+k (Mk)− µ1k − ai)/σ1k))
}
Di
]
I(Xik > 0)
+
2∑
k=1
δOiklogH
−
k {X˜ik}I(X˜ik > 0) +
2∑
k=1
[{
− δ
O
ik
2
(H−k (X˜ik) + µ0k + ai)
2
+(1− δOik − δRik)log(1− Φ(H−k (m˜k) + µ0k + ai))
}
(1−Di)
+
2∑
k=1
{
− δ
O
ik
2
(
logσ21k +
1
σ21k
(H−k (X˜ik) + µ1k + ai)
2
)
+(1− δOik − δRik)log(1− Φ((H−k (m˜k) + µ1k + ai)/σ1k))
}
Di
]
I(X˜ik > 0) + logφ(ai;σ
2) (2.16)
The elements of Ui(δ) and U˙i(δ) for fixed i (i = 1, · · · , n) are computed below.
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B.3. Ui(δ) = (Ui(θ
∗), Ui(H+), Ui(H−))′
Ui(µ0k) =
∂li
∂µ0k
=
[
δOik(H
+
k (Xik)− µ0k − ai) + δRik
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
]
I(Xik > 0)(1−Di)−
[
δOik(H
−
k (X˜ik) + µ0k + ai)
+(1− δOik − δRik)
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
]
I(X˜ik > 0)(1−Di)
Ui(µ1k) =
∂li
∂µ1k
=
[
δOik
σ21k
(H+k (Xik)− µ1k − ai)
+δRik(σ
2
1k)
−1/2 φ((H
+
k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
]
I(Xik > 0)Di
−
[
δOik
σ21k
(H−k (X˜ik) + µ1k + ai)
+(1− δOik − δRik)(σ21k)−1/2
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]
I(X˜ik > 0)Di
Ui(σ
2
1k) =
∂li
∂σ21k
=
1
2
[
δOik
σ41k
(−σ21k + (H+k (Xik)− µ1k − ai)2 + δRik(σ21k)−3/2
(H+k (Mk)− µ1k − ai)
φ((H+k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
]
I(Xik > 0)Di
+
1
2
[
δOik
σ41k
(−σ21k + (H−k (X˜ik) + µ1k + ai))2 + (1− δOik − δRik)
(σ21k)
−3/2(H−k (m˜k) + µ1k + ai)
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
]
I(X˜ik > 0)Di
Ui(σ
2) =
∂li
∂σ2
= − 1
2σ2
+
a2i
2σ4
Ui(H
+
k {Xjk}) =
∂li
∂H+k {Xjk}
=
δOjkI(i = j)
H+k {Xjk}
−
[
δOik(H
+
k (Xik)− µ0k − ai)I(Xjk ≤ Xik)
+δRik
φ(H+k (Mk)− µ0k − ai)
1− Φ(H+k (Mk)− µ0k − ai)
I(Xjk ≤Mk)
]
I(Xik > 0)(1−Di)
−
[
δOik
σ21k
(H+k (Xik)− µ1k − ai)I(Xjk ≤ Xik)
+δRik(σ
2
1k)
−1/2 φ((H
+
k (Mk)− µ1k − ai)/σ1k)
1− Φ((H+k (Mk)− µ1k − ai)/σ1k)
I(Xjk ≤Mk)
]
I(Xik > 0)Di, Xjk > 0, j = 1, · · · , n+k
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Ui(H
−
k {X˜jk}) =
∂li
∂H−k {X˜jk}
=
δOjkI(i = j)
H−k {X˜jk}
−
[
δOik(H
−
k (X˜ik) + µ0k + ai)I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)
φ(H−k (m˜k) + µ0k + ai)
1− Φ(H−k (m˜k) + µ0k + ai)
I(X˜jk ≤ m˜k)
]
I(X˜ik > 0)(1−Di)−
[
δOik
σ21k
(H−k (X˜ik) + µ1k + ai)I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)(σ21k)−1/2
φ((H−k (m˜k) + µ1k + ai)/σ1k)
1− Φ((H−k (m˜k) + µ1k + ai)/σ1k)
I(X˜jk ≤ m˜k)
]
I(X˜ik > 0)Di, X˜jk > 0 j = 1, · · · , n−k
B.4. U˙i(δ) =
∂
∂δ
Ui(δ)
∂Ui(µ0k)
∂µ0k
=
[
−δOik + δRik
∂O1k
∂µ0k
]
I(Xik > 0)(1−Di)
−
[
δOik + (1− δOik − δRik)
∂O2k
∂µ0k
]
I(X˜ik > 0)(1−Di)
∂Ui(µ0k)
∂µ1k
=
∂Ui(µ1k)
∂µ0k
= 0
∂Ui(µ0k)
∂σ21k
=
∂Ui(σ
2
1k)
∂µ0k
= 0
∂Ui(µ0k)
∂σ2
=
∂Ui(σ
2)
∂µ0k
= 0
∂Ui(µ0k)
∂H+k {Xjk}
=
∂Ui(H
+
k {Xjk})
∂µ0k
=
[
δOikI(Xjk ≤ Xik) + δRik
∂O1k
∂H+k {Xjk}
]
I(Xik > 0)
(1−Di), Xjk > 0, j = 1, · · · , n+k
∂Ui(µ0k)
∂H−k {X˜jk}
=
∂Ui(H
−
k {X˜jk})
∂µ0k
= −
[
δOikI(X˜jk ≤ X˜ik) + (1− δOik − δRik)
∂O2k
∂H−k {X˜jk}
]
I(X˜ik > 0)(1−Di), X˜jk > 0, j = 1, · · · , n−k
∂Ui(µ1k)
∂µ1k
=
[
− δ
O
ik
σ21k
+
δRik
σ1k
∂O3k
∂µ1k
]
I(Xik > 0)Di
−
[
δOik
σ21k
+
(1− δOik − δRik)
σ1k
∂O4k
∂µ1k
]
I(X˜ik > 0)Di
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∂Ui(µ1k)
∂σ21k
=
∂Ui(σ
2
1k)
∂µ1k
=
[
− δ
O
ik
σ41k
(H+k (Xik)− µ1k − ai) + δRik
{
− 1
2
(σ21k)
−3/2O3k
+(σ21k)
−1/2∂O3k
∂σ21k
}]
I(Xik > 0)Di −
[
− δ
O
ik
σ41k
(H−k (X˜ik) + µ1k + ai)
+(1− δOik − δRik)
{
− 1
2
(σ21k)
−3/2O4k + (σ21k)
−1/2∂O4k
∂σ21k
}]
I(X˜ik > 0)Di
∂Ui(µ1k)
∂σ2
=
∂Ui(σ
2)
∂µ1k
= 0
∂Ui(µ1k)
∂H+k {Xjk}
=
∂Ui(H
+
k {Xjk})
∂µ1k
=
[
δOik
σ21k
I(Xjk ≤ Xik) + δRik(σ21k)−1/2
∂O3k
∂H+k {Xjk}
]
I(Xik > 0)Di, Xjk > 0, j = 1, · · · , n+k
∂Ui(µ1k)
∂H−k {X˜jk}
=
∂Ui(H
−
k {Xjk})
∂µ1k
= −
[
δOik
σ21k
I(X˜jk ≤ X˜ik) + (1− δOik − δRik)
(σ21k)
−1/2 ∂O4k
∂H−k {X˜jk}
]
I(X˜ik > 0)Di, X˜jk > 0, j = 1, · · · , n−k
∂Ui(σ
2
1k)
∂σ21k
=
1
2
[
δOik
{ 1
σ41k
− 2
σ61k
(H+k (Xik)− µ1k − ai)2
}
+δRik
{
− 3
2
(σ21k)
−5/2O5k + (σ21k)
−3/2∂O5k
∂σ21k
}]
I(Xik > 0)Di
+
1
2
[
δOik
{ 1
σ41k
− 2
σ61k
(H−k (X˜ik) + µ1k + ai)
2
}
+ (1− δOik − δRik){
− 3
2
(σ21k)
−5/2O6k + (σ21k)
−3/2∂O6k
∂σ21k
}]
I(X˜ik > 0)Di
∂Ui(σ
2
1k)
∂σ2
=
∂Ui(σ
2)
∂σ21k
= 0
∂Ui(σ
2
1k)
∂H+k {Xjk}
=
∂Ui(H
+
k {Xjk})
∂σ21k
=
[
δOik
σ41k
(H+k (Xik)− µ1k − ai)I(Xjk ≤ Xik)
−δRik
(
− 1
2
(σ21k)
−3/2O3k + (σ21k)
−1/2∂O3k
∂σ21k
)
I(Xjk ≤Mk)
]
I(Xik > 0)Di
Xjk > 0, j = 1, · · · , n+k
∂Ui(σ
2
1k)
∂H−k {X˜jk}
=
∂Ui(H
−
k {X˜jk})
∂σ21k
=
[
δOik
σ41k
(H−k (X˜ik) + µ1k + ai)I(X˜jk ≤ X˜ik)
−(1− δOik − δRik)
(
− 1
2
(σ21k)
−3/2O4k + (σ21k)
−1/2∂O4k
∂σ21k
)
I(X˜jk ≤ m˜k)
]
I(X˜ik > 0)Di, X˜jk > 0, j = 1, · · · , n−k
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∂Ui(σ
2)
∂σ2
=
1
2σ4
− a
2
i
σ6
∂Ui(σ
2)
∂H+k {Xjk}
=
∂Ui(H
+
k {Xjk})
∂σ2
= 0, j = 1, · · · , n+k
∂Ui(σ
2)
∂H−k {X˜jk}
=
∂Ui(H
−
k {X˜jk})
∂σ2
= 0, j = 1, · · · , n−k
∂Ui(H
+
k {Xjk})
∂H+k {Xj′k}
= −δ
O
jkI(i = j = j
′)
(H+k {Xjk})2
I(Xjk > 0)−
[
δOikI(Xj′k ≤ Xik)I(Xjk ≤ Xik)
+δRik
∂O1k
∂H+k {Xj′k}
I(Xjk ≤Mk)
]
I(Xik > 0)(1−Di)
−
[
δOik
σ21k
I(Xj′k ≤ Xik)I(Xjk ≤ Xik) + δRik(σ21k)−1/2
∂O3k
∂H+k {Xj′k}
I(Xjk ≤Mk)
]
I(Xik > 0)Di, Xjk > 0, Xj′k > 0, j, j
′ = 1, · · · , n+k
∂Ui(H
+
k {Xjk})
∂H−k {X˜j′k}
=
∂Ui(H
−
k {X˜j′k})
∂H+k {Xjk}
= 0, Xjk > 0, X˜j′k > 0, j = 1, · · · , n+k ; j′ = 1, · · · , n−k
∂Ui(H
−
k {X˜jk})
∂H−k {X˜j′k}
= −δ
O
jkI(i = j = j
′)
(H−k {X˜jk})2
I(X˜jk > 0)−
[
δOikI(X˜j′k ≤ X˜ik)I(X˜jk ≤ X˜ik)
+(1− δOik − δRik)
∂O2k
∂H−k {X˜j′k}
I(X˜jk ≤ m˜k)
]
I(X˜ik > 0)(1−Di)
−
[
δOik
σ21k
I(X˜j′k ≤ X˜ik)I(X˜jk ≤ X˜ik) + (1− δOik − δRik)(σ21k)−1/2
∂O4k
∂H−k {X˜j′k}
I(X˜jk ≤ m˜k)
]
I(X˜ik > 0)Di, X˜jk > 0, X˜j′k > 0, j, j
′ = 1, · · · , n−k
2.9.3 The Optimal AUC and its Variance
The linear combination of H1(X1) and H2(X2), β1H1(X1) + β2H2(X2) (β = (β1, β2)
′
)
follows a multivariate normal distribution with
β1H1(X1) + β2H2(X2)|D = 0 ∼ N(β′µ0, β′(σ211′ + Σ0)β)
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β1H1(X1) + β2H2(X2)|D = 1 ∼ N(β′µ1, β′(σ211′ + Σ1)β).
The coefficients for the best linear combination are βopt,Z = (Σ1+Σ0+2σ
211′)−1(µ1−
µ0) and the area under the ROC curve of the optimal linear combination is
AUCopt,Z = Φ
√
(µ1 − µ0)T (Σ1 + Σ0 + 2σ211′)−1(µ1 − µ0).
Define η =
√
(µ1 − µ0)T (Σ1 + Σ0 + 2σ211′)−1(µ1 − µ0) and θ∗ ≡(θ, σ2) with θ ≡
(µ01, µ02, µ11, µ12, σ
2
11, σ
2
12). Then, using the multivariate delta method, the variance
of AUCopt,Z given by
(φ(η))2
{
g2
4g31
V ar(g1) +
1
4g1g2
V ar(g2)− 1
2g21
Cov(g1, g2)
}
,
where
g1(θ
∗) = (σ211 + 2σ
2 + 1)(σ212 + 2σ
2 + 1)− 4σ2 and
g2(θ
∗) = (σ212+2σ
2+1)(µ11−µ01)2+(σ211+2σ2+1)(µ12−µ02)2−4σ2(µ11−µ01)(µ12−µ02).
Let Σθ∗ denote the covariance of θ
∗. The covariance of g1 and g2 is Σg1,g2 = ∇g(θ∗)TΣθ∗∇g(θ∗),
where
∇g(θ∗) =

0 −2(µ11 − µ01)(σ212 + 2σ2a + 1) + 4σ2a(µ12 − µ02)
0 −2(µ12 − µ02)(σ211 + 2σ2a + 1) + 4σ2a(µ11 − µ01)
0 2(µ11 − µ01)(σ212 + 2σ2a + 1)− 4σ2a(µ12 − µ02)
0 2(µ12 − µ02)(σ211 + 2σ2a + 1)− 4σ2a(µ11 − µ01)
(σ212 + 2σ
2
a + 1) (µ12 − µ02)2
(σ211 + 2σ
2
a + 1) (µ11 − µ01)2
2(σ211 + σ
2
12 + 2) 2(µ11 − µ01)2 + 2(µ12 − µ02)2 − 4(µ11 − µ01)(µ12 − µ02)

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Chapter 3
Accelerated Regression Model in
the ROC Analysis
3.1 Introduction
Recent technological advances continue to provide non-invasive and more accurate
biomarkers for evaluating disease status and patients’ treatment response. Examples
include the use of Prostate-Specific Antigen and CA-125 to detect the presence of
prostate cancer and ovarian cancer, respectively. The Receiver-Operating Character-
istic (ROC) curve is a useful tool to assess the accuracy of biomarkers for diagnosis
and prognosis of disease (Swets and Pickett, 1982; Hanley, 1989; Pepe 2000b). Let Y1
denote the biomarker for diseased subjects and Y0 denote the biomarker for nondiseased
subjects. Let c be a threshold value that any test results greater than c are considered
to be positive. Without loss of generality, we assume that higher values of test results
are more indicative of disease. Then, for a given threshold c, the true positive and false
positive rates are respectively
S1(c) = P (Y1 ≥ c) and S0(c) = P (Y0 ≥ c).
The ROC curve is a plot of the true positive rates versus the false positive rates,
ROC(· ) = {(S0(c), S1(c)), c ∈ (−∞,∞)}. Equivalently, the ROC function can be
expressed as ROC(· ) = {(t, ROC(t)), t ∈ (0, 1)} = {(t, S1(S−10 (t)), t ∈ (0, 1)}.
The performance of a diagnostic test can be influenced by risk factors. For example,
subject characteristics such as age and gender, the experience and expertise of persons
performing the test, and the environment in which and the time when a test is performed
can affect test results. Thus, it is important to identify such factors to understand and
determine the optimal conditions for the best performance.
In the existing literature, three approaches to incorporating covariate effects into
ROC analysis have been suggested (Pepe, 1998). The first approach is to model the
ROC curve summary indices as a function of covariates. Dorfman et al. (1992) and
Obuchowski (1995) suggested modeling the area under the curve (AUC), while Thomp-
son and Zucchini (1989) recommended modelling the partial area under the curve
(pAUC). This approach is feasible only when covariates are discrete and there are
enough patients in each covariate combination to permit the reliable calculation of the
summary accuracy measure. The second approach is to model the distributions of
test results as a function of disease status and covariates. Tosteson and Begg (1988)
described the use of ordinal regression model to induce the regression models for the
ROC curve for tests with ordinal outcomes. Their method has been extended to random
effects models (Beam, 1995; Gatsonis, 1995) and Bayesian methods (Peng and Hall,
1996; Hellmich et al. 1998; Ishwaran and Gatsonsis, 2000). However, in this approach,
the parameter estimates do not reflect the covariate effects on the ROC curve. The
third approach directly models covariate effects on the ROC curve (Pepe 1997, 2000a;
Alonzo and Pepe, 2001). It is called the parametric distribution free approach since it
only assumes a parametric model for the ROC curve but is distribution-free regarding
the distribution of the test results. The most important advantage of this approach is
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that the interpretation of model parameters pertains directly to the ROC curves.
Specifically, in the the third approach mentioned above, Pepe (1997, 2000a) pro-
posed the parametric ROC regression models of the generalized linear model (GLM)
form,
ROCX(t) = g(h(t) + β
TX), t ∈ (0, 1),
where ROCX(t) denotes the ROC curve at a false positive rate t associated with co-
variates X, g(.) is a known link function, and h(.) is a baseline function specified up
to some real parameters. The baseline function h defines the location and shape of the
ROC curve, and β quantifies covariate effects. Recently, Cai and Pepe (2002) extended
the parametric ROC regression model to a semi-parametric approach by allowing an
arbitrary nonparametric baseline function for h. They assumed a semiparametric lo-
cation model for S0(y|X) (Pepe 1998; Heagerty and Pepe 1999) and constructed high-
dimensional estimating equations for β and h. They showed that their semiparametric
methods fit the model with efficiency comparable to that of the fully parametric ap-
proach. Note that the last two models assume that the effects of covariates are related
to the location shift of the same ROC curve. This may not be true in some practice.
In this chapter, we develop an alternative regression model, namely, the acceler-
ated ROC model by adjusting for covariates that can influence the performance of a
biomarker. We consider modeling covariates directly on the ROC curve and our model
generalizes the usual accelerated failure time model in the survival context to the ROC
analysis. In Section 3.2, we describe an accelerated ROC model as well as the proce-
dures for estimating parameters of covariates β and the ROC function. The asymptotic
properties of β and the ROC function are given in Section 3.3 and the simulation studies
are followed in Section 3.4. As an example, we apply our method to a prostate cancer
dataset in Section 3.5. A discussion and all technical proofs are given in Sections 3.6
and 3.7, respectively.
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3.2 Model and Inference Procedure
Suppose we observe n1 biomarker measurements from diseased subjects and n0 biomarker
measurements from nondiseased subjects. Yi1 (i = 1, · · · , n1) denotes the biomarker
measurement for diseased subject i and Yj0 denotes biomarker measurements for nondis-
eased subject j. We assume that each subject may have more than one type of covariates
and denote them asXi1 andXj0 for diseased subject i and nondiseased subject j, respec-
tively. In most practice, the biomarker measurement is subject to an upper detection
limit, denoted by τ . Thus, the observed data consist of {(min(Yi1 ∧ τ), Xi1,∆i1), i =
1, · · · , n1} for diseased subjects and {(min(Yj0∧τ), Xj0,∆j0), j = 1, · · · , n0} for nondis-
eased subjects, where ∆i1 = I(Yi1 ≤ τ) and ∆j0 = I(Yj0 ≤ τ).
To model the covariate effects on the ROC curve, we propose the following acceler-
ated ROC model,
ROCX(t) = G(e
βTX logt), t ∈ (0, 1), (3.1)
where G(.) is an unknown and increasing function satisfying G(0) = 1 and G(−∞) = 0.
The latter is because ROC(1) = 1 and ROC(0) = 0. Note that the effect of X in the
ROC model relates to rescaling the original ROC curve. To see how this is different from
the model in Pepe (1997, 2000a), we plot the ROC curves based on these two models in
Figure 3.1, where the the ROC curve on the left side is based on the parametric ROC
regression model by Pepe (1997, 2000a) and the ROC curve on the right side is based
on our accelerated ROC model (3.1). It is clear that our model implies the covariate
affects sensitivity dramatically for the low false positive rates compared to the model
in Pepe (1997, 2000a).
The model (3.1) can be rewritten as
S1(Y |X) = G(eβTX logS0(Y |X)). (3.2)
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Figure 3.1: ROC1(t) = Φ(0.6X + 0.8Φ
−1(t)), ROC2(t) = exp(0.5e−0.8X log(t))
Note that we do not make any assumptions on the model for S0(Y |X). To estimate β,
we define Zi1 = −logS0(Yi1|Xi1). Using equation (3.2), it can be shown that
P (Zi1 ≤ z|Xi1) = 1− P (−logS0(Yi1) > z|Xi1) = 1−G(eβTXi1 loge−z)
= 1−G(−zeβTXi1) ≡ F (zeβTXi1),
with F (x) = 1−G(−x). Hence, Zi1 satisfies the accelerated failure time model, so the
inference for β can be conducted by solving the log-rank estimating equation, which is
commonly used for the estimation in the accelerated failure time model. Specifically,
the log-rank estimating equation is given by
n1∑
i=1
∆i1
{
Xi1 −
∑
j I(logZj1 + β
TXj1 ≥ logZi1 + βTXi1)Xj1∑
j I(logZj1 + β
TXj1 ≥ logZi1 + βTXi1)
}
= 0. (3.3)
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Since S0 is unknown, we estimate S0 nonparametrically using the smoothed Breslow
estimator as follows:
Sˆ0(y|x) = exp
{
−
n0∑
j=1
I(Yj0 ≤ y) 4j0Kan(Xj0 − x)∑n0
k=1 I(Yk0 ≥ Yj0)Kan(Xk0 − x)
}
, (3.4)
where Kan(x) = K(x/an)/a
d
n with an being the bandwidth and d the dimension of X.
Thus, Zi1 is estimated by Zˆi1 = −logSˆ0(Yi1|Xi1). After plugging Zˆi1 into (3.3), βˆ is
obtained by solving
n1∑
i=1
∆i1
{
Xi1 −
∑
j I(logZˆj1 + βˆ
TXj1 ≥ logZˆi1 + βˆTXi1)Xj1∑
j I(logZˆj1 + βˆ
TXj1 ≥ logZˆi1 + βˆTXi1)
}
= 0.
Remark 3.1. When X is discrete, the estimator for S0, Sˆ0(y|x) in (3.4) can be replaced
by the Breslow estimator using the data with Xj0 = x. i.e.,
Sˆ0(y|x) = exp
{
−
n0∑
j=1
I(Yj0 ≤ y)4j0I(Xj0 = x)∑n0
k=1 I(Yk0 ≥ Yj0)I(Xk0 = x)
}
.
Remark 3.2. When X has more than one continuous covariate, the kernel estimate Sˆ0
may not perform well with a moderate sample size. In this case, we suggest estimating
S0(y|x) based on the Cox regression model using the nondiseased data. That is,
Sˆ0(y|x) = exp
[
− Λˆ(y)exp(γˆTx)
]
,
where Λˆ(y) is the estimated cumulative baseline cumulative function and γˆ is the re-
gression parameter estimate.
We next describe the procedures for estimating the functionG and the ROC function
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given in (3.1). Clearly, P (Zi1e
βTXi1 ≤ z|Xi1) = 1 − G(−z). Therefore, Zi1eβTXi1 is
independent of Xi1 and has distribution function 1−G(−z). This implies that we can
estimate G consistently by using the empirical distribution of Wi1 ≡ Zi1eβTXi1 . Since
Zi1 is subject to right-censoring, so is Wi1. We use the Kaplan-Meier estimator to
estimate the survival function of Wi1. After replacing Wi1 with its estimate
Wˆi1 = −eβˆTXi1 log Sˆ0(Yi1;Xi1), i = 1, ..., n1,
we estimate G(·) using
Gˆ(t) =
n1∏
i=1
[
1− ∆i1I(Wˆi1 ≤ −t)∑n1
j=1 I(Wˆj1 ≥ Wˆi1)
]
. (3.5)
Finally, the ROC curve for any covariate value X is estimated by
R̂OCX(t) = Ĝ(e
βˆTX logt), t ∈ (0, 1). (3.6)
To make inference, we estimate the variances of βˆ and Gˆ using the bootstrap
method; Bootstrap samples are drawn repeatedly with replacement from the dataset,
and for each bootstrap sample, β and G are estimated. We then use the variances of
these βˆ’s and Gˆ’s as our estimates. Alternatively, the variances can be estimated by a
different resampling method, which is described in Section 3.7.2.
Remark 3.3. The proposed approach can be generalized to handle the situation when
each subject may have multiple or repeated biomarkers. In this case, the estimating
equation for β is replaced by
n1∑
i=1
ni1∑
k=1
∆ik1
{
Xik1 −
∑
j
∑nj1
l=1 I(logZˆjl1 + βˆ
TXjl1 ≥ logZˆik1 + βˆTXik1)Xjl1∑
j
∑nj1
l=1 I(logZˆjl1 + βˆ
TXjl1 ≥ logZˆik1 + βˆTXik1)
}
= 0,
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where ∆ij1, Zˆij1 and Xij1 are the observations of jth measurement for subject i in the
diseased group, and Zˆij1 can be estimated similarly as Zˆi1. The bootstrapping method
can still be used for inference by randomly selecting subjects for each bootstrap sample.
3.3 Asymptotic Properties
In this section, we derive the asymptotic properties of βˆ and Gˆ. First, we assume the
following conditions hold.
(C.1) The true parameter value, β0, belongs to a compact set B.
(C.2) The true densities with respective to a dominating measure for (Y1, C1, X1) and
(Y0, C0, X0) are (χ + 1)-continuously differentiable, where χ > d/2. Additionally, X1
and X0 have bounded support.
(C.3) The matrix [1, X1] is linearly independent with positively.
(C.4) The kernel function K(·) is differentiable with bounded symmetric support and
first (χ− 1) moments begin zero. Moreover, nadn →∞ and na2χn → 0.
(C.5) n0/n→ ν ∈ (0, 1), where n = n0 + n1.
(C.1) and (C.5) are standard conditions for this type of problem. In (C.2), both
C1 and C2 are same as τ based on our model. (C.3) ensures the identifiability of the
regression parameters, and (C.4) states the restrictions on the choice of possible ker-
nel functions. Examples of the kernel function include the Gaussian kernel and the
Epanechnikov kernel for χ = 2. Both (C.2) and (C.4) are necessary conditions to
prove the asymptotic distribution of βˆ. Obviously, if S0 is estimated using the Breslow
method with discrete X1 or from the Cox regression method, (C.4) is not needed.
Under these conditions, the following consistency theorem holds.
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Theorem 3.1. Under Conditions (C1)-(C5), |β̂ − β0| →a.s. 0.
The following two theorems state the asymptotic normality of βˆ and Gˆ.
Theorem 3.2. Under Conditions (C1)-(C5),
√
n(βˆ − β0) converges in distribution to
a mean zero normal random vector as n→∞.
Theorem 3.3. Under Conditions (C1)-(C5),
√
n(Gˆ(log t)−G0(log t)) converges weakly
to a zero mean Gaussian process in l∞([0, 1]).
The proofs of Theorems 3.1-3.3 are provided in Section 3.7. For the proof of Theorem
3.1, we use the fact that Sˆ0(y;x) converges uniformly in (y, x) to S0(y;x) as n goes to
∞, which is given in Zeng (2004). We then apply Theorems 2.10.3 and 5.9 of van der
Vaart (1998). The proofs of Theorem 3.2 and 3.3 follow the same arguments as in
Zeng (2004), and we use the central limit theorems for the empirical process indexed
by classes depending on samples (Theorem 2.11.23, van der Vaart and Wellner, 1996).
3.4 Simulation Studies
Simulation studies were conducted to examine the performance of the proposed method.
First, we defined the true function of G as G(x) = exp(αx). Then, the ROC function
given in (3.1) becomes ROCX(t) = exp[αe
βTX log(t)]. The biomarker values for diseased
and non-diseased subjects, y1 and y0, were generated by
y0 = −ln(U0)/(exp(γTX)) and y1 = −ln(U1)/(αexp(γTX + βTX)), (3.7)
where U0 and U1 are uniform random variables from U [0, 1]. It is easy to check such (y0,
y1) gives the above ROC function. We used an equal number of diseased and nondis-
eased subjects but varied the total sample size n from 200 to 400. Additionally, we set
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the upper detection limit τ as the 95th percentile of the biomarker in the nondiseased
group.
We conducted three different simulations with different types of covariates. For
the first simulation, a binary covariate X was generated from a Bernoulli distribution
with probability 0.5 and true parameters in (3.7) were set to β = 0.5, γ = −0.5 and
α = 0.5. Because X was discrete, we estimated S0(y|x) using the Breslow estimator
given in Remark 3.1. In the second simulation, we used a continuous covariate generated
from uniform (0,1) distribution, and true parameters were set to β = −1, γ = −0.5
and α = 1.5. In this simulation, S0(y|x) was estimated using the smoothed Breslow
estimator given in (3.4), where the Gaussian kernel function K(x) =
1√
2pi
exp(−x2/2)
with an = n1
−1/3 were applied. For the last simulation, two continuous covariates,
both generated from uniform (0,1), were used with β = (−1.2,−2)T , γ = (−2, 2)T and
α = 5. We then fitted the Cox model to estimate Sˆ0 as described in Remark 3.2. In
all the simulation studies, we obtained βˆ by solving the log-rank estimating equation
(3.3) through bisection search.
Table 3.1 summarizes the simulation results based on 1000 replicates. Column
“Est” is the average value of the estimates from 1,000 replicates; column “ASE” is the
average of the estimated standard errors by the bootstrap method with 1000 replicates;
column “SE” is the standard deviation of the estimates; column “CP” gives the (100×)
coverage proportion of the 95% confidence intervals based on the asymptotic normality.
Overall, the estimates for β are very close to the actual values across sample sizes, and
the estimated standard errors using the bootstrap method approximate the empirical
standard errors well. In addition, the coverage proportions of 95% CIs are close to the
nominal level of 95% across sample sizes. In the same table, we present the true and
estimated function G at three fixed points, where the three points were chosen to be
the quartiles of the true distribution of −W1 (= −eβTX1 logS0(Y1;X1)). The coverage
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Table 3.1: Simulation results with G(t) = exp(αt)
n1 = n0 = 100 n1 = n0 = 200
Par. True Est ASE SE CP Est ASE SE CP
Simulation Study 1. X: 0 or 1
β 0.5 0.479 0.309 0.302 95.7 0.517 0.219 0.210 94.9
G(−2.7) 0.259 0.255 0.081 0.080 95.6 0.262 0.060 0.060 93.0
G(−1.3) 0.522 0.519 0.084 0.082 94.8 0.524 0.060 0.059 94.0
G(−0.5) 0.779 0.774 0.063 0.060 96.0 0.778 0.044 0.042 94.3
Simulation Study 2. X ∼ Uniform(0,1)
β -1 -1.120 0.510 0.494 95.4 -1.123 0.364 0.346 94.7
G(−0.8) 0.301 0.282 0.103 0.101 96.9 0.279 0.076 0.076 94.9
G(−0.4) 0.549 0.525 0.109 0.106 94.3 0.526 0.080 0.077 94.3
G(−0.15) 0.799 0.780 0.080 0.076 95.1 0.782 0.056 0.053 95.0
Simulation Study 3. X1 ∼ Uniform(0,1), X2 ∼ Uniform(0,1)
β1 -1.2 -1.196 0.582 0.564 95.2 -1.198 0.393 0.376 95.4
β2 -2 -2.064 0.578 0.575 95.6 -2.029 0.392 0.384 95.0
G(−0.26) 0.273 0.272 0.135 0.141 92.3 0.275 0.101 0.101 95.0
G(−0.14) 0.497 0.479 0.148 0.153 94.1 0.492 0.108 0.106 94.5
G(−0.06) 0.741 0.715 0.121 0.195 95.3 0.732 0.083 0.077 95.2
proportions of 95% CIs for G were calculated based on the log transformation of G.
For all simulations, the estimated values of G are very close to the actual values at
all three points. Figures 3.2-3.4 display the true and estimated ROC curves from the
three simulations. Apparently, all three figures show that estimated ROC curves are
extremely close to the true ROC curves.
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Figure 3.2: Plots of the true and estimated function G (n=200) from Simulation Study
1 (X: 0 or 1): the solid curve is the true G and the dashed curve is the average of the
estimated curves from 1,000 replicates.
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Figure 3.3: Plots of the true and estimated function G (n=200) from Simulation Study
2 (X∼ Uniform(0,1)): the solid curve is the true G and the dashed curve is the average
of the estimated curves from 1,000 replicates.
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Figure 3.4: Plots of the true and estimated function G (n=200) from Simulation Study
3 (X1, X2∼ Uniform(0,1)): the solid curve is the true G and the dashed curve is the
average of the estimated curves from 1,000 replicates.
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3.5 Application
We illustrate our approach with a prostate cancer dataset. Prostate-specific antigen
(PSA) is a protein produced by the prostate gland, and the PSA test measures the
level of PSA in the blood. Most healthy men have PSA levels under 4 nanograms per
milliliter (ng/mL) of blood, and the chance of having prostate cancer goes up as the
PSA level increases. PSA occurs in 2 major forms in the blood. One form is attached
to blood proteins while the other circulates free (unattached). The free PSA (fPSA)
is the ratio of how much PSA circulates free compared to the total PSA level. Low
free PSA may indicate prostate cancer and most men with prostate cancer have a free
PSA below 15%. If free PSA is below 7%, prostrate cancer is most likely. According to
American Cancer Society and National Cancer Institute, men with free PSA at 7% or
lower should undergo biopsy. We used a dataset of 71 prostate cancer subjects and 68
controls who participated in the Beta-Carotene and Retinol Efficacy Trial (CARET).
The objective of this analysis was to evaluate the capacity of free PSA for dis-
criminating men with prostate cancer from those without before the onset of clinical
symptoms. This trial enrolled 12,025 men at high risk of lung cancer as a result of
smoking or asbestos exposure and evaluated the efficacy of beta-carotene and retinol
in preventing lung cancer, which began in 1985 and terminated in 1994. Subjects who
participated in CARET had serum samples drawn at baseline and at two-year intervals
thereafter (Goodman et al., 1993; Etzioni et al., 1999). Blood samples drawn after
diagnosis of prostate cancer were excluded from this analysis, leaving on average 1 to 7
blood samples per subject (average 3.2 samples per case and 3.5 samples per control).
The average age was 63.7 (range from 46.7 to 80.8) and the average time was -3.06
years (range from -9.008 to -0.003 yrs). Previous studies have suggested that age and
the time PSA measured may affect the discrimination of prostate cancer. Let X be the
age when PSA was measured and T be the time between the onset of symptoms and
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the time at which the serum sample was drawn, so that time is negative and increase
to 0 as measurements are closer to the time of clinical diagnosis. We then fitted the
following accelerated ROC model adjusting for age X and time T :
ROCT,X(u) = G(e
βxX+βtT logu).
We found βˆx = 0.0485 with SE 0.0248 (p-value 0.0505) and βˆt = −0.0587 with SE
0.0442 (p-value 0.1841). The positive coefficient for age suggests that discrimination is
better in younger men than in old men, and the negative coefficient for time implies
that discrimination improves when PSA is measured closer to diagnosis although the
time T is not significant. Figure 3.5 displays the estimated ROC curves at age=57, 63,
and 68 when T=-2.82, which is the median of time T. The AUCs are 0.8579, 0.8103, and
0.7623 at age=57, 63, and 68, respectively. Again, it appears that free PSA performes
better for younger men. To assess the fit of our model, in Figure 3.6, we plotted the
empirical ROC curves for free PSA for each of three age groups where the groups were
based on the categorization of age X. The figure shows a similar pattern as Figure 3.5.
The empirical AUCs of each age group are 0.8575, 0.8062, and 0.7527 for age ≤ 61,
61< age ≤ 65, and age ≥ 65. The AUCs based on the proposed method agree well
with the empirical AUCs for these groups, demonstrating the good fit of the accelerated
regression model.
3.6 Discussion
In this chapter, we have focused on assessing the accuracy of biomarkers by adjusting
for covariates that could influence the performance of biomarkers. We developed an
accelerated ROC model by employing the properties of the accelerated failure time
model. Based on Pepe (1997, 2000a)’s method, the covariate effect is related to the
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Figure 3.5: Estimated ROC curve for PSA adjusted for age and time T
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Figure 3.6: Empirical ROC curve for PSA by time
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location-shift of the original ROC curves. On the other hand, in our proposed method,
the effect of covariates in the ROC model relates to rescaling the original ROC curve.
Therefore, our model provides a useful alternative to the traditional method. Note that
the parameter estimates of covariates based on the log-rank estimating equation may
not be efficient. Regarding this issue, we will explore other methods which attain the
semiparametric efficiency.
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3.7 Appendix
3.7.1 Proof of Theorem 3.1
With direct calculations, condition (C.3) implies that matrix
σ1 ≡ − ∂
∂β
E
[
∆1
Q1(logZ1 + β
TX1)
Q0(logZ1 + βTX1)
]
is positive for β ∈ B, where Q1(x) = E[X1I(logZ1+βTX1 ≥ x)] and Q0 = E[I(logZ1+
βTX1 ≥ x)]. Therefore, β0 must be the unique solution to the following equation
E
[
∆
(
X1 − Q1(logZ1 + β
TX1)
Q0(logZ1 + βTX1)
)]
= 0,
We introduce the following notations. We use Pn1 and P1 to denote the empir-
ical measure and expectation base on i.i.d observations in the diseased group, i.e.,
(Yi1, Xi1,∆i1), i = 1, ..., n1. Similarly, we use Pn0 and P0 to denote the empirical
measure and expectation based on i.i.d observations in the non-diseased group, i.e.,
(Yj0, Xj0,∆j0), j = 1, ..., n0. Moreover, we use Gn1 and Gn0 denote empirical processes
√
n1(Pn1 −P1) and √n0(Pn0 −P0) respectively. Thus, by definition, βˆ should solve
0 = Pn1
[
∆1
{
X1 −
∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βˆTX1)Xi1∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βˆTX1)
}]
.
We start to show the consistency of βˆ. First, conditional on non-diseased data,
(Zˆi1, Xi1,∆i1) are i.i.d. Therefore, the class
F ≡
{
I(x ≥ log Zˆ1 + βTX1) : x ∈ (−∞,∞), β ∈ B
}
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is the VC-class, so is Donsker. Note that the following random functions
n−1
n1∑
i=1
I(log Zˆi1+β
TXi1 ≥ log Zˆ1+βTX1)Xi1, n−1
n1∑
i=1
I(log Zˆi1+β
TXi1 ≥ log Zˆ1+βTX1),
and
E∗
[
I(log Zˆ1 + β
TX1 ≥ log Zˆ∗1 + βTX∗1 )X1
n−1
∑n1
i=1 I(log Zˆi1 + β
TXi1 ≥ log Zˆ∗1 + βTX∗1 )
]
,
where here and in the squeal, E∗ and E∗∗ denote the expectation with respect to those
random variables with asterisk and double asterisk respectively, can be expressed as
the limit of the convex combinations of F and are bounded from above. Thus, they
belong to sconvF , which is a Donsker class from Theorem 2.10.3 of van der Vaart and
Wellner (1996). Therefore, by the Glivenko-Cantelli theorem, it is easy to see
sup
β
∣∣∣Pn1 [∆1{X1 − ∑n1i=1 I(log Zˆi1 + βTXi1 ≥ log Zˆ1 + βTX1)Xi1∑n1
i=1 I(log Zˆi1 + β
TXi1 ≥ log Zˆ1 + βTX1)
}]
−E
[
∆1
{
X1 − E
∗[I(log Zˆ∗1 + β
TX∗1 ≥ log Zˆ1 + βTX1)X∗1 ]
E∗[I(log Zˆ∗1 + βTX
∗
1 ≥ log Zˆ1 + βTX1)]
}] ∣∣∣→a.s. 0.
Furthermore, as n goes to∞, Sˆ0(y; x) converges uniformly in (y, x) to S0(y;x) as shown
in Zeng (2004). Thus, the limit function
E
[
∆1
{
X1 − E
∗[I(log Zˆ∗1 + β
TX∗1 ≥ log Zˆ1 + βTX1)X∗1 ]
E∗[I(log Zˆ∗1 + βTX
∗
1 ≥ log Zˆ1 + βTX1)]
}]
converges uniformly in β to
E
[
∆1
{
X1 − Q1(logZ1 + β
TX1)
Q0(logZ1 + βTX1)
}]
.
The latter has a unique minimum zero at β0 by condition (C.1). Additionally, it satisfies
the separability at β0 by condition (C.3). Therefore, from Theorem 5.9 of van der Vaart
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(1998), βˆ converges almost surely to β0.
3.7.2 Proof of Theorem 3.2
Next, we derive the asymptotic distribution of βˆ. From equation
Pn1
[
∆1
{
X1 −
∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βTX1)Xi1∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βˆTX1)
}]
= 0. (3.8)
if we define
Qˆ1(x) = E[X1I(log Zˆ1 + βˆ
TX1 ≥ x)], Qˆ0(x) = E[I(log Zˆ1 + βˆTX1 ≥ x)],
then we obtain that
Gn1
[
∆1
{
X1 −
∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βˆTX1)Xi1∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ1 + βˆTX1)
}]
−Gn1E∗
[
∆∗1I(log Zˆ1 + βˆ
TX1 ≥ log Zˆ∗1 + βˆTX∗1 )X1
n−1
∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ∗1 + βˆTX∗1 )
]
+Gn1E
∗
[
∆∗1I(log Zˆ1 + βˆ
TX1 ≥ log Zˆ∗1 + βˆTX∗1 )Qˆ1(log Zˆ∗1 + βˆTX∗1 )
n−1
∑n1
i=1 I(log Zˆi1 + βˆ
TXi1 ≥ log Zˆ∗1 + βˆTX∗1 )Qˆ0(log Zˆ∗1 + βˆTX∗1 )]
]
= −√n1E
[
∆1
{
X1 − E
∗[I(log Zˆ∗1 + βˆ
TX∗1 ≥ log Zˆ1 + βˆTX1)X∗1 ]
E∗[I(log Zˆ∗1 + βˆTX
∗
1 ≥ log Zˆ1 + βˆTX1)]
}]
.
From the Donsker theorem, we have
−√n1E
[
∆1
{
X1 − Qˆ1(log Zˆ1 + βˆ
TX1)
Qˆ0(log Zˆ1 + βˆTX1)
}]
= Gn1g(∆1, X1, Z1; β0) + op(1), (3.9)
where
g(∆1, X1, Z1; β0) = ∆1
{
X1 − Q1(logZ1 + β
T
0 X1)
Q0(logZ1 + βT0 X1)
}
96
−E∗
[
∆∗1I(logZ1 + β
TX1 ≥ logZ∗1 + βTX∗1 )X1
Q0(logZ∗1 + β
T
0 X
∗
1 )
]
+E∗
[
∆∗1I(logZ1 + β
TX1 ≥ logZ∗1 + βTX∗1 )Q1(logZ∗1 + βT0 X∗1 )
Q0(logZ∗1 + β
T
0 X
∗
1 )
2
]
.
On the other hand, from condition (C.2),
Qˆ0(x) = E
[
P
(
Y1 ≥ Hˆ−10 (ex−βˆ
TX1 ;X1)
∣∣∣X1)] ,
where Hˆ−10 (y;x) denotes the inverse of H0(y;x) ≡ − logS0(y;x) for given x. Thus, if
letting f1(y|x) be the conditional density of Y1 given X1, then
Qˆ0(x) = −E
[
f1
(
H−10 (e
x−βˆTX1 ;X1)
∣∣∣X1)(Hˆ−10 (ex−βˆTX1 ;X1)−H−10 (ex−βˆTX1 ;X1))]
+E
[
P
(
Y1 ≤ H−10 (ex−βˆ
TX1);X1)
∣∣∣X1)]+ o(1).
By slightly modifying the inverse map lemma (Lemma 3.9.20, van der Vaart andWellner
1996), we can show
Hˆ−10 (e
x−βˆTX1 ;X1)−H−10 (ex−βˆ
TX1 ;X1)
= −Hˆ0(H
−1
0 (e
x−βˆTX1 ;X1);X1)−H0(H−10 (ex−βˆTX1 ;X1);X1)
H ′0(H
−1
0 (e
x−βT0 X1 ;X1);X0 = X1)
+ o(1),
and it holds uniformly in x, βˆ and X1. Moreover, since Hˆ0(·;x) converges to H0(·;x) in
D[0, τ ] uniformly in x, we obtain
Qˆ0(log Zˆ
∗
1 + β
T
1 X
∗
1 )
= E
 f1
(
H−10 (Z
∗
1e
βT0 X
∗
1−βT0 X1 ;X1)|X1
)
H ′0(H
−1
0 (Z
∗
1e
βT0 X
∗
1−βT0 X1 ;X1);X0 = X1)
×
(
Hˆ0(H
−1
0 (Z
∗
1e
βT0 X
∗
1−βT0 X1 ;X1);X1)−H0(H−10 (Z∗1eβ
T
0 X
∗
1−βT0 X1 ;X1);X1)
)]
+E
[
P
(
Y1 ≥ H−10 (Zˆ∗1eβˆ
T
0 X
∗
1−βˆTX1 ;X1)
∣∣∣X1)]+ o(1).
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The last term on the right-hand side can be further approximated by
E
[
P
(
Y1 ≥ H−10 (Z∗1eβ
T
0 X
∗
1−βT0 X1 ;X1)
∣∣∣X1)]
E
[
f1(H
−1
0 (Z
∗
1e
βT0 X
∗
1−βT0 X1 ;X1)|X1)
H ′0(H
−1
0 (Z
∗
1e
βT0 X
∗
1−βT0 X1 ;X1);X0 = X1)
Z∗1e
βT0 X
∗
1−βT0 X1
×
{
Hˆ0(Y
∗
1 ;X
∗
1 )−H0(Y ∗1 ;X∗1 )
H0(Y ∗1 ;X
∗
1 )
+ (βˆ − β0)(X∗1 −X1)
}]
.
Similarly, we can expand the numerator term in the left-hand side of (3.11), i.e.,
Qˆ1(log Zˆ1 + βˆ
TX1). We eventually obtain that (3.11) is equivalent to
Gn1g(∆1, X1, Z1; β0) + op(1) =
√
n1σ1(βˆ − β0)
+
√
n1E
[
σ2(Z1, X1, X
∗
1 )
(
Hˆ0(H
−1
0 (Z1e
βT0 X1−βT0 X∗1 ;X∗1 );X
∗
1 )
−H0(H−10 (Z1eβ
T
0 X1−βT0 X∗1 ;X∗1 )
)]
+
√
n1E
[
σ3(Y1, X1)
(
Hˆ0(Y1;X1)−H0(Y1;X1)
)]
, (3.12)
for some differentiable functions σ2 and σ3. Particularly, σ1 has the same expression as
given in condition (C.3) with β = β0 so σ1 is non-singular.
Using the same arguments as in Zeng (2004) and condition (C.4), we can show that
uniformly in x and y ∈ [0, τ ],
(Hˆ0(y;x)−H0(y, x))
=
{
(Pn0 −P0)
[
∆I(Y0 ≤ y)(n0adn)−1Kan(X0 − x)
(n0adn)
−1∑n0
k=1 I(Yk0 ≥ Y0)Kan(Xk0 − x)
]
−(Pn0 −P0)
E∗
[
∆∗I(Y0 ≥ Y ∗0 )(n0an)−1Kan(X∗0 − x)
(n0adn)
−1∑n0
k=1 I(Yk0 ≥ Y ∗0 )Kan(Xk0 − x)E∗∗[I(Y ∗∗0 ≥ Y ∗0 )Kan(X∗∗0 − x)]
]}
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+O(aχn)
≡ (Pn0 −P0)qn(y, x, Y0, X0) + op(1).
We plug the above expression into equation (3.13) then (3.11). From condition (C.4),
we obtain
Gn1g(∆1, X1, Z1; β0) + op(1)
=
√
n1σ1(βˆ − β0)
+
√
n1(Pn0 −P0)E
[
σ2(Z1, X1, X
∗
1 )qn(H
−1
0 (Z
∗
1e
−βT0 X1+βT0 X∗1 ;X∗1 ), X
∗
1 , Y0, X0)
]
+
√
n1(Pn0 −P0)E [σ3(Y1, X1)qn(Y1, X1, Y0, X0)] (3.13)
Finally, we apply Theorem 2.11.23 in van der Vaart and Wellner (1996) to the last
two terms in the right-hand side of equation (3.13). Particularly, their conditions are
satisfies by observing that after integration by parts, both
E
[
σ2(Z1, X1, X
∗
1 )qn(H
−1
0 (Z1e
βT0 X1−βT0 X∗1 ;X∗1 ), X
∗
1 , Y0, X0)
]
and
E [σ3(Y1, X1)qn(Y1, X1, Y0, X0)]
converges uniformly in (Y0, X0) and they have bounded total variation in Y0 uniformly
in X0 and are Lipschitz continuous in X0. The latter implies the entropy condition in
Theorem 2.11.23. Therefore, combined the above results and the non-singularity of σ1
in (3.13), we obtain the asymptotic normality of βˆ.
Remark A.1. When X’s take discrete values, the proof can be much simplified. Par-
ticulary, we can set an = 1/n and Kan(x) = I(x = 0) in the above arguments.
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Remark A.2. From the proof, it is clear that the asymptotic variance for βˆ is the
summation of two sources of variations: one is that the variability, denoted by V1, in
the log-rank estimation conditional on the non-diseased data; the other one, denote by
V2, is due to estimating S0(y;x) using the non-diseased data. Therefore, to estimate
the asymptotic variance of βˆ, we can estimate these two source of variation separately.
Specifically, we estimate V1 using the log-rank estimation procedure as given in Zeng and
Lin (2008). While, we estimate V2 using the following resampling method: according
to the expansion in Zeng (2004), we generate G1, ..., Gn0 from N(0, 1) and define
H˜0(y, x) = Hˆ0(y, x) + n
−1
0
n0∑
j=1
Gj
[
∆jI(Yj0 ≤ y)Kan(Xj0 − x)∑n0
k=1 I(Yk0 ≥ Yj0)Kan(Xk0 − x)
]
−n−10
n0∑
j=1
Gj
n0∑
s=1
[
∆s0I(Yj0 ≥ Ys0)Kan(Xs0 − x)
(
∑n0
k=1 I(Yk0 ≥ Ys0)Kan(Xk0 − x))2
]
.
We then replace Zˆ1i by H˜0(Y1i;X1i) and re-estimate β. Then V2 can be estimated as the
sample variance of β’s by repeating this procedure for a number of times. The validity
of such a resampling method can be justified using the procedure as in the previous
proof.
Remark A.3. When S0(y|x) is estimated by the Cox model, the only difference is in
the expressions of Hˆ0(y;x) − H0(y, x); the influence function qn(y, x, Y0, X0) is given
by the influence function of exp[−Λˆ(y)exp(γˆTx)], where (Λˆ, γˆ) is the nonparametric
maximum likelihood estimator in the Cox model.
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3.7.3 Proof of Theorem 3.3
The asymptotic property of Gˆ(t) follows the same expansion as the proof of Theorem
3.2 but we utilize the differentiability of the product-limit function. Let SW denote the
survival function for W1 and HW denote the cumulative hazard function of W1. We
have
Gˆ(t)−G0(t) = −G0(t)(Pn1−P1)
[
∆1I(W1 ≤ −t)
E∗[I(W ∗1 ≥ W1)]
− E∗
{
I(W1 ≥ W ∗1 )∆∗1I(W ∗1 ≤ −t)
SW (W ∗1 )2
}]
−G0(t)
{
E
[
∆1I(Wˆ1 ≤ −t)
E∗[I(Wˆ ∗1 ≥ Wˆ1)]
]
−HW (t)
}
+ op(n
−1/2).
We further expand the second term in the right-hand side as in the previous section to
obtain
σ˜1(βˆ − β0) + E
[
σ˜2(Z1, X1, X
∗
1 )
(
Hˆ0(H
−1
0 (Z1e
βT0 X1−βT0 X∗1 ;X∗1 );X
∗
1 )
−H0(H−10 (−Z1eβ
T
0 X1−βT0 X∗1 ;X∗1 )
)]
+
√
n1E
[
σ˜3(Y1, X1)
(
Hˆ0(Y1;X1)−H0(Y1;X1)
)]
+ op(n
−1/2).
Hence, the asymptotic distribution of Gˆ(t) follows from the same arguments as in
Theorem 3.2.
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Chapter 4
Comparing Areas under ROC
Curves in a Paired-Patient,
Paired-Reader Design
4.1 Introduction
The Receiver Operating Characteristic (ROC) curve is widely used to evaluate the
performance of a diagnostic test when test results are based on a continuous or ordinal
variable (Metz, 1978; Hanly and McNeil, 1982; Swets and Pickett, 1982). In an ROC
curve, the true positive rate is plotted in function of the false positive rate across all
possible cutpoints. The area under the receiver operating characteristic curve (AUC)
is a commonly used summary measure to evaluate the accuracy of a diagnostic test and
relative accuracies of diagnostic tests can be compared by their corresponding areas
under the ROC curves.
Diagnostic test results often depend on a reader’s subjective interpretation, exper-
tise, or experience. Because of the variability in readers’ accuracy, studies of such
diagnostic tests usually involve several readers. The most popular design for such a
multi-reader study is the paired-patient, paired-reader design (Obuchowski and Rock-
ette, 1995), in which multiple readers interpret all test results of a sample of patients
who undergoes multiple diagnostic tests. This design is most likely to occur in a radi-
ology setting and is most efficient for comparing tests because it requires the smallest
number of subjects. In addition, it demands one of the smallest reader samples and one
of the fewest number of interpretations per reader compared with other study design
(Zhou et al., 2002).
The AUCs of diagnostic tests are correlated since diagnostic tests are based on the
same patients or from the same readers. Therefore, the correlated structure of data
must be taken into account in the analysis to avoid the inflation of testing powers. For
the correlated ROC curves, nonparametric approaches have been proposed to estimate
the AUCs. Especially, DeLong et al. (1988) developed a fully nonparametric approach
to the comparison of correlated ROC curves by using the theory on U-statistics. This
method, however, is applicable to the cases when each patient is examined by multiple
tests or repeatedly examined using a single test. Obuchowski (1997) extended Delong
et al. (1988)’s method and proposed a method for comparing the AUCs when there are
multiple test results per subject. Under this data structure, test results from different
patients are assumed to be independent although test results from the same patients
are correlated. This method is not appropriate for the paired-patient, paired-reader
design since, in this design, test results from different patients are correlated if they are
read by a same reader. In addition, these two nonparametric methods do not consider
the reader-variability caused by differences in interpretations.
On the other hand, several methods have been developed using the mixed-effects
analysis of variance (ANOVA) models for the analysis of multi-reader ROC studies with
multiple tests (Dorfman et al., 1992; Obuchowski and Rockette, 1995; Beiden et al.,
2000). Dorfman et al. (1992) proposed a mixed-effects ANOVA model on the jackknife
103
pseudovalues of the summary measures of ROC curve. Obuchowski and Rockette (1995)
applied a mixed-effects ANOVA model to the estimated summary measures of the ROC
curve for each combination of patients, readers and tests. They developed the adjusted
the ANOVA F-test in order to test differences in diagnostic accuracies. However, the
validity of these methods depends heavily on assumptions on the underlying distribution
of the random variables.
In this chapter, we introduce a latent model to estimate and compare correlated
AUCs in a paired-patient, paired-reader design. We assume diagnostic test results come
from some unknown and monotone functions of continuous latent variables and further
assume reader variability is characterized by random effects due to a specific reader
from a given diagnostic test. In Section 4.2, we estimate the AUCs nonparametrically
based on the ranks of test results and suggest inference procedure to account for com-
plicated correlated structures of test results. We also provide the asymptotic normality
of the AUC estimates in Section 4.2. Since, it is common that disease status may be
misclassified, in Section 4.3, we present a method for comparing correlated AUCs when
an imperfect gold standard bias is presented. A sample size formula is presented in
Section 4.4. In Section 4.5, we conduct simulation studies to investigate the perfor-
mance of the correlated AUC differences for two diagnostic tests and to evaluate power
by varying the number of patients and readers. In Section 4.6, we present an example
from a breast cancer study. A discussion is followed in Section 4.7 and all proofs are
provided in Section 4.8.
4.2 Inference for Correlated AUCs
Suppose a total of h tests are performed on a sample of N patients (m diseased, n
non-diseased, N = m+n) where r readers independently examine the test results from
N patients. Let X lik be the test result of diseased subject i obtained from reader k with
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diagnostic test l (i = 1, · · · ,m; k = 1, · · · , r; l = 1, · · · , h). Likewise, let Y ljk be the test
result of non-diseased subject j from reader k with diagnostic test l (j = 1, · · · , n; k =
1, · · · , r; l = 1, · · · , h). The test results can be based on either continuous or ordinal
random variables. Without loss of generality, we assume that higher values of test
results are more indicative of disease. Suppose X lik and Y
l
jk come from distributions of
f(W lik) and f(W
l
jk) for an unknown increasing function f. W
l
ik andW
l
jk denote unobserved
continuous latent variables of X lik and Y
l
jk, respectively.
W lik = b
l
k + ²
l
ik
W ljk = b
l
k + ²˜
l
jk,
(4.1)
where blk is a random effect due to reader k of diagnostic test l, ²i = (²
l
ik)k=1,··· ,r; l=1,··· ,h
is a random error of diseased subject i, and ²˜j = (²
l
jk)k=1,··· ,r; l=1,··· ,h is a random error
of non-diseased subject j. It is assumed that ²li’s (or ²˜
l
j’s) are iid for a fixed l, and b
l
k,
²lik, and ²˜
l
jk are independent.
Let θlk denote the AUC of diagnostic test l by reader k. When the AUC is calculated
by the trapezoidal rule, θlk is equal to Pr(X
l
k > Y
l
k)+
1
2
Pr(X lk = Y
l
k) by Bamber(1975)’s
formula. The empirical AUC of θlk applying the Mann-Whitney U statistic is given by
θˆlk =
1
mn
m∑
i=1
n∑
j=1
φ(X lik, Y
l
jk),
with
φ(X,Y ) =

1 if X > Y ,
1/2 if X = Y ,
0 if X < Y .
E(θˆlk) = Pr(X
l
k > Y
l
k) +
1
2
Pr(X lk = Y
l
k) = θ
l
k with Pr(X
l
k = Y
l
k) = 0 for continuous
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test results. Since X lik and Y
l
jk are assumed to follow underlying distributions of W
l
ik
and W ljk from (4.1), φ(X
l
ik, Y
l
jk) is equal to φ(W
l
ik,W
l
jk) and φ(²
l
ik, ²˜
l
jk). Let θˆ
l be the
empirical AUC of diagnostic test l. The accuracy of diagnostic test l is described by
the average of the reader specific AUCs from diagnostic test l.
θˆl =
1
r
r∑
k=1
θˆlk =
1
mnr
m∑
i=1
n∑
j=1
r∑
k=1
φ(X lik, Y
l
jk)
=
1
mnr
m∑
i=1
n∑
j=1
r∑
k=1
φ(²lik, ²˜
l
jk),
where E(θˆl) =
1
r
∑r
k=1 θ
l
k(= let θ
l).
Let θˆ = (θˆlk)k=1,··· ,r;l=1,··· ,h. θˆ
l
k’s are correlated each other because of having same
patients or same readers. We consider three different types of correlations among
φ(²lik, ²˜
l
jk) values.
ρ1((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
j′k′)], j 6= j′
ρ2((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
i′k′ , ²˜
l′
jk′)], i 6= i′
ρ3((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
jk′)].
(4.2)
ρ1((k,l),(k′,l′)) denotes the correlation due to same diseased subjects with two different
non-diseased subjects; ρ2((k,l),(k′,l′)), the correlation due to same non-diseased subjects
with two different diseased subjects; and ρ3((k,l),(k′,l′)), the correlation due to same dis-
eased and non-diseased subjects.
The asymptotic normality is derived from the theory of U-statistics by Hoeffding
(1948).
Theorem 4.1. Let θˆ = (θˆlk)k=1,··· ,r;l=1,··· ,h and θ = (θ
l
k)k=1,··· ,r;l=1,··· ,h. If limN→∞m/N =
λ and limN→∞ n/N = 1−λ with 0 < λ < 1, and if E[φ2(²lik, ²˜ljk)] <∞, then
√
N(θˆ−θ)
is asymptotically normal with zero mean vector and covariance matrix Σ = (σ((k,l),(k′,l′)))
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where
σ((k,l),(k′,l′)) =
[
1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
]
and
ξ
((k,l),(k′,l′))
10 = Cov[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
j′k′)|Di = 1, Dj = 0, Dj′ = 0], j 6= j′
ξ
((k,l),(k′,l′))
01 = Cov[φ(²
l
ik, ²˜
l
jk), φ(²
l′
i′k′ , ²˜
l′
jk′)|Di = 1, Dj = 0, Di′ = 1], i 6= i′.
To assess statistical significance, we use the test statistic
√
N(θˆ − θ) → N(0, Σˆ),
with Σˆ = (σˆ((k,l),(k′,l′))) =
[
1
λ
ξˆ
((k,l),(k′,l′))
10 +
1
(1− λ) ξˆ
((k,l),(k′,l′))
01
]
. Σ can be estimated by
the method of structural components developed by Sen (1960).
Corollary 4.2. Under the above assumptions and if the number of readers r is bounded,
for any two correlated empirical ROC areas θˆl and θˆl
′
,
√
N((θˆl − θˆl′) − (θl − θl′)) is
asymptotically normal with mean zero and variance σl,l′, where
σl,l′ =
1
r2
∑
t=l,l′
[
r∑
k=1
(1
λ
ξ
((k,t),(k,t))
10 +
1
(1− λ)ξ
((k,t),(k,t))
01
)
+
∑
k 6=k′
(1
λ
ξ
((k,t),(k′,t))
10
+
1
(1− λ)ξ
((k,t),(k′,t))
01
)]
− 2
r2
[
r∑
k=1
(1
λ
ξ
((k,l),(k,l′))
10 +
1
(1− λ)ξ
((k,l),(k,l′))
01
)
+
∑
k 6=k′
(1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
)]
.
4.3 Inference with an Imperfect Gold Standard Bias
The imperfect gold standard bias refers to the misclassification of disease status in which
disease status based on a gold standard and true disease status are not consistent. A
perfect gold standard is often not available or too expensive to implement for many
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diseases, which leads investigators to use an imperfect gold standard. If an imperfect
gold standard is used, the estimated accuracy of the tests would be biased. In this
section, we present a method for comparing correlated AUCs when an imperfect gold
standard bias is presented. Let Z lik be the test result of subject i by reader k of
diagnostic test l (i = 1, · · · ,m + n; k = 1, · · · , r; l = 1, · · · , h). Di denotes disease
status of subject i based on a gold standard and D0i denotes true disease status of
subject i in which Di and D
0
i are assumed to be independent. Both of Di and D
0
i have
1 for diseased and 0 for non-diseased. m and n are the number of diseased and non-
diseased subjects based on a gold standard. Z lik|Di = 1 and Z ljk|Dj = 0 are assumed to
follow underlying distributions of W lik and W
l
jk, respectively, where W
l
ik = b
l
k + ²
l
ik and
W ljk = b
l
k+²˜
l
jk. The assumptions for b
l
k, ²
l
ik, and ²˜
l
jk are described in section 4.2. Suppose
the probability of having disease based on a gold standard given that a subject is truly
non-diseased, Pr(Di = 1|D0i = 0), equals p, the probability of having non-diseased
based on a gold standard given that a subject is truly diseased, Pr(Di = 0|D0i = 1),
equals q, and the prevalence of truly diseased population, Pr(D0i = 1), equals ω. In
addition, we assume that test results do not depend on observed disease status given
true disease status.
The area under the empirical ROC curve of diagnostic test l by reader k in the
presence of misclassification of disease status is
θˆlk =
1∑m+n
i=1 Di
∑m+n
j=1 (1−Dj)
m+n∑
i=1
m+n∑
j=1
φ(Z lik, Z
l
jk)Di(1−Dj) =
1
mn
m∑
i=1
n∑
j=1
φ(²lik, ²˜
l
jk),
where
φ(Z lik, Z
l
jk) =

1 if Z lik > Z
l
jk,
1/2 if Z lik = Z
l
jk,
0 if Z lik < Z
l
jk.
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Similar to (4.2), three different types of correlations are considered.
ρ∗1((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
j′k′)|Di = 1, Dj = 0, Dj′ = 0], j 6= j′
ρ∗2((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
i′k′ , ²˜
l′
jk′)|Di = 1, Dj = 0, Di′ = 1], i 6= i′
ρ∗3((k,l),(k′,l′)) = Corr[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
jk′)|Di = 1, Dj = 0].
(4.3)
Theorem 4.3. The expectation and variance of an empirical AUC of diagnostic test l
by reader k.
i. E(θˆlk) = aθ
l
k + b with
a =
(1− p)(1− q)ω(1− ω)− pqω(1− ω)
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2
b =
1
2
p(1− p)(1− ω)2 + pqω(1− ω) + 1
2
q(1− q)ω2
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2 .
ii. V ar(θˆlk) =
V l∗k
mn
[1 + (n− 1)ρ∗1((k,l),(k,l)) + (m− 1)ρ∗2((k,l),(k,l))], where
V l∗k = V ar(φ(²
l
ik, ²˜
l
jk)|Di = 1, Dj = 0)
= (aθlk + b)−
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj = 0)− (aθlk + b)2.
It is noted that the empirical AUC θˆlk is biased if imperfect gold standard bias is
present. Define θˆl∗k = (θˆ
l
k − b)/a is the bias corrected AUC estimate of θˆlk. Then,
the bias corrected AUC estimate of diagnostic test l is defined by the average of θˆl∗k ’s
(k = 1, · · · , r).
θˆl∗ =
1
r
r∑
k=1
θˆl∗k =
1
r
r∑
k=1
θˆlk − b
a
,
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and
V ar(θˆl∗) = V ar
[
1
r
r∑
k=1
(
θˆlk − b
a
)]
=
1
a2r2
[
r∑
k=1
V ar(θˆlk) +
∑
k 6=k′
Cov(θˆlk, θˆ
l
k′)
]
=
1
mna2r2
[
r∑
k=1
V l∗k (1 + (n− 1)ρ∗1((k,l),(k,l)) + (m− 1)ρ∗2((k,l),(k,l)))
+
∑
k 6=k′
√
V l∗k
√
V l∗k′ ((n− 1)ρ∗1((k,l),(k′,l)) + (m− 1)ρ∗2((k,l),(k′,l)) + ρ∗3((k,l),(k′,l)))
]
.
Theorem 4.4. Let θˆ∗ = (θˆl∗k )k=1,··· ,r;l=1,··· ,h and θ = (θ
l
k)k=1,··· ,r;l=1,··· ,h. If limN→∞m/N =
λ and limN→∞ n/N = 1 − λ with 0 < λ < 1, and if E[φ2(²lik, ²˜ljk)] < ∞, then
√
N(θˆ∗ − θ) is asymptotically normal with zero mean vector and covariance matrix
Σ∗ = (σ∗((k,l),(k′,l′))) with
σ∗((k,l),(k′,l′)) =
1
a2
[
1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
]
.
Corollary 4.5. If the conditions of Theorem 4.4 hold and the number of readers r is
bounded, for any two correlated empirical ROC areas θˆl∗ and θˆl
′∗,
√
N((θˆl∗ − θˆl′∗) −
(θl − θl′)) is asymptotically normal with mean zero and variance σ∗l,l′ with
σ∗l,l′ =
1
a2r2
∑
t=l,l′
[
r∑
k=1
(1
λ
ξ
((k,t),(k,t))
10 +
1
(1− λ)ξ
((k,t),(k,t))
01
)
+
∑
k 6=k′
(1
λ
ξ
((k,t),(k′,t))
10
+
1
(1− λ)ξ
((k,t),(k′,t))
01
)]
− 2
a2r2
[
r∑
k=1
(1
λ
ξ
((k,l),(k,l′))
10 +
1
(1− λ)ξ
((k,l),(k,l′))
01
)
+
r∑
k 6=k′
(1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
)]
.
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4.4 Sample Size Calculation
There exists only one method for determining sample sizes for multi-reader studies in
the literature (Obuchowski, 1995a, 1995b). The method is based on a mixed-effects
ANOVA model for the summary measure of the ROC curve. Let θˆijq be the estimated
summary measure of the ROC curve for ith test by jth reader at the qth occasion. The
mixed effect linear model is defined by θˆijq = µ+ µi + rj + (µr)ij + ²ijq, 1 ≤ i ≤ I, 1 ≤
j ≤ J, and 1 ≤ q ≤ Q. Here µ is overall mean, µi is a fixed effect corresponding to the
ith test, rj is a random effect due to the jth reader, (µr)ij is a random effect due to the
interaction between the ith test and jth reader, and ²ijq is a random error. Each of rj,
(µr)ij, and ²ijq is assumed to follow a normal distribution. For sample size calculations,
the diagnostic accuracies of the J readers of the two tests are assumed to follow a
multivariate normal distribution and an approximated F statistic with 1 and (J − 1)
degrees of freedom is used for testing the null hypothesis that the mean diagnostic
accuracies of the tests are equal (Zhou et al., 2002). However, sample sizes under this
approach are sensitive to the assumptions on variance components of the mixed model.
In addition, the response of the mixed model is fitted nonparametrically first and then
this nonparametric estimate is fitted again based on the model assumptions. This two-
stage sample size determination can be misleading because the nonparametric estimates
of the response are not considered in the second step of fitting a mixed model.
Instead, we propose to make an inference under the asymptotic normality of the
empirical area under the ROC curves. Based on the test statistic ((θˆl∗ − θˆl′∗) − (θl −
θl
′
))/
√
V ar(θˆl∗ − θˆl′∗), which possesses approximately a standard normal distribution,
we determine the asymptotic power for a hypothesis test of the difference in accuracy:
H0 : δ0 = θ
l − θl′ = 0 H1 : δ1 = θl − θl′ 6= 0
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Corollary 4.6. The variance of difference between two correlated, bias corrected em-
pirical AUCs
V ar(θˆl∗ − θˆl′∗)
=
1
mna2r2
∑
t=l,l′
[
r∑
k=1
V t∗k ((1 + (n− 1)ρ∗1((k,t),(k,t)) + (m− 1)ρ∗2((k,t),(k,t)))
+
∑
k 6=k′
√
V t∗k
√
V t∗k′ ((n− 1)ρ∗1((k,t),(k′,t)) + (m− 1)ρ∗2((k,t),(k′,t)) + ρ∗3((k,t),(k′,t)))
]
− 2
mna2r2
[
r∑
k=1
√
V l∗k
√
V l
′∗
k ((n− 1)ρ∗1((k,l),(k,l′)) + (m− 1)ρ∗2((k,l),(k,l′)) + ρ∗3((k,l),(k,l′)))
+
r∑
k 6=k′
√
V l∗k
√
V l
′∗
k′ ((n− 1)ρ∗1((k,l),(k′,l′)) + (m− 1)ρ∗2((k,l),(k′,l′)) + ρ∗3((k,l),(k′,l′)))
]
,
where V l∗k = V ar(φ(²
l
ik, ²˜
l
jk|Di = 1, Dj = 0)) = (aθlk + b)−
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj =
0)− (aθlk + b)2 from Theorem 4.3(ii).
For sample size determination, the followings are assumed:
a. Some of correlations defined in (4.3) are simplified as
ρ∗1((k,l),(k,l′)) = ρ
∗
2((k,l),(k,l′)) = ρa,
ρ∗1((k,l),(k′,l)) = ρ
∗
2((k,l),(k′,l)) = ρb,
ρ∗1((k,l),(k′,l′)) = ρ
∗
2((k,l),(k′,l′)) = ρc.
(4.4)
b. V l∗k = V ar(φ(²
l
ik, ²˜
l
jk|Di = 1, Dj = 0)) = (aθlk + b) −
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj =
0) − (aθlk + b)2 from Corollary 4.6 is simplified as V ∗ = (aθ¯ + b) − (aθ¯ + b)2
assuming that the variance of φ(²lik, ²˜
l
jk|Di = 1, Dj = 0) is same across readers
and modalities. Here θ¯ denotes average of two comparing AUCs and Pr(²lik =
²˜ljk|Di = 1, Dj = 0) is assumed to be zero.
112
Then, the variance of the difference between two AUCs from corollary 4.6 is simplified
as
V ar(θˆl∗ − θˆl′∗) ≈ 2(m+ n)V
∗
mna2r
[(1− ρa) + (r − 1)(ρb − ρc)], V ∗ = (aθ¯ + b)− (aθ¯ + b)2.
Under the above assumptions, the power at level α is
Power = Φ
(
−z1−α/2
√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r + δ1√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r
)
+Φ
(
−z1−α/2
√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r − δ1√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r
)
(4.5)
with V ∗ = (aθ¯ + b)− (aθ¯ + b)2.
4.5 Simulation Studies
4.5.1 Data Generation
Let m and n denote the number of diseased and non-diseased subjects and r de-
note the number of readers. X = (Xi)i=1,··· ,m denotes diseased results and Y =
(Yj)j=1,··· ,n denotes non-diseased results with Xi = ((X1ik)k=1,··· ,r, (X
2
ik)k=1,··· ,r)
′ and
Yj = ((Y
1
jk)k=1,··· ,r, (Y
2
jk)k=1,··· ,r)
′. X lik is the ith diseased subject’s test result by the
kth reader of the lth test and Y ljk is the jth non-diseased subject’s test result by the
kth reader of the lth test. For the purpose of illustration, X and Y are assumed to be
independent. Regarding correlations among X lik’s (Y
l
jk’s) for the ith (jth) subject with
varying k and l, we assume that the correlation when same subjects are evaluated by
different readers using a same test is 0.3, the correlation when same subjects are evalu-
ated by a same reader using different tests 0.8, and the correlation when same subjects
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are evaluated by different readers using different tests is 0.25 for both continuous and
ordinal data.
Continuous data
Xi’s and Yj’s (i = 1, · · · ,m; j = 1, · · · , n) are generated from multivariate normal
distributions; Xi ∼ N((µd11, µd21)′,Σ) and Yj ∼ N(0,Σ) where 1 = (1, · · · , 1)′r×1 and
Σ =
 Σ11(r×r) Σ12(r×r)
Σ12(r×r) Σ11(r×r)
 with Σ11(i, i) = 1, Σ11(i, j) = 0.3, Σ12(i, i) = 0.8, and
Σ12(i, j) = 0.25 (i 6= j). The true AUC for diagnostic test l is given by
θl =
1
r
r∑
k=1
θlk =
1
r
r∑
k=1
Pr(X lk > Y
l
k). (4.6)
µd1 and µd2 values are set to 1.465738 and 1.190232 sinceX
1
ik ∼ N(1.465738, 1), Y 1jk ∼
N(0, 1), X2ik ∼ N(1.190232, 1) and Y 2jk ∼ N(0, 1) give θ1k = 0.85 and θ2k = 0.8 for a fixed
k (k = 1, · · · , r). It follows that θ1k = 0.85 and θ1k = 0.8 by equation (4.6). Similarly,
we set µd1 = µd2 = 1.190232 to make θ
1 = θ2 = 0.8.
Ordinal data
We generated ordinal data by making true AUCs as close as 0.85 or 0.8. We found the
following setup makes θ1 = 0.8502313 and θ2 = 0.8005894 which is used for the true
AUCs; First we generated continuous values from
X1 ∼ N(2.325216, 1.75) Y 1 ∼ N(0, 0.75)
X2 ∼ N(1.81, 1.75) Y 2 ∼ N(0, 0.75)
and categorized them as
-2 (X lik ≤ −2), -1 (−2 < X lik ≤ −1), 0 (−1 < X lik ≤ 0), 1 (0 < X lik ≤ 1), 2 (X lik > 1);
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-2 (Y ljk ≤ −2), -1 (−2 < Y ljk ≤ −1), 0 (−1 < Y ljk ≤ 0), 1 (0 < Y ljk ≤ 1), 2 (Y ljk > 1).
4.5.2 Simulation Results
We set the number of diseased and non-diseased subjects at 50, 100, and 200 (m = n =
50, 100, 200) and the number of readers at 2, 5, and 10 (r = 2, 5, 10). In each combina-
tion of subject and reader sample sizes, we used 5000 stimulations and accounted for
an imperfect gold standard bias (p = q = 0, 0.02, or 0.05). Correlations defined in (4.4)
are assumed to be ρa = 0.7 and ρb = ρc = 0. Tables 4.1 (continuous) and 4.3 (ordinal)
contain the results when there is no difference between the two AUCs. In each scenario
of sample sizes, the empirical power (when α=0.05) is very close to 0.05, and the cover-
age proportions of 90% and 95% confidence intervals based on the asymptotic normal
approximation are close to 0.9 or 0.95, respectively. Next, we tested to see if there is
a statistically significant difference between the two AUCs when the true difference is
0.05. Results are given in Table 4.2 (continuous) and Table 4.4 (ordinal). In Table 4.2,
when there is no imperfect gold standard bias (p = q = 0), empirical powers are greater
than 80% in all sample sizes except for m = n = 50 and k = 2. When p = q = 0.02
or 0.05, the empirical powers increase as the number of subjects or readers increase.
Similar results are shown in Table 4.4.
4.6 Application to Breast Cancer Data
We used mammographic images of 201 women with dense breast (Cole et al., 2005).
The goal of this study was to compare the diagnostic accuracy of digital mammography
with that of screen-film mammography in distinguishing breast cancer status (benign,
malignant).
There were a total of nine readers who participated in the reader study. The readers
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Table 4.1: Continuous data, θ1 = θ2 = 0.8
m,n k p, q CP
(1)
1 CP
(2)
2 emp.power
(3)
50 2 0 0.911 0.954 0.046
0.02 0.907 0.95 0.047
0.05 0.906 0.951 0.049
5 0 0.901 0.950 0.050
0.02 0.903 0.950 0.050
0.05 0.905 0.955 0.045
10 0 0.895 0.947 0.053
0.02 0.902 0.954 0.046
0.05 0.900 0.953 0.047
100 2 0 0.899 0.953 0.047
0.02 0.896 0.949 0.051
0.05 0.892 0.947 0.053
5 0 0.899 0.952 0.048
0.02 0.896 0.948 0.052
0.05 0.899 0.950 0.050
10 0 0.902 0.954 0.046
0.02 0.894 0.945 0.055
0.05 0.897 0.953 0.047
200 2 0 0.891 0.947 0.053
0.02 0.897 0.949 0.051
0.05 0.896 0.948 0.052
5 0 0.900 0.949 0.051
0.02 0.899 0.951 0.050
0.05 0.906 0.954 0.046
10 0 0.900 0.949 0.051
0.02 0.892 0.947 0.053
0.05 0.899 0.949 0.051
(1) CP1: coverage proportion of 90% confidence interval based on normal approximation
(2) CP2: coverage proportion of 95% confidence interval based on normal approximation
(3) emp.power: Empirical power based on the significance level 0.05
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Table 4.2: Continuous data, θ1 = 0.85 and θ2 = 0.8
m,n k p, q CP
(1)
1 CP
(2)
2 emp.power
(3)
50 2 0 0.894 0.943 0.590
0.02 0.906 0.957 0.365
0.05 0.902 0.955 0.203
5 0 0.896 0.953 0.837
0.02 0.897 0.946 0.551
0.05 0.905 0.949 0.298
10 0 0.898 0.949 0.921
0.02 0.896 0.947 0.652
0.05 0.897 0.950 0.385
100 2 0 0.899 0.950 0.892
0.02 0.905 0.957 0.641
0.05 0.891 0.944 0.377
5 0 0.914 0.956 0.991
0.02 0.892 0.951 0.851
0.05 0.894 0.948 0.542
10 0 0.892 0.944 0.997
0.02 0.890 0.947 0.918
0.05 0.897 0.949 0.646
200 2 0 0.905 0.953 0.996
0.02 0.900 0.954 0.920
0.05 0.887 0.944 0.646
5 0 0.901 0.952 1.000
0.02 0.895 0.950 0.989
0.05 0.896 0.947 0.843
10 0 0.899 0.954 1.000
0.02 0.892 0.947 0.997
0.05 0.903 0.952 0.915
(1) CP1: coverage proportion of 90% confidence interval based on normal approximation
(2) CP2: coverage proportion of 95% confidence interval based on normal approximation
(3) emp.power: Empirical power based on the significance level 0.05
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Table 4.3: Ordinal data, θ1 = θ2 = 0.8
m,n k p, q CP
(1)
1 CP
(2)
2 emp.power
(3)
50 2 0 0.901 0.952 0.048
0.02 0.907 0.951 0.049
0.05 0.891 0.948 0.053
5 0 0.892 0.943 0.057
0.02 0.899 0.948 0.052
0.05 0.896 0.947 0.053
10 0 0.901 0.948 0.052
0.02 0.902 0.951 0.050
0.05 0.898 0.953 0.047
100 2 0 0.898 0.946 0.054
0.02 0.897 0.949 0.051
0.05 0.894 0.942 0.058
5 0 0.900 0.953 0.047
0.02 0.903 0.953 0.047
0.05 0.889 0.947 0.054
10 0 0.899 0.952 0.048
0.02 0.887 0.946 0.054
0.05 0.903 0.945 0.055
200 2 0 0.894 0.947 0.053
0.02 0.894 0.947 0.053
0.05 0.893 0.943 0.057
5 0 0.892 0.947 0.053
0.02 0.901 0.953 0.047
0.05 0.904 0.949 0.051
10 0 0.905 0.953 0.047
0.02 0.902 0.951 0.049
0.05 0.890 0.944 0.056
(1) CP1: coverage proportion of 90% confidence interval based on normal approximation
(2) CP2: coverage proportion of 95% confidence interval based on normal approximation
(3) emp.power: Empirical power based on the significance level 0.05
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Table 4.4: Ordinal data, θ1 = 0.85 and θ2 = 0.8
m,n k p, q CP
(1)
1 CP
(2)
2 emp.power
(3)
50 2 0 0.892 0.947 0.857
0.02 0.896 0.950 0.543
0.05 0.896 0.946 0.280
5 0 0.871 0.937 0.988
0.02 0.877 0.934 0.780
0.05 0.880 0.942 0.457
10 0 0.857 0.924 0.999
0.02 0.869 0.932 0.900
0.05 0.887 0.939 0.556
100 2 0 0.870 0.934 0.991
0.02 0.876 0.937 0.835
0.05 0.884 0.942 0.501
5 0 0.828 0.900 1.000
0.02 0.862 0.926 0.975
0.05 0.882 0.936 0.744
10 0 0.795 0.882 1.000
0.02 0.845 0.918 0.995
0.05 0.872 0.934 0.854
200 2 0 0.808 0.892 1.000
0.02 0.851 0.917 0.983
0.05 0.872 0.932 0.784
5 0 0.732 0.836 1.000
0.02 0.815 0.894 1.000
0.05 0.863 0.923 0.955
10 0 0.683 0.790 1.000
0.02 0.797 0.883 1.000
0.05 0.851 0.924 0.985
(1) CP1: coverage proportion of 90% confidence interval based on normal approximation
(2) CP2: coverage proportion of 95% confidence interval based on normal approximation
(3) emp.power: Empirical power based on the significance level 0.05
119
reported a probability of malignancy based on 5-point scale, with the scale defined as 1-
No Findings or definitely not, 2-Probably not, 3-Probably, 4- Possibly and 5-Definitely.
Due to a large number of missing test results across readers, we created three imputed
readers for each patient. The scores of the three readers were created by taking average
scores of the actual readers 1-3, 4-6, and 7-9, respectively, where the decimal points of
mean scores were rounded up. A total of 137 patients (benign 81, malignant 56) out
of 210 were used for the analysis after excluding patients with missing mean scores (64
patients) and with invalid cancer status (9 patients).
The reader averaged AUCs were 0.770 (SE 0.028) for the screen-film mammography
and 0.683 (SE 0.033) for the digital mammography. The estimated AUC difference
between the two modalities was 0.087 (SE 0.03) and the estimated AUC for the screen-
film was significantly larger than that of the digital (p-value 0.004). Therefore, we
concluded that screen-film mammography perform better than digital mammography
in discriminating benign and malignant breast tumors.
4.7 Discussion
The paired-patient, paired-reader design is most widely used in radiological studies
to compare different diagnostic techniques because it requires the smallest number of
subjects. Our method can be applied to compare correlated ROC curves of this design
and to a situation in which there is an imperfect gold standard bias. We propose to
make an inference under the asymptotic normality of the empirical AUCs and determine
the asymptotic power for a hypothesis test of the AUC differences. In seeking a formula
for sample size, we found that the theoretical powers are very conservative compared
to empirical powers, especially when the imperfect gold standard bias is present. A
more accurate sample size formula is needed.
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4.8 Appendix
Proof of Theorem 4.1 and Corollary 4.2. Since there exists no imperfect gold stan-
dard bias, Theorem 4.1 and Corollary 4.2 hold when p = Pr(D = 1|D0 = 0) = 0 and
q = Pr(D = 0|D0 = 1) = 0 from Theorem 4.4 and Corollary 4.5, respectively.
Proof of Theorem 4.3. The expectation and variance of the empirical AUC of di-
agnostic test l by reader k are given as follows.
E(θˆlk) = Pr(Z
l
ik > Z
l
jk|Di = 1, Dj = 0) +
1
2
Pr(Z lik = Z
l
jk|Di = 1, Dj = 0)
=
[Pr(Z lik > Z
l
jk, Di = 1, Dj = 0) +
1
2
Pr(Z lik = Z
l
jk, Di = 1, Dj = 0)]
Pr(Di = 1, Dj = 0)
.
We define Pr(Di = 1|D0i = 0) = p, Pr(Di = 0|D0i = 1) = q, and Pr(D0i = 1) = ω.
Furthermore, we assume that test results do not depend on observed disease status
given true disease status. Then, the numerator is computed as
Pr(Z lik > Z
l
jk, Di = 1, Dj = 0) +
1
2
Pr(Z lik = Z
l
jk, Di = 1, Dj = 0)
=
1∑
r=0
1∑
s=0
{
Pr(Z lik > Z
l
jk|Di = 1, Dj = 0, D0i = r,D0j = s)Pr(Di = 1, Dj = 0|D0i
= r,D0j = s)Pr(D
0
i = r,D
0
j = s) +
1
2
Pr(Z lik = Z
l
jk|Di = 1, Dj = 0, D0i = r,
D0j = s)Pr(Di = 1, Dj = 0|D0i = r,D0j = s)Pr(D0i = r,D0j = s)
}
=
1∑
r=0
1∑
s=0
{
Pr(Z lik > Z
l
jk|D0i = r,D0j = s)Pr(Di = 1, Dj = 0|D0i = r,D0j = s)
Pr(D0i = r,D
0
j = s) +
1
2
Pr(Z lik = Z
l
jk|D0i = r,D0j = s)Pr(Di = 1, Dj = 0|
D0i = r,D
0
j = s)Pr(D
0
i = r,D
0
j = s)
}
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=
1∑
r=0
1∑
s=0
{
(Pr(Z lik > Z
l
jk|D0i = r,D0j = s) +
1
2
Pr(Z lik = Z
l
jk|D0i = r,D0j = s)
}
Pr(Di = 1, Dj = 0|D0i = r,D0j = s)Pr(D0i = r,D0j = s)
=
1
2
p(1− p)(1− ω)2 + (1− θlk)pqω(1− ω) + θlk(1− p)(1− q)ω(1− ω) +
1
2
q(1− q)ω2
=
{1
2
p(1− p)(1− ω)2 + pqω(1− ω) + 1
2
q(1− q)ω2
}
+
{
(1− p)(1− q)ω(1− ω)− pqω(1− ω)
}
θlk
where
Pr(Z lik > Z
l
jk|D0i = 0, D0j = 0) +
1
2
Pr(Z lik = Z
l
jk|D0i = 0, D0j = 0) = 1/2
Pr(Z lik > Z
l
jk|D0i = 1, D0j = 1) +
1
2
Pr(Z lik = Z
l
jk|D0i = 1, D0j = 1) = 1/2
Pr(Z lik > Z
l
jk|D0i = 1, D0j = 0) +
1
2
Pr(Z lik = Z
l
jk|D0i = 1, D0j = 0) = θlk
Pr(Z lik > Z
l
jk|D0i = 0, D0j = 1) +
1
2
Pr(Z lik = Z
l
jk|D0i = 0, D0j = 1) = 1− θlk
and the denominator Pr(Di = 1, Dj = 0) is given by
Pr(Di = 1, Dj = 0)
=
1∑
r=0
1∑
s=0
Pr(Di = 1, Dj = 0|D0i = r,D0j = s)Pr(D0i = r,D0j = s)
= (1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2.
Thus
E(θˆlk) =
[
1
2
p(1− p)(1− ω)2 + pqω(1− ω) + 1
2
q(1− q)ω2]
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2
+
[
(1− p)(1− q)ω(1− ω)− pqω(1− ω)]θlk
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2
= aθlk + b. (4.7)
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where
a =
(1− p)(1− q)ω(1− ω)− pqω(1− ω)
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2 , (4.8)
b =
1
2
p(1− p)(1− ω)2 + pqω(1− ω) + 1
2
q(1− q)ω2
(1− p)(1− q)ω(1− ω) + p(1− p)(1− ω)2 + pqω(1− ω) + q(1− q)ω2 . (4.9)
Let V l∗k denote V ar
(
φ(Z lik, Z
l
jk)|Di = 1, Dj = 0
)
for test l by reader k. Then V l∗k is
computed as follows.
V l∗k = V ar(φ(Z
l
ik, Z
l
jk)|Di = 1, Dj = 0) = V ar(φ(²lik, ²˜ljk)|Di = 1, Dj = 0)
= E[φ2(²lik, ²˜
l
jk)|Di = 1, Dj = 0]− E2[φ(²lik, ²˜ljk)|Di = 1, Dj = 0]
= Pr(²lik > ²˜
l
jk|Di = 1, Dj = 0) +
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj = 0)
−E2(θˆlk|Di = 1, Dj = 0)
= E(θˆlk|Di = 1, Dj = 0)−
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj = 0)− E2(θˆlk|Di = 1, Dj = 0)
= (aθlk + b)−
1
4
Pr(²lik = ²˜
l
jk|Di = 1, Dj = 0)− (aθlk + b)2 (4.10)
using E(θˆlk) = Pr(²
l
ik > ²˜
l
jk|Di = 1, Dj = 0) +
1
2
Pr(²lik = ²˜
l
jk|Di = 1, Dj = 0) and
E(θˆlk) = (aθ
l
k + b) from (4.7).
Finally, by using three types correlations in (4.3), the variance of the empirical ROC
curve for test l by reader k is expressed as below.
V ar(θˆlk) = V ar
[
1
mn
m∑
i=1
n∑
j=1
φ(Z lik, Z
l
jk)|Di = 1, Dj = 0
]
= V ar
[
1
mn
m∑
i=1
n∑
j=1
φ(²lik, ²˜
l
jk)|Di = 1, Dj = 0
]
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=
1
m2n2
[
m∑
i=1
n∑
j=1
V ar(φ(²lik, ²˜
l
jk)|Di = 1, Dj = 0)
+
m∑
i
n∑
j 6=j′
Cov(φ(²lik, ²˜
l
jk), φ(²
l
ik, ²˜
l
j′k)|Di = 1, Dj = 0, Dj′ = 0)
+
m∑
i 6=i′
n∑
j
Cov(φ(²lik, ²˜
l
jk), φ(²
l
i′k, ²˜
l
jk)|Di = 1, Dj = 0, Di′ = 1)
]
=
1
m2n2
[
mnV l∗k +mn(n− 1)ρ∗1((k,l),(k,l))V l∗k +mn(m− 1)ρ∗2((k,l),(k,l))V l∗k
]
=
V l∗k
mn
[
1 + (n− 1)ρ∗1((k,l),(k,l)) + (m− 1)ρ∗2((k,l),(k,l))
]
(4.11)
Proof of Theorem 4.4. Let θˆ = (θˆlk)k=1,··· ,r;l=1,··· ,h and θ = (θ
l
k)k=1,··· ,r;l=1,··· ,h. If
we denote Ui = (²
l
ik)k=1,··· ,r;l=1,··· ,h and Vj = (²˜
l
jk)k=1,··· ,r;l=1,··· ,h, θˆ can be expressed as
θˆ =
1
mn
∑m
i=1
∑n
j=1 h(Ui, Vj). If limN→∞m/N = λ and limN→∞ n/N = 1 − λ with
0 < λ < 1, and if E[φ2(²lik, ²˜
l
jk)] < ∞, by the central limit theorem for U statistics,
√
N(θˆ − (aθ + b1)) converges in distribution to a multivariate normal with zero mean
vector and covariance matrix Σ = (σ((k,l),(k′,l′))) where
σ((k,l),(k′,l′)) =
[
1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
]
and
ξ
((k,l),(k′,l′))
10 = Cov[φ(²
l
ik, ²˜
l
jk), φ(²
l′
ik′ , ²˜
l′
j′k′)|Di = 1, Dj = 0, Dj′ = 0], j 6= j′
ξ
((k,l),(k′,l′))
01 = Cov[φ(²
l
ik, ²˜
l
jk), φ(²
l′
i′k′ , ²˜
l′
jk′)|Di = 1, Dj = 0, Di′ = 1], i 6= i′.
Let θˆ∗ = (θˆl∗k )k=1,··· ,r;l=1,··· ,h with θˆ
l∗
k =
1
a
(θˆlk−b). θˆ∗ =
1
a
(θˆ−b1), 1 = (1, 1, · · · , 1)Trh×1
denotes the bias corrected AUC estimates of θˆ. Then, it follows
√
N(θˆ∗−θ) is asymp-
totically normally distributed with zero mean vector and covariance matrix Σ∗ where
Σ∗ =
1
a2
Σ.
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Proof of Corollary 4.5. θˆ∗ = (θˆl∗k )k=1,··· ,r;l=1,··· ,h. The bias corrected empirical AUC
for diagnostic test l is θˆl∗ =
1
r
∑r
k=1 θˆ
l∗
k under the condition that the number of readers
r is bounded. Without loss of generality, we assume that θˆl∗ and θˆl
′∗ correspond to
averages of first and second r elements of θˆ∗, respectively. Let g be a linear func-
tion of θˆ∗ that has bounded second derivatives in a neighborhood of θ. If the same
conditions of Theorem 4.4 hold,
√
N(g(θˆ∗) − g(θ)) is asymptotically normally dis-
tributed with mean zero and variance σ∗l,l′ . In this case, g(θˆ
∗) = L′θˆ∗ = θˆl∗ − θˆl′∗ and
L = (
1
r
1r×1,−1
r
1r×1,0(h−2)r×1)T . Note that E[g(θˆ∗)] = g(θ) = L′θ =
1
r
∑r
k=1 θ
l
k −
1
r
∑r
k=1 θ
l′
k = let (θ
l − θl′) and
σ∗l,l′ =
1
a2r2
∑
t=l,l′
[
r∑
k=1
(1
λ
ξ
((k,t),(k,t))
10 +
1
(1− λ)ξ
((k,t),(k,t))
01
)
+
∑
k 6=k′
(1
λ
ξ
((k,t),(k′,t))
10
+
1
(1− λ)ξ
((k,t),(k′,t))
01
)]
− 2
a2r2
[
r∑
k=1
(1
λ
ξ
((k,l),(k,l′))
10 +
1
(1− λ)ξ
((k,l),(k,l′))
01
)
+
r∑
k 6=k′
(1
λ
ξ
((k,l),(k′,l′))
10 +
1
(1− λ)ξ
((k,l),(k′,l′))
01
)]
.
Proof of Corollary 4.6. First V ar(θˆlk) =
V l∗k
mn
[
1+(n−1)ρ∗1((k,l),(k,l))+(m−1)ρ∗2((k,l),(k,l))
]
from (4.11) and similarly, Cov(θˆl∗k , θˆ
l′∗
k′ ) =
V l∗k
mn
[
(n−1)ρ∗1((k,l),(k′,l′))+(m−1)ρ∗2((k,l),(k′,l′))+
ρ∗3((k,l),(k′,l′))
]
(k 6= k′ or l 6= l′).
Using V ar(θˆl∗ − θˆl′∗) = V ar(θˆl∗) + V ar(θˆl′∗) − 2Cov(θˆl∗, θˆl′∗) and the above two
equations,
V ar(θˆl∗) = V ar
[
1
r
r∑
k=1
(
θˆlk − b
a
)]
=
1
a2r2
[
r∑
k=1
V ar(θˆlk) +
∑
k 6=k′
Cov(θˆlk, θˆ
l
k′)
]
=
1
mna2r2
[
r∑
k=1
V l∗k (1 + (n− 1)ρ∗1((k,l),(k,l)) + (m− 1)ρ∗2((k,l),(k,l)))
+
∑
k 6=k′
√
V l∗k
√
V l∗k′ ((n− 1)ρ∗1((k,l),(k′,l)) + (m− 1)ρ∗2((k,l),(k′,l)) + ρ∗3((k,l),(k′,l)))
]
.
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Similarly, for diagnostic test l′,
V ar(θˆl
′∗) =
1
mna2r2
[
r∑
k=1
V l
′∗
k (1 + (n− 1)ρ∗1((k,l′),(k,l′)) + (m− 1)ρ∗2((k,l′),(k,l′)))
+
∑
k 6=k′
√
V l
′∗
k
√
V l
′∗
k′ ((n− 1)ρ∗1((k,l′),(k′,l′)) + (m− 1)ρ∗2((k,l′),(k′,l′)) + ρ∗3((k,l′),(k′,l′)))
]
.
Cov(θˆl∗, θˆl
′∗)
= Cov
[
1
r
r∑
k=1
θˆlk − b
a
,
1
r
r∑
k=1
θˆl
′
k − b
a
]
=
1
a2r2
[
r∑
k=1
Cov(θˆlk, θˆ
l′
k ) +
∑
k 6=k′
Cov(θˆlk, θˆ
l′
k′)
]
=
1
mna2r2
[
r∑
k=1
√
V l∗k
√
V l
′∗
k ((n− 1)ρ∗1((k,l),(k,l′)) + (m− 1)ρ∗2((k,l),(k,l′)) + ρ∗3((k,l),(k,l′)))
+
r∑
k 6=k′
√
V l∗k
√
V l
′∗
k′ ((n− 1)ρ∗1((k,l),(k′,l′)) + (m− 1)ρ∗2((k,l),(k′,l′)) + ρ∗3((k,l),(k′,l′)))
]
.
Therefore,
V ar(θˆl∗ − θˆl′∗)
=
1
mna2r2
∑
t=l,l′
[
r∑
k=1
V t∗k ((1 + (n− 1)ρ∗1((k,l),(k,l)) + (m− 1)ρ∗2((k,l),(k,l)))
+
∑
k 6=k′
√
V t∗k
√
V t∗k′ ((n− 1)ρ∗1((k,l),(k′,l)) + (m− 1)ρ∗2((k,l),(k′,l)) + ρ∗3((k,l),(k′,l)))
]
− 2
mna2r2
[
r∑
k=1
√
V l∗k
√
V l
′∗
k ((n− 1)ρ∗1((k,l),(k,l′)) + (m− 1)ρ∗2((k,l),(k,l′)) + ρ∗3((k,l),(k,l′)))
+
r∑
k 6=k′
√
V l∗k
√
V l
′∗
k′ ((n− 1)ρ∗1((k,l),(k′,l′)) + (m− 1)ρ∗2((k,l),(k′,l′)) + ρ∗3((k,l),(k′,l′)))
]
.
Proof of Equation (4.5). The asymptotic power for a hypothesis of the difference
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in accuracy.
H0 : δ0 = θ
l − θl′ = 0 H1 : δ1 = θl − θl′ 6= 0
Based on the test statistic ((θˆl∗ − θˆl′∗) − (θl − θl′))/
√
V ar(θˆl∗ − θˆl′∗), the power is
computed as below.
Rejection region =

∣∣∣∣∣ θˆl∗ − θˆl
′∗ − 0√
V ar0(θˆl∗ − θˆl′∗)
∣∣∣∣∣ > Z1−α/2

which is same as
{(θˆl∗ − θˆl′∗) > z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)} ∪ {(θˆl∗ − θˆl′∗) < −z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)}.
Power = 1− β = Pr
(
(θˆl∗ − θˆl′∗) > z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)
∣∣∣H1)
+Pr
(
(θˆl∗ − θˆl′∗) < −z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)
∣∣∣H1)
= Φ
−z1−α/2
√
V ar0(θˆl∗ − θˆl′∗) + δ1√
V ar1(θˆl∗ − θˆl′∗)
+ Φ
−z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)− δ1√
V ar1(θˆl∗ − θˆl′∗)

≈ Φ
−z1−α/2
√
V ar0(θˆl∗ − θˆl′∗) + δ1√
V ar0(θˆl∗ − θˆl′∗)
+ Φ
−z1−α/2
√
V ar0(θˆl∗ − θˆl′∗)− δ1√
V ar0(θˆl∗ − θˆl′∗)

= Φ
(
−z1−α/2
√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r + δ1√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r
)
+Φ
(
−z1−α/2
√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r − δ1√
2(m+ n)V ∗((1− ρa) + (r − 1)(ρb − ρc))/mna2r
)
,
with V ∗ = (aθ¯ + b)− (aθ¯ + b)2.
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Chapter 5
Conclusions and Future Research
In this dissertation, we have proposed semiparametric and nonparametric methods for
evaluating biomarkers and diagnostic tests for a specific disease or conditions. We
utilized the ROC analysis as a framework for developing the methods.
In Chapter 2, we proposed a semiparametric transformation model to combine
multiple biomarkers in order to optimize diagnostic accuracy. The simulation stud-
ies and applications to the real data suggest that the proposed method performs well
in small-sample settings, and the obtained optimal AUC is comparable to those using
the nonparametric and logistic regression methods when biomarkers have a weak asso-
ciation, and is superior to the existing approaches for highly correlated biomarkers. As
mentioned in the discussion section of Chapter 2, the proposed transformation model
has several advantages over the methods that use the linear combinations of original
biomarkers in the previous work: First, we allow a completely unknown transforma-
tion, so the diagnostic rule is less sensitive to the extreme values of biomarkers. Second,
since our method is applied to the biomarkers characterized by left or right censoring
and accounts for the correlated structure of biomarkers by introducing random effects,
it handles practical data more properly and uses more data information for inference.
Third, in our method, finding the optimal linear combination of biomarkers is straight-
forward and the final result does not depend on any monotone transformation of the
biomarkers.
In Chapter 3, we focused on assessing the accuracy of biomarkers by adjusting
for covariates that could influence the performance of biomarkers. We developed an
accelerated ROC model by generalizing the usual accelerated failure time model in the
survival context to the ROC analysis. Our method models the covariate effects on the
ROC curves, so that the interpretation of model parameters pertains directly to the
rescaling of the ROC curves. Comparatively, the traditional model models such effects
as the location-shift of the ROC curves. Thus, our model provides a useful alternative
to the traditional method.
Finally, in Chapter 4, we developed a latent model to estimate and compare cor-
related AUCs in a paired-patient, paired-reader design. We assumed diagnostic test
results come from some unknown and monotone functions of continuous latent vari-
ables, and further assumed reader variability is characterized by random effects due to
a specific reader from a given diagnostic test. We also presented a method for correcting
an imperfect gold standard bias and sample size formula in this design.
High-throughput technologies such as microarrays allow researchers to gather tens
of thousands of genes simultaneously. Thus, there is a need for developing statistical
methods to select biomarkers from thousands of genes and construct a classification rule
of disease. Currently, few methods exist for evaluating high dimensional biomarkers
using ROC techniques. We will extend our transformation models in Chapter 2 and
will address biomarker selection as well as classification of disease.
Another application of our approach is to combine multiple biomarkers for diag-
nosing disease outcomes which may have more than two levels or even take ordinal
values. Moreover, we will develop methods to evaluate longitudinal or repeated mea-
sures of biomarkers for disease detection. For one example, we are considering methods
to combine multiple biomarkers in which different types of biomarkers are accumulated
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at different time points. Finally, the model proposed in Chapter 3 can be extended
to evaluate two or more biomarkers, so that one can evaluate the covariate effects on
multiple biomarkers simultaneously. Furthermore, since the parameter estimates of co-
variates based on the log-rank estimating equation may not be efficient, we will explore
other methods to attain the semiparametric efficiency.
The paired-patient and paired-reader design is the most popular and efficient to
compare diagnostic tests. In Section 4.4, we developed a sample size formula based
on the asymptotic normality of the AUC and by simplifying various correlations due
to same readers or tests. However, we found that the theoretical powers are very
conservative compared to empirical powers, especially when the imperfect gold standard
bias is present as discussed in Section 4.7. Moreover, currently available methods do not
accommodate this design properly for sample size calculations. The very next extension
to this research will be to develop a more accurate sample size formula in this design. In
broad perspective, we will develop statistical methods to assess and compare diagnostic
techniques accommodating a particular situation or a study design.
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